Document:

exv10w20

 

Exhibit 10.20

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

LICENSE AGREEMENT

PREAMBLE

     This LICENSE AGREEMENT (the “Agreement”) is entered into as of the 30th day of November, 2007
(the “Effective Date”) by and between Santarus, Inc., a Delaware corporation, with its principal
place of business at 10590 West Ocean Air Drive, Suite 200, San Diego, CA 92130 (“Santarus”) and
Glaxo Group Limited, an English company with its principal place of business at 40 Berkeley Avenue
Greenford Middlesex United Kingdom on behalf of itself and its Affiliates (together “GSK”).
Santarus and GSK are sometimes referred to herein collectively as the “Parties” and separately as a
“Party.”

     WHEREAS, Santarus has developed, manufactures, and is commercializing in the United States a
line of pharmaceutical products based on proton pump inhibitors in combination with one or more
buffering agents under the trademark Zegerid®;

     WHEREAS, GSK is interested in developing, manufacturing and commercializing Licensed Products
in the GSK Territory (each as defined below);

     WHEREAS, Santarus is willing to grant GSK licenses to develop, manufacture and commercialize
Licensed Products for use in the Field (as defined below) and in the GSK Territory, all on the
terms and conditions set forth herein below; and

     WHEREAS, effective concurrently herewith, the Parties are entering into that certain Puerto
Rico Distribution Agreement (the “Distribution Agreement”) pursuant to which GSK will distribute
and sell PR Products (as defined in the Distribution Agreement) for the Commonwealth of Puerto Rico
and the U.S. Virgin Islands (collectively, the “PR Territory”), all on the terms and conditions set
forth therein.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein below
and other good and valuable consideration, the receipt and legal sufficiency of which are hereby
mutually acknowledged, GSK and Santarus hereby agree as follows:

ARTICLE 1

DEFINITIONS

     The following capitalized terms shall have the meanings set forth below when used in this
Agreement:

     1.1 “Adverse Event” means any untoward medical occurrence in a patient or clinical trial
subject who has been administered a Licensed Product, where the untoward medical occurrence

 

is temporally associated with the use of the Licensed Product, whether or not considered
related to the Licensed Product. An Adverse Event can therefore be any unfavourable and unintended
sign (including an abnormal laboratory finding) symptom or disease (new or exacerbated) temporally
associated with the use of a Licensed Product. For a marketed Licensed Product, this can also
include failure to produce expected benefits (i.e. lack of efficacy), and adverse events associated
with circumstances of abuse or misuse. In addition to the foregoing, in the context of clinical
trials, an Adverse Event will also mean events associated with or possibly attributable to the
clinical trial protocol design or clinical trial procedures.

     1.2 “Affiliate” with respect to any Person, means any other Person, whether de jure or de
facto, that directly or indirectly, controls, is controlled by, or is under common control with
such first Person, as applicable, for as long as such control exists. Solely as used in this
definition, “control” means (a) direct or indirect ownership of more than fifty percent (50%) of
the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction) having the power to vote on or direct the affairs of such
Person, as applicable, or (b) the possession, directly or indirectly, of the power to direct or
cause the direction of the policies and management of such Person, as applicable, whether by the
ownership of stock, by contract, or otherwise.

     1.3 “API” means any active pharmaceutical ingredient in a Licensed Product.

     1.4 “Applicable Law” means all applicable provisions of any and all Federal, national,
multinational, state, provincial, and local statutes, laws, rules, regulations, administrative
codes, ordinances, decrees, orders, decisions, injunctions, awards judgments, permits and licenses
of or from governmental authorities relating to or governing the use or regulation of the subject
item.

     1.5 [***].

     1.6 “Business Day” means any day other than a day which is a Saturday, a Sunday or any day
banks are authorized or required to be closed in New York, New York.

     1.7 “Calendar Quarter” means each of the consecutive three (3) month periods ending March 31,
June 30, September 30, and December 31, as the case may be.

     1.8 “Commercially Reasonable Efforts” means those diligent efforts and resources, with respect
to a particular Party, at the relevant point in time, that are comparable to those generally used
by that Party, in good faith, in the exercise of its reasonable and prudent business judgment
relating to other prescription pharmaceutical products owned or licensed by it or to which it has
exclusive rights in the GSK Territory, which have market potential and are at a stage of product
life similar to the Licensed Product in the GSK Territory, taking into account measures of relative
safety and efficacy, product profile, the competitiveness of the marketplace, the regulatory
structure involved, the relative profitability of the products and other relevant factors including
comparative technical, scientific or medical factors. Such Commercially Reasonable Efforts shall
include (i) promptly assigning responsibility for manufacturing and commercialization activities to
specific employees who are held accountable for progress and monitoring such progress on an
on-going basis, (ii) setting and consistently seeking to achieve specific and meaningful objectives
and

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

2

 

timelines for carrying out such manufacturing and commercialization activities, (iii)
consistently making and implementing decisions and allocating resources designed to advance
progress with respect to such objectives and timelines, and (iv) employing compensation systems for
its employees working with the Licensed Product that are similar to the compensation systems the
applicable Party applies with respect to its other programs with products of similar potential.

     1.9 “Competing Third Party” means any Person which [***].

     1.10 “Confidential Information” means any and all information disclosed to or obtained by
Recipient pursuant to or in connection with the negotiation, execution, delivery and performance of
this Agreement or the consummation of the transactions contemplated hereby and any and all
information regarding, related to, or associated with any or all elements of this Agreement,
including Licensed Products or each Party’s operations, that is disclosed by the Disclosing Party
to the Recipient; provided, however, that Confidential Information will not include information
which: (a) at the time of disclosure is in the public domain; (b) after disclosure becomes part of
the public domain, except through breach of this Agreement; (c) the Recipient can demonstrate by
reasonable proof was in its possession prior to the time of disclosure by the Disclosing Party
hereunder, and was not acquired directly or indirectly from the Disclosing Party; (d) the Recipient
can demonstrate by reasonable proof was developed by or on behalf of Recipient independent of and
without reference to the Disclosing Party’s Confidential Information; or (e) becomes available to
Recipient from a Third Party who did not acquire such information directly or indirectly from the
Disclosing Party and who is not otherwise prohibited from disclosing such information.

     1.11 “Control” means, with respect to any Santarus IP or GSK IP, possession by the Party
granting the applicable right, license or sublicense to the other Party as provided herein of the
power and authority, whether arising by ownership, license, or other authorization (in each case
other than pursuant to this Agreement) to disclose and deliver the particular Know-How to the other
Party, and to grant and authorize under such Santarus IP or GSK IP the right, license or
sublicense, as applicable, of the scope granted to such other Party in this Agreement without
giving rise to a violation of the terms of any written agreement with any Third Party.
“Controlled” or “Controlling” shall have their correlative meanings.

     1.12 “Data” means any and all research and development data, such as preclinical data,
pharmacology data, chemistry data (including analytical, product characterization, manufacturing,
and stability data), toxicology data, clinical data (including investigator reports (both
preliminary and final), statistical analyses, expert opinions and reports, safety and other
electronic databases), together with supporting data, in each case specifically directed to, or
used in the development of, a Licensed Product. For clarity, “Data” includes results from any
post-approval clinical studies of Licensed Products.

     1.13 “FDA” means the United States Food and Drug Administration or any successor thereto.

     1.14 “Field” means all approved and future human therapeutic indications, for either
prescription or over-the-counter (OTC) distribution.

 

			
	***  	 	 Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

3

 

     1.15 “Force Majeure” means occurrences beyond the reasonable control of the Party affected,
including acts of God, embargoes, governmental restrictions, terrorism, materials shortages or
failure of any supplier (where such shortage or failure is attributable to an event of Force
Majeure suffered by such supplier), fire, flood, explosion, earthquake, hurricanes, storms,
tornadoes, riots, wars, civil disorder, failure of public utilities or common carriers, labor
disturbances, rebellion or sabotage.

     1.16 “GAAP” means United States generally accepted accounting principles, in each case
consistently applied.

     1.17 “Generic Competitive Product” means a pharmaceutical product sold by a Third Party in a
particular country in the GSK Territory, which pharmaceutical product (a) contains the same APIs
(e.g.. omeprazole and sodium bicarbonate with respect to the capsule and powder formulations of
Licensed Product) as the applicable Licensed Product being sold in such country by GSK under this
Agreement (the “Comparable Licensed Product”), (b) does not infringe any of the Santarus Patents,
(c) is bioequivalent with respect to pharmacokinetic properties to the Comparable Licensed Product,
(d) is substantially the same dosage form, strength (for each API) and route of administration, as
the Comparable Licensed Product and (e) is approved for marketing and sale by the applicable
Regulatory Authority in such country.

     1.18 “GSK IP” means (a) any Patent Controlled by GSK or its Affiliates covering any [***] and
(b) any [***].

     1.19 “GSK Territory” means those countries of the world set forth on Exhibit 1.19
hereto to the extent GSK maintains its license pursuant to Section 2.1.1 in such countries.

     1.20 “Important Medical Event” means an Adverse Event that may not be immediately
life-threatening or result in death or hospitalisation but may jeopardise the subject or require
medical or surgical intervention to prevent one of the outcomes listed in (a) — (e) of the
definition of Serious Adverse Event. Examples of such events include invasive or malignant
cancers, intensive treatment (in an emergency room or at home) for allergic bronchospasm, blood
dyscrasias or convulsions that do not result in hospitalisation, or the development of drug
dependency or abuse, overdose or misuse.

     1.21 “Know-How” means any and all information and tangible materials comprising (a) ideas,
discoveries, inventions, improvements or trade secrets, (b) Data, (c) databases, practices,
methods, techniques, specifications, formulations, formulae, knowledge, (d) techniques, methods,
formulas, processes, manufacturing information, and (e) research materials, reagents and
compositions of matter and biological materials. Know-How shall not include any Patent rights with
respect thereto.

     1.22 “Licensed Product” means any pharmaceutical product incorporating omeprazole in
combination with one or more buffering agents.

     1.23 “Major GSK Country” means each of the following: Brazil, Mexico, People’s Republic of
China, South Africa, South Korea, Taiwan and Turkey.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

4

 

     1.24 “Marketing Authorization” means, with respect to a Licensed Product in a particular
jurisdiction, all approvals, licenses, registrations or authorizations necessary for the
commercialization of such Product in such jurisdiction, including only where mandatory for
initiation of commercialization of such Licensed Product, approval of labeling, price,
reimbursement and manufacturing.

     1.25 “MAA” (Marketing Authorization Application) means any filing, application or submission
filed with or submitted to any Regulatory Authority in the applicable jurisdiction to obtain
permission to initiate commercialization in the Field.

     1.26 “Missouri Agreement” means that certain Exclusive License Agreement between Santarus and
the Curators of the University of Missouri (“UMissouri”) effective as of January 26, 2001, as
amended from time to time.

     1.27 “Net Sales” means the gross amount invoiced by GSK and its Affiliates and Sublicensees
(the “Selling Party”) to Third Parties for the sales of Licensed Products in the GSK Territory. To
the extent that the gross amounts invoiced by the Selling Party for such sales of Licensed Products
do not already reflect deductions or exclusions of the following amounts, the following may be
deducted in calculation of Net Sales, in accordance with GAAP, to the extent such deductions are at
rates customary within the industry:

	 	(a)	 	[***];
	 
	 	(b)	 	[***]; and
	 
	 	(c)	 	[***].

Net Sales shall not include sales of Licensed Products between and among GSK and its Affiliates and
Sublicensees; provided, however, that Net Sales shall include the amounts invoiced by the Selling
Party (with applicable deductions as set forth above) upon any resale of such Licensed Products to
a Third Party. With respect to Licensed Products, if any, that are sold in “bundles” with other
products or services, if the amount invoiced for the applicable Licensed Products represents a
discount greater than the average discount for all products and services in the applicable
“bundle,” then Net Sales for such “bundled” Licensed Product shall be determined using a sales
price based on [***].

     1.28 “Patent” means any of the following, whether existing now or in the future anywhere in
the world: (a) any issued patent, including any inventor’s certificate, substitution, extension,
supplemental protection certificate, registration, confirmation, reissue, re-examination, renewal
or any like governmental grant for protection of inventions; and (b) any pending application for
any of the foregoing, including any continuation, divisional, substitution, continuations-in-part,
provisional and converted provisional applications.

     1.29 “Person” means any individual, corporation, partnership, firm, association, joint
venture, joint stock company, trust or other entity, or any government or regulatory administrative
or political subdivision or agency, department or instrumentality thereof.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

5

 

     1.30 “PPI” means any proton pump inhibitor, e.g. omeprazole.

     1.31 “PPI Pharmaceutical Product” means a pharmaceutical product containing one or more PPIs
as active pharmaceutical ingredients.

     1.32 “Regulatory Authority” means any federal, national, multinational, state, provincial or
local regulatory agency, department, bureau or other governmental entity with authority over the
development, commercialization or other use or exploitation (including the granting of Marketing
Authorizations) of any Licensed Product in any jurisdiction.

     1.33 “Regulatory Filing” means any filing, application or submission filed with or submitted
to any Regulatory Authority, including applications to initiate or continue clinical or other
studies and MAAs and authorizations, approvals or clearances arising from the foregoing, including
Marketing Authorizations, and all correspondence with any Regulatory Authority, as well as minutes
of any material meetings, telephone conferences or discussions with the relevant Regulatory
Authority, in each case with respect to a Licensed Product.

     1.34 “Santarus IP” means, individually and collectively, the Santarus Know-How and Santarus
Patents.

     1.35 “Santarus Know-How” means any and all Know-How Controlled by Santarus during the Term
that is reasonably necessary for the development, manufacture (including testing) or
commercialization of a Licensed Product within the Field in the GSK Territory in accordance with
this Agreement.

     1.36 “Santarus Patents” means the Patents listed on Exhibit 1.36, together with any
and all other Patents in the GSK Territory that are Controlled by Santarus and claim (specifically
or generically) subject matter developed after the Effective Date which is (a) a formulation of any
Licensed Product, (b) a method or process for the manufacture or synthesis of any Licensed Product
(or any formulation thereof) or (c) a method of use or administration of any Licensed Product (or
any formulation thereof) and for which GSK has exercised its option therefor in accordance with
Section 8.1.2. The list of Santarus Patents existing as of the Effective Date which is appended
hereto as Exhibit 1.36 will be updated upon request from GSK to reflect changes thereto
during the Term.

     1.37 “Serious Adverse Event” means an Adverse Event which (a) results in death; (b) is
life-threatening; that is, an event where the patient or clinical trial subject was at risk of
death at the time of the event: it does not refer to an event that, hypothetically, might have
caused death if it had been more severe; (c) requires hospitalisation or prolongation of existing
hospitalisation; (d) results in persistent or significant disability or incapacity; (e) is a
congenital anomaly or birth defect; (f) is an Important Medical Event or (g) involves suspected
transmission via a PR Product of an infectious agent.

     1.38 “Sublicensee” means any Third Party to whom GSK or its Affiliates have granted a
sublicense under the licenses conveyed to GSK under the Santarus IP to make, have made, use, sell,
offer for sale or import a Licensed Product in the Field in the GSK Territory. As used in this
Agreement, the term “Sublicensee” shall also include a Third Party to whom GSK or its Affiliate

6

 

have granted, directly or indirectly, the right to distribute a Licensed Product; provided
that such Third Party has the responsibility for marketing or promotion of a Licensed Product
within the markets or territories for which such distribution rights are granted, but “Sublicensee”
shall not include a Third Party whose only role with respect to a Licensed Product is as contract
manufacturer.

     1.39 “Third Party” means any Person other than the Parties or their respective Affiliates.

     1.40 Additional Definitions. Each of the following capitalized terms shall have the
meanings defined in the corresponding section of this Agreement indicated below:

	 	 	 	 	 	 	 	 	 	 	 
	Definition	 	Section	 	Definition	 	Section
	AAA

	 	 	14.2	 	 	Indemnitor
	 	 	10.3	 
	Agreement

	 	Preamble
	 	Infringing Product
	 	 	8.4.1	 
	Aggregate Product Net Sales

	 	 	7.2.1	 	 	Losses
	 	 	10.1	 
	Buyout Payment

	 	 	7.2.4	 	 	Manufacturing Technology
	 	 	5.3.3	 
	CGL

	 	 	10.5.1	 	 	[***]
	 	 	[***]	 
	Confidentiality Agreement

	 	 	12.1	(h)	 	[***]
	 	 	[***]	 
	Cure Period

	 	 	13.2	 	 	Parties
	 	Preamble

	Defending Party

	 	 	8.3	 	 	Party
	 	Preamble

	Designated Manufacturer

	 	 	5.3.2	 	 	PR Territory
	 	Preamble

	Diligence Failure

	 	 	4.2	 	 	Prosecute and Maintain
	 	 	8.2.3	 
	Disclosing Party

	 	 	12.1	(a)	 	Prosecution and Maintenance
	 	 	8.2.3	 
	Dispute

	 	 	14.1	 	 	Recipient
	 	 	12.1	(a)
	Dispute Notice

	 	 	14.1	 	 	Santarus
	 	Preamble

	Distribution Agreement

	 	Preamble
	 	Santarus Indemnitees
	 	 	10.2	 
	Effective Date

	 	Preamble
	 	Santarus Invention
	 	 	8.1.1	 
	Enforcement Action

	 	 	8.4.1	 	 	Santarus Marks
	 	 	4.6	 
	GSK

	 	Preamble
	 	Substantial Generic Competition	 	 	7.2.2	 
	GSK Indemnitees

	 	 	10.1	 	 	Term
	 	 	13.1	 
	GSK Invention

	 	 	8.1.1	 	 	UMissouri
	 	 	1.26	 
	GSK Indemnitee

	 	 	10.3	 	 	 	 	 	 	 
	GSK Marks

	 	 	4.7	 	 	 	 	 	 	 

     1.41 General Interpretation. Except where the context requires otherwise, (a) the use
of any gender herein shall be deemed to be or include the other gender; (b) the use of the singular
shall be deemed to include the plural (and vice versa); (c) the word “or” is used in the inclusive
sense typically associated with the phrase “and/or”; (d) the words “include”, “includes” and
“including” shall be deemed to be followed by the phrase “without limitation” and shall not be
construed to limit any general statement which it follows to the specific or similar items or
matters immediately following it; (e) the word “will” shall be construed to have the same meaning
and effect as the word “shall”; (f) the words “under authority” shall mean, with respect to a
Person, any other Person (including with respect to GSK, its Affiliates and any Sublicensees)
acting, directly or indirectly, within the scope of authorization or engagement of the first
Person; for clarity, an Affiliate of a Party shall be deemed to be acting “under authority” of such
Party for all purposes hereunder, however neither Party or its Affiliates shall be deemed to be
acting “under authority” of the other Party or the other Party’s Affiliates for any purposes of
this Agreement; (g) any definition of or reference to any

 

			
	***  	 	 Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

7

 

agreement, instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise
modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein); (h) any reference herein to any Person shall be construed to include the Person’s
successors, heirs and assigns; (i) the words “herein”, “hereof” and “hereunder”, and words of
similar import, shall be construed to refer to this Agreement in its entirety and not to any
particular provision hereof; (j) all references herein to Articles, Sections or Exhibits shall be
construed to refer to Articles, Sections and Exhibits of this Agreement, and references to this
Agreement include all Exhibits hereto; and (k) references to any specific law or article, section
or other division thereof shall be deemed to include the then-current amendments thereto or any
replacement or successor law thereof. Each accounting term used in this Agreement that is not
specifically defined in this Agreement shall have the meaning given to it under GAAP, but only to
the extent consistent with its usage and the other definitions in this Agreement, and all
calculations hereunder shall be made in accordance with GAAP.

ARTICLE 2

LICENSES

     2.1 Licenses to Santarus IP.

          2.1.1 General. Subject to the terms and conditions of this Agreement, Santarus hereby
grants to GSK an exclusive license under the Santarus IP to sell, offer for sale and import for
sale Licensed Products for applications in the Field in the GSK Territory. Additionally, subject
to the terms and conditions of this Agreement, Santarus hereby grants to GSK a non-exclusive
license under the Santarus IP: (a) to develop and use Licensed Products for applications in the
Field in the GSK Territory; and (b) to make and have made Licensed Products anywhere in the world
to support the other licenses granted in this Section 2.1.1. [***].

          2.1.2 Sublicenses. The licenses under Section 2.1.1 include the right for GSK to
grant sublicenses within the scope thereof to its Affiliates and Third Parties, subject to the
terms and conditions of this Section 2.1.2; and accordingly, except as otherwise expressly provided
herein, GSK shall have the right to fulfill any or all of its obligations hereunder through one or
more Affiliates or Sublicensees:

                    (a) Each sublicense shall be consistent with the terms and conditions of this Agreement.

                    (b) GSK shall promptly notify Santarus in writing of the grant of each sublicense to a Third
Party and provide Santarus a copy of the final executed sublicense agreement, redacted for
financial information not pertinent to this Agreement.

                    (c) GSK shall be responsible for the failure by its Affiliates and Sublicensees to comply
with, and GSK guarantees the compliance by each of its Affiliates and Sublicensees with, all
relevant restrictions, limitations and obligations in this Agreement.

 

			
	***  	 	 Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

8

 

                    (d) GSK shall remain responsible for all payments and other obligations under this Agreement
arising from activities of its Affiliates and Sublicensees.

     2.2 License to Santarus. Subject to the terms and conditions of this Agreement, GSK
hereby grants to Santarus [***] license under all GSK IP to [***]. Additionally, subject to the
terms and conditions of this Agreement, GSK hereby grants to Santarus [***] license under the GSK
IP to [***]. Notwithstanding anything herein to the contrary, the licenses granted in this Section
2.2 shall not include any GSK IP subject to payment obligations to a Third Party (and GSK shall
promptly disclose such obligations to Santarus in writing), unless Santarus agrees in writing to
reimburse all amounts owed to such Third Party as a result of Santarus’ exercise of such license.
In addition, in the event Santarus elects to take a license to such GSK IP, the terms for such
license shall be [***]; provided that no compensation shall be due to GSK if [***].

     2.3 No Other Rights. Each Party acknowledges that the rights and licenses granted
under this Article 2 and elsewhere in this Agreement are limited to the scope expressly granted.
Accordingly, except for the rights expressly granted under this Agreement, no right, title, or
interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or
otherwise, by either Party to the other Party. All rights with respect to Know-How, Patent or
other intellectual property rights that are not specifically granted herein are reserved to the
owner thereof.

ARTICLE 3

DEVELOPMENT / REGULATORY

     3.1 Development of Licensed Products.

          3.1.1 General. GSK shall have the right and be responsible for conducting at its
expense: (a) all development (including clinical studies) with respect to the Licensed Products
necessary to file for and obtain Marketing Authorizations to launch the Licensed Products for
application in the Field, subject to the limitations in Section 2.1.1, throughout the GSK Territory
in accordance with this Agreement and (b) all phase IV clinical studies, quality of life
assessments, pharmacoeconomic, label expansion or other post-marketing studies as may be required
by any applicable Regulatory Authority or as GSK may elect to perform in the GSK Territory.
Without limiting the foregoing, GSK shall have the right, but not the obligation, to develop line
extensions and new formulations within the Licensed Products in the GSK Territory; provided that
GSK shall keep Santarus informed with respect to such activities in accordance with Section 6.5.

          3.1.2 Stability Data. Without limiting Santarus’ obligations in Section 5.3.1, GSK
shall have the right and be responsible for generating at its expense any stability data necessary
to expeditiously file for and obtain Marketing Authorizations throughout the GSK Territory to the
extent such data is beyond the current or scheduled Santarus stability programs. In the event that
Santarus wishes to use any of this stability data in Regulatory Filings for Licensed Products
outside of the GSK Territory and Territory under the Distribution Agreement, [***].

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

9

 

     3.2 Regulatory Matters.

          3.2.1 Interactions. GSK shall have, at its expense, the responsibility for all
interactions with any Regulatory Authority in the GSK Territory and for filing, obtaining and
maintaining approvals for development and commercialization of Licensed Products for applications
in the Field in the GSK Territory, subject to the limitations in Section 2.1.1, including any MAA
or Marketing Authorization therefor. Notwithstanding the foregoing, Santarus shall be able to
communicate with any Regulatory Authority in the GSK Territory regarding any Licensed Product, but
only to the extent that such communication is [***]. Santarus shall provide GSK at least [***]
days advance notice (or, if [***] days advance notice is not possible, such advance notice that is
possible under the circumstances) of any meetings between Santarus and Regulatory Authorities in
the GSK Territory relating to the activities set out in [***] above. Santarus shall provide to GSK
copies of correspondence received by Santarus from Regulatory Authorities in the GSK Territory
promptly (within [***] following Santarus’ receipt thereof), and Santarus shall (i) provide GSK an
opportunity to review and comment on such Regulatory Filings and correspondence with Regulatory
Authorities in the GSK Territory prior to submission, and (ii) consider in good faith the comments
of GSK in such Regulatory Filings and correspondence. To the extent not prohibited by Applicable
Laws, GSK shall own all Regulatory Filings filed by or under authority of it for the Licensed
Products for applications in the Field in the GSK Territory. For clarity, as between the Parties,
Santarus shall retain the right and, at its expense, the responsibility for all interactions with
any Regulatory Authority and filing, obtaining and maintaining approvals for development and
commercialization of Licensed Products outside the GSK Territory, including any MAA or Marketing
Authorization therefor.

          3.2.2 Assistance. Each Party agrees to provide in a timely manner such assistance in
connection with the other Party exercising its rights or fulfilling its responsibilities described
in Section 3.2.1 as such other Party may reasonably request; provided that the requesting Party
shall reimburse the other Party for all reasonable costs and expenses incurred in providing such
assistance. Without limiting the foregoing, Santarus agrees to so provide GSK access to
manufacturing data Controlled by Santarus and required to generate Regulatory Filings for Licensed
Products for applications in the Field in the GSK Territory, subject to the limitations in Section
2.1.1. In addition, each Party shall provide the other Party information regarding plans to make
any Regulatory Filings to the extent such Regulatory Filings are reasonably likely to affect the
other Party’s Regulatory Filings in their respective territories.

          3.2.3 Safety Data Exchange. Each of Santarus and GSK agree to notify each other
concerning possible Serious Adverse Events, and possible Adverse Events that are not Serious
Adverse Events, within the respective time periods, and in accordance with the applicable
procedures, set forth in a pharmacovigilance agreement to be mutually agreed and executed by the
Parties within thirty (30) days of the Effective Date but in any event prior to the first
administration of any Licensed Product to a human in a clinical trial conducted by or under
authority of GSK or, if earlier, the first sale of Licensed Product by or under authority of GSK,
which pharmacovigilance agreement shall be reviewed and revised, as may be necessary, annually by
the Parties. 

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

10

 

     3.3 Access to Data.

          3.3.1 By GSK.

          (a) Without limiting Section 5.3.2, promptly after the Effective Date and in any event within
[***] thereafter, Santarus shall make available to GSK all Regulatory Filings and Santarus Know-How
in its Control as of the Effective Date reasonably necessary for GSK to manufacture or have
manufactured Licensed Products and obtain and maintain Marketing Authorizations for Licensed Products in accordance with this Agreement. Data provided under
this Section 3.3.1(a) shall be provided in editable format.

          (b) The Parties acknowledge that Santarus has no obligation, express or implied, to generate
additional Data or Regulatory Filings related to the Licensed Products hereunder. However, if
Santarus does generate such additional Data or Regulatory Filings during the Term, to the extent
such Data or Regulatory Filings are Controlled by Santarus and are reasonably necessary for GSK to
manufacture or have manufactured Licensed Products and obtain Marketing Authorizations for Licensed
Products in accordance with this Agreement, Santarus shall make such Data and Regulatory Filings
available to GSK hereunder.

          (c) The mode that Santarus makes available Data and Regulatory Filings under this Section
3.3.1 shall be as mutually determined by Santarus and GSK in good faith with the goals of
efficiency and cost-effectiveness. For clarity, GSK shall have the right to use and reference all
such Regulatory Filings and Data made available under this Section 3.3.1 in connection with its
development, manufacture and commercialization of Licensed Products in accordance with this
Agreement; provided that all such Regulatory Filings and Data received by GSK, together with all
embodiments thereof, shall be deemed the Confidential Information of Santarus, subject to the terms
and conditions of Article 12.

          3.3.2 By Santarus. GSK shall provide to Santarus the core regulatory file used by GSK
to generate all Regulatory Filings within [***] after its initial completion and [***] after any
updates thereto. In addition, from time to time or upon Santarus’ reasonable request, GSK shall
provide to Santarus all Data in its Control during the Term. Santarus shall have the right to use
and reference all Data and Regulatory Filings in connection with Santarus’ development, manufacture
and commercialization of Licensed Products outside of the GSK Territory; provided that such core
regulatory file and Data received by Santarus, together with all embodiments thereof, shall be
deemed the Confidential Information of GSK, subject to the terms and conditions of Article 12. The
mode that GSK provides Data and the core regulatory file under this Section 3.3.2 shall be mutually
determined by Santarus and GSK in good faith with the goals of efficiency and cost-effectiveness.

ARTICLE 4

COMMERCIALIZATION

     4.1 Commercialization of Licensed Products. GSK shall have the right and be
responsible at its expense for commercializing the Licensed Products for applications in the Field
throughout the GSK Territory, subject to the limitations in Section 2.1.1. GSK agrees to use
Commercially Reasonable Efforts to (a) seek and obtain Marketing Authorizations necessary to

 

			
	***  	 	 Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

11

 

launch Licensed Products for applications in the Field in the GSK Territory, (b) after receipt of such
Marketing Authorizations to launch Licensed Products for applications in the Field in the GSK
Territory, and thereafter (c) to market, promote and sell such Licensed Products for application in
the Field in the GSK Territory. In the event that GSK elects, in its sole discretion, not to launch
and commercialize Licensed Products for applications in the Field in any country in the GSK
Territory, GSK shall promptly notify Santarus in writing of such decision, in which case Santarus
shall have the right to terminate this Agreement with respect to such country in accordance with
Section 13.3. For clarity, nothing in the previous sentence shall be construed to prejudice GSK’s right to
terminate this Agreement pursuant to Section 13.4.2.

     4.2 Specific Requirements. Without limiting the provisions of Section 4.1, GSK shall
file a MAA in (a) each Major GSK Country (other than [***]) within [***] after the Effective Date
and (b) [***] within [***] after the Effective Date. In addition, GSK shall launch the Licensed
Products (i) within [***] after the date of receipt of Marketing Authorization in each Major GSK
Country and (ii) within [***] of receipt of Marketing Authorization in each other country in the
GSK Territory, but in the case of (i) and (ii) no later than [***] after the Effective Date. In
order to allow Santarus to monitor the progress of the activities described in this Section 4.2,
GSK shall notify Santarus in writing within [***] days of each filing for an MAA, approval of a
Marketing Authorization and launch of a Licensed Product, in each case in any country in the GSK
Territory. In the event that GSK fails to file an MAA or launch License Products within the
timeframes set forth in this Section 4.2 in a country (each such failure, a “Diligence Failure”),
then Santarus shall have as its sole remedy for such breach, but without limiting the remedies for
other breaches the right to terminate this Agreement with respect to such country in accordance
with Section 13.3.

     4.3 Managed Care. For clarity, GSK shall be responsible for decisions and
negotiations with relevant governmental authorities, agencies and managed care organizations
(including health maintenance organizations, preferred provider organizations, exclusive provider
organizations, independent practice associations, point-of-service plans and the like) and other
institutions regarding price and reimbursement status of Licensed Products in the GSK Territory.

     4.4 OTC. GSK shall have the right to switch any or all Licensed Products hereunder
from prescription to OTC distribution at any time during the Term or indeed launch any Licensed
Product hereunder as OTC, in any case at its sole discretion.

     4.5 Sales Outside of Territories.

          4.5.1 GSK. Subject to Applicable Law, GSK will implement reasonable safeguards
consistent with those safeguards that it uses in relation to its own products so that Licensed
Product is sold to customers for resale only in the GSK Territory and not for resale anywhere
outside the GSK Territory. If GSK becomes aware that any of its customers has shipped Licensed
Product outside the GSK Territory, or has reason to believe that a customer intends to ship
Licensed Product outside the GSK Territory, GSK, to the extent permitted by Applicable Law, will
take Commercially Reasonable Efforts to cause such customer to cease such activities. GSK shall,
within [***] days after learning that any Licensed Products sold by or under authority of GSK under
this Agreement have been sold, distributed or dispensed outside of the GSK Territory, notify
Santarus in writing of

 

			
	***  	 	 Certain information on this page has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

12

 

all pertinent information relating to such occurrence and the actions GSK plans to take in response thereto.

          4.5.2 Santarus. Subject to Applicable Law, Santarus will implement reasonable
safeguards consistent with those safeguards that it uses in relation to its own products so that
Licensed Product is sold to customers for resale only outside of the GSK Territory and not for
resale anywhere in the GSK Territory. If Santarus becomes aware that any of its customers has
shipped Licensed Product into the GSK Territory, or has reason to believe that a customer intends
to ship Licensed Product into the GSK Territory, Santarus, to the extent permitted by Applicable Law,
will take Commercially Reasonable Efforts to cause such customer to cease such activities.
Santarus shall, within [***] days after learning that any Licensed Products sold by or under
authority of Santarus under this Agreement have been sold, distributed or dispensed into of the GSK
Territory, notify GSK in writing of all pertinent information relating to such occurrence and the
actions Santarus plans to take in response thereto.

     4.6 No Use of Santarus Marks. GSK acknowledges that no license is conveyed under this
Agreement to GSK, its Affiliates or Sublicensees with respect to Santarus’ corporate name and logo,
the ZEGERID® trademark or any modifications or variations thereof, or to any replacements thereof
that Santarus may or its licensees may use in connection with Licensed Products outside of the GSK
Territory or outside the Field (collectively, the “Santarus Marks”). GSK hereby acknowledges
Santarus’ ownership rights in the Santarus Marks, and accordingly agrees that (i) except as
expressly licensed with respect to PR Product under the Distribution Agreement, GSK and its
Affiliates and Sublicensees shall not use the Santarus Marks in connection with the development,
importation, marketing or promotion of Licensed Products without first entering into a written
license therefor from Santarus, and (ii) at no time during the Term or thereafter will it challenge
or assist others to challenge the Santarus Marks, or the registration thereof, or attempt to
register any trademarks, service marks or trade names confusingly similar to the Santarus Marks, or
domain names based thereon.

     4.7 No Use of GSK Marks. Santarus acknowledges that, subject to Section 13.8.3, no
license is conveyed under this Agreement to Santarus or its Affiliates with respect to GSK’s
corporate name and logo or any trademarks used by GSK or its Affiliates or Sublicensees in
connection with Licensed Products in the GSK Territory (collectively, the “GSK Marks”). Santarus
hereby acknowledges GSK’s ownership rights in the GSK Marks, and accordingly agrees that (i)
subject to Section 13.8.3, Santarus and its Affiliates shall not use the GSK Marks in connection
with the development, importation, marketing or promotion of Licensed Products without first
entering into a written license therefor from GSK, and (ii) at no time during the Term or
thereafter will it challenge or assist others to challenge the GSK Marks, or the registration
thereof, or attempt to register any trademarks, service marks or trade names confusingly similar to
the GSK Marks, or domain names based thereon.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

13

 

ARTICLE 5

MANUFACTURE

     5.1 Manufacture of Licensed Products. GSK shall have the right and, at its expense
shall be responsible to, manufacture or have manufactured all Licensed Products (including all API
used therein) in accordance with the terms and conditions of this Agreement necessary for GSK to
fulfill its obligations with respect to the development and commercialization of Licensed Products
hereunder.

     5.2 Coordination of Supply.

          5.2.1 Introductions. From time to time during the Term, if either Party engages a
Third Party contractor with respect to the manufacture, testing, handling, finishing, storage or
other activities related to the production of Licensed Product or API, then such Party shall
introduce the other Party to such Third Party and use reasonable efforts, upon the other Party’s
request, to facilitate one or more meetings between such other Party and the Third Party for the
purpose of such Third Party supplying Licensed Product or API for the other Party.

          5.2.2 Supply Shortage. In the event that Santarus and GSK are using the same contract
manufacturer for Licensed Products or API and there is any shortage of supply of Licensed Products
or API to either Party as a result of a Force Majeure event, [***].

     5.3 Technology Transfer.

          5.3.1 Stability Data. Notwithstanding anything herein to the contrary, Santarus
agrees to transfer to GSK all stability data related to the Licensed Products Controlled by
Santarus that it may generate from time to time during the Term.

          5.3.2 Designated Manufacturer. If GSK elects to manufacture Licensed Products itself
or have a Third Party, who is not then manufacturing Licensed Products for Santarus, manufacture
for GSK, then Santarus shall assist in the transfer of Manufacturing Technology to GSK or such
Third Party on a one-time basis, at GSK’s expense; provided that such Third Party is not a
Competing Third Party. Accordingly, within [***] days of written notice from GSK designating the
Person to whom such transfer will be made (i.e., either GSK or such Third Party, the “Designated
Manufacturer”) and the physical facility(ies) that will be used in such manufacturing processes,
Santarus shall transfer or caused to be transferred to the Designated Manufacturer a copy of the
Manufacturing Technology. For clarity, GSK shall be responsible for ensuring any Third Party
Designated Manufacturer’s compliance with all applicable terms and conditions of this Agreement and
ensuring that the Designated Manufacturer is approved by applicable Regulatory Authorities to
manufacture and supply Licensed Product in the GSK Territory. All Manufacturing Technology received
by the Designated Manufacturer, together with all embodiments thereof shall be deemed the
Confidential Information of Santarus, subject to the terms and conditions of Article 12. Santarus
shall promptly request the inclusion of the name of any Designated Manufacturer on its NDA (as that
term is defined in the Distribution Agreement) for the Licensed Product.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

14

 

          5.3.3 Manufacturing Technology. “Manufacturing Technology” means any and all
specifications (raw material (including API) and finished product), protocols, documentation and
instructions (including validation, quality control and assurance, storage and other supporting
documentation) and master batch records Controlled by Santarus, in each case (a) in the form used
in the manufacture (including packaging, labeling, quality control and assurance testing and
storage and handling) of Licensed Products under authority of Santarus as of the date of GSK’s
written notice described in Section 5.3.2 and (b) reasonably necessary for GSK to manufacture or
have manufactured Licensed Products pursuant to this Agreement.

ARTICLE 6

NON-COMPETE/OTHER RESTRICTIONS/REPORTING

     6.1 Non-Compete.

          6.1.1 By GSK. During the Term, and for a period of two (2) years thereafter or, if
GSK exercises its right of termination pursuant to Section 13.4.2 in relation to the Agreement in
its entirety or on a country-by-country basis, until the later of (a) the fifth (5th)
anniversary of the Effective Date or (b) the second (2nd) anniversary of the effective
date of any termination of this Agreement in its entirety or with respect to a given country as the
case may be, neither GSK nor any of its Affiliates or Sublicensees will directly or indirectly
distribute, market, promote, detail, advertise or sell any PPI Pharmaceutical Product containing
one or more PPIs formulated in combination with one or more buffering agents, or which is otherwise
formulated to provide, in either case, for immediate release of the PPI (other than Licensed
Products pursuant to this Agreement) in or for such country. The foregoing covenants shall not
restrict GSK or any Affiliate or Sublicensee from obtaining rights to, or engaging in research and
development activities related to, products in such class during the restricted time period, so
long as GSK or its Affiliate or Sublicensee does not engage in the activities set forth in the
first sentence of this Section 6.1.1.

          6.1.2 By Santarus. Until the earlier of (a) the fifth (5th) anniversary of
the Effective Date or (b) termination of GSK’s license pursuant to Section 2.1.1 to sell, offer for
sale and import Licensed Products in a given country within the GSK Territory, neither Santarus nor
any of its Affiliates will directly or indirectly distribute, market, promote, detail, advertise or
sell any PPI Pharmaceutical Product containing one or more PPIs which is either formulated in
combination with one or more buffering agents, or which is otherwise formulated to provide, in
either case, for immediate release of the PPI in or for such country in the GSK Territory. On or
after the fifth (5th) anniversary of the Effective Date (for so long as GSK’s license
under Section 2.1.1 is still in effect with respect to the applicable country), Santarus and any
Affiliates shall have the right to directly or indirectly distribute, market, promote, detail,
advertise or sell any PPI Pharmaceutical Product containing one or more PPIs which is either
formulated in combination with one or more buffering agents, or which is otherwise formulated to
provide, in either case, for immediate release of the PPI, in or for such country in the GSK
Territory; provided that Santarus shall discuss with GSK the out-license of such product to GSK for
such country; and provided further that in the event that Santarus grants the right to
commercialize the product to any Third Party, or commercializes the product in its own right, in
such country in the GSK Territory, GSK shall be released from its obligations under

15

 

Section 6.1.1 on the first commercial sale of such product in such country by such Third Party
or Santarus, as the case may be. The foregoing covenants shall not restrict Santarus or any
Affiliate from obtaining rights to, or engaging in research and development activities related to,
products in such class during the restricted time period, so long as Santarus or its Affiliate does
not engage in the activities set forth in the first sentence of this Section 6.1.2.

     6.2 Know-How Restrictions and Firewall. GSK shall not, and shall ensure its
Affiliates and Persons acting under its authority do not, use or practice (or authorize the use or
practice of) any Santarus Know-How or other Confidential Information of Santarus (including Data
regarding the manufacture, formulation, release profile, efficacy or safety, use, sale or promotion
of any Licensed Product, for the purposes of manufacturing, developing or commercializing any
product (other than Licensed Products for applications in the Field in the GSK Territory in
accordance with this Agreement or the PR Product in the PR Territory in accordance with the
Distribution Agreement). GSK recognizes that, while GSK is Santarus’ licensee of Licensed Products
in the GSK Territory pursuant to this Agreement, GSK could, subject to Section 6.1 and this Section
6.2, develop a PPI Pharmaceutical Product which would, once launched, compete with Santarus with
respect to the Licensed Products. GSK acknowledges that Santarus is disclosing to GSK Santarus
Know-How and other Confidential Information of Santarus for GSK’s use solely with respect to the
Licensed Products for applications in the Field in the GSK Territory under this Agreement (or as
otherwise provided with respect to PR Products in the PR Territory pursuant to the Distribution
Agreement), and GSK agrees not to use the Santarus Know-How or other Confidential Information of
Santarus, directly or indirectly, in the research, manufacture, development, sale or marketing of
any PPI Pharmaceutical Product other than (a) Licensed Products to the extent permitted under this
Agreement or (b) the PR Product to the extent permitted under the Distribution Agreement. GSK
shall limit disclosure of Santarus Know-How or other Confidential Information of Santarus to its
and its Affiliates’ employees, consultants and other agents located in the Territory (or the PR
Territory to the extent permitted under and in accordance with the Distribution Agreement) who need
to access such Santarus Know-How or other Confidential Information of Santarus for the development,
manufacture or commercialization of Licensed Products in the GSK Territory in accordance with this
Agreement (or the PR Territory to the extent permitted under the Distribution Agreement) and who
are bound by obligations of confidentiality and non-use no less burdensome than those set forth in
this Agreement. Santarus Know-How or other Confidential Information of Santarus shall not be
disclosed to any of GSK’s or its Affiliates’ employees, consultants or other agents involved in the
research, development, manufacture or commercialization of any PPI Pharmaceutical Product other
than Licensed Products as permitted under this Agreement or the PR Product as permitted under the
Distribution Agreement, nor use or consider any such information or GSK’s plans with regard to any
Licensed Product in the development, manufacture or commercialization of any PPI Pharmaceutical
Product, and GSK agrees to institute reasonable procedures and safeguards intended to prevent such
prohibited disclosures.

     6.3 No Patent Challenges. In partial consideration for the licenses and other rights
granted herein, and access to Santarus Know-How or other Confidential Information of Santarus, GSK
agrees that if GSK or any of its Affiliates commences, participates in or actively supports in any
way any challenge to the validity, enforceability, claim construction or coverage of any Patents
Controlled by Santarus claiming or covering the composition, formulation, manufacture, use or sale
of Licensed Products in the GSK Territory in any court or before any government or regulatory

16

 

agency (national or international) with authority to determine the validity, enforceability or
scope of such patents, or cause or request a review by any such court or government or regulatory
agency of the same, then at any time thereafter Santarus shall be entitled to elect to treat such
activity as permissive termination by GSK under Section 13.4.2 of this Agreement in its entirety,
and such termination shall be effective immediately upon written notice to GSK.

     6.4 Missouri Agreement. Santarus shall have the obligation to pay all amounts owed to
the UMissouri under the Missouri Agreement, and in accordance with the terms set forth therein,
with respect to sales of Licensed Products by GSK (and any of its Affiliates and Sublicensees)
pursuant to the terms and conditions of this Agreement. It is understood and agreed that the
sublicense to GSK under this Agreement of rights licensed to Santarus under the Missouri Agreement
is subject to the terms and conditions of the Missouri Agreement applicable to such a sublicense,
and that such obligations are incorporated by reference herein. In the event of termination (but
not earlier expiration) of the Missouri Agreement during the Term of this Agreement, (a) GSK’s
sublicense under the Missouri Agreement shall be assigned by Santarus to the UMissouri with respect
to Licensed Products for applications in the Field in the GSK Territory, and this Agreement will be
assigned in part to the UMissouri to effect such assignment of the sublicense, (b) this Agreement
(including all payment obligations of GSK hereunder) shall otherwise be retained by Santarus with
respect to all matters other than the sublicense of rights under the Missouri Agreement and (c) GSK
shall thereafter be responsible for making all payments that would have been owed by Santarus to
UMissouri pursuant to the Missouri Agreement (if the Missouri Agreement had not been terminated) in
respect of GSK’s, its Affiliates’ and their Sublicensees’ sales of Licensed Products for
applications in the Field in the GSK Territory after the date of such assignment; provided that GSK
shall have the right to offset the amounts so paid to UMissouri in respect of the sales of Licensed
Products during the Term against amounts due hereunder to Santarus with respect to such sales.

     6.5 Reporting. Without limiting any other provision herein, GSK agrees to provide
Santarus during the Term with [***] reports describing the activities taken during the previous
period and GSK’s plans for activities during the upcoming period with respect to GSK’s obligations
to develop (including plans for and results of non-clinical and clinical studies regarding Licensed
Products), manufacture (including establishment of Third Party contractors) and commercialize the
Licensed Products (including sales forecasts) and interactions with Regulatory Authorities in the
GSK Territory with respect to the Licensed Products (including status of MAA filings and receipt of
Market Authorizations in each country within the GSK Territory). On [***] basis, the Parties shall
meet (telephonically or in person) to discuss GSK’s then current and anticipated development,
manufacturing, commercialization and regulatory activities conducted by or under authority of GSK
in or for the GSK Territory.

ARTICLE 7

PAYMENTS; ROYALTIES; REPORTS

     7.1 Up-Front Payment. Within three (3) days after the Effective Date, GSK shall pay
Santarus an up-front license fee of Eleven Million Five Hundred Thousand U.S. Dollars

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

17

 

(US$11,500,000), which amount shall be non-refundable and non-creditable against other amounts
due to Santarus hereunder or under the Distribution Agreement.

     7.2 Royalties on Net Sales. In partial consideration for the rights and licenses
granted to GSK under this Agreement, GSK shall pay to Santarus tiered royalties on Net Sales of
Licensed Products in the GSK Territory during the Term at the applicable rates set forth in Section
7.2.1, subject to adjustment as set forth in Section 7.2.2 below and subject to Section 7.2.3.
Royalties with respect to Net Sales made in each Calendar Quarter shall be paid within [***] days
following the applicable Calendar Quarter end.

          7.2.1 Royalty Rates. It is understood and agreed that applicable royalty rates on Net
Sales of Licensed Products under this Agreement shall be determined based on the total aggregate of
(a) Net Sales of Licensed Products under this Agreement, together with (b) any and all Net Sales
(as defined under the Distribution Agreement) of PR Products (as defined under the Distribution
Agreement) under the Distribution Agreement (collectively, “Aggregate Product Net Sales”) during
the applicable calendar year, as follows:

	 	 	 	 	 	 	 
	 	 	Aggregate Product Net Sales	 	 	 	 
	 	 	(in U.S. Dollars) During	 	 	 	 
	 	 	Applicable Calendar Year	 	Royalty Rate	 	 
	 

	 	[***]
	 	[***]
	 	 
	 
	 	 	 	 	 	 
	 

	 	[***]
	 	[***]	 	 
	 
	 	 	 	 	 	 
	 

	 	[***]
	 	[***]	 	 

          7.2.2 Reduction for Substantial Generic Competition.

          (a) In the event that, and for so long as, there exists Substantial Generic Competition in a
Major GSK Country: (a) the royalty rates payable under Section 7.2.1 for Net Sales in such country
shall be reduced from the rates of [***] specified in Section 7.2.1 above to [***], respectively,
and (b) [***]. As used herein, “Substantial Generic Competition” means that, during the
immediately preceding [***] Calendar Quarters, combined sales of Generic Competitive Products in a
particular country in the GSK Territory by Third Parties equate to at least [***], as measured by
IMS [***] data. For clarity, the royalty reduction set forth in this Section 7.2.2 shall only
apply for so long as there is Substantial Generic Competition, and the royalty rates set forth in
Section 7.2.1 shall again apply if Substantial Generic Competition ceases at any time during the
Term following a royalty reduction pursuant to this Section 7.2.2. GSK shall notify Santarus in
writing within [***] days after GSK becomes aware of any Substantial Generic Competition.

          (b) Allocation of Reduction Among Royalty Tiers. In the event that Substantial
Generic Competition (as set forth in this Section 7.2.2 or Section 6.2.2 of the Distribution
Agreement, as applicable) occurs in any one or more, but not all, of the countries in the GSK
Territory under this Agreement and the Territory under the Distribution Agreement, then the royalty
reduction described in Section 7.2.2(a) above and under Section 6.2.2(a) of the Distribution

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

18

 

Agreement shall be allocated to a portion of Net Sales in each royalty tier described in
Section 7.2.1 above (or Section 6.2.1 of the Distribution Agreement, as applicable) equal to the
proportion of Aggregate Product Net Sales under this Agreement and the Distribution Agreement
eligible for such reduction compared to the total Aggregate Product Net Sales. By way of example,
and not limitation, if the total Aggregate Product Net Sales for the first Calendar Quarter of a
given calendar year is $50 million, and $10 million of such Aggregate Product Net Sales occurs in
countries with Substantial Generic Competition (meaning 20% of total Aggregate Product Net Sales
for such Calendar Quarter occurred in countries with Substantial Generic Competition), then (A) the
reduced royalty rates set forth in Section 7.2.2(a) above and in Section 6.2.2(a) of the
Distribution Agreement shall apply to 20% of the Aggregate Product Net Sales in each applicable
royalty tier, and (B) the unreduced royalty rates set forth in Section 7.2.1 above and in Section
6.2.1 of the Distribution Agreement shall apply to the remaining 80% of the Aggregate Product Net
Sales in each applicable royalty tier.

          7.2.3 Waiver of Certain Amount of Initial Royalties. To support GSK’s
commercialization of Licensed Products in the GSK Territory and help defray start-up costs of GSK,
Santarus agrees to waive the first Two Million Five Hundred Thousand U.S. Dollars (U.S. $2,500,000)
of combined royalties due from GSK under this Section 7.2 of this Agreement and Section 6.2 of the
Distribution Agreement. For clarity, the waiver of royalties under this Section 7.2.3 and under
Section 6.2. of the Distribution Agreement together shall not exceed Two Million Five Hundred
Thousand U.S. Dollars (U.S. $2,500,000) in the aggregate.

          7.2.4 Royalty Term; Buyout Payment. The obligation of GSK to pay royalties under this
Section 7.2 shall continue for so long as GSK manufactures, markets, promotes, uses or sells
Licensed Product in the GSK Territory, unless GSK pays to Santarus within thirty (30) days
following the twentieth (20th) anniversary of the Effective Date an amount (the “Buyout
Payment”) equal to [***], Upon GSK’s timely payment of the Buyout Payment, GSK’s obligation to pay
royalties under this Section 7.2 shall cease; provided, however, that GSK shall thereafter continue
to pay Santarus continuing royalties equal to the amount of royalties (if any) that Santarus is
required to pay under the Missouri Agreement with respect to Licensed Products sold by or under
authority of GSK in the GSK Territory.

          7.2.5 Convenience. GSK agrees that substantial commercial value has been and will be
contributed by Santarus’ grant to GSK of the rights and licenses under this Agreement with respect
to the Licensed Products in the GSK Territory and other rights and licenses conveyed to GSK on the
terms and conditions set forth in this Agreement, and acknowledges that Santarus may not Control
Patents covering the manufacture, use or commercialization of Licensed Products throughout the Term
or throughout the GSK Territory. For their mutual convenience, the Parties have agreed to the
royalty rates and payment obligations set forth in this Agreement with respect to Net Sales of
Licensed Products in the GSK Territory, regardless of whether the manufacture, use or
commercialization of Licensed Products sold by GSK hereunder is covered by Patents Controlled by
Santarus.

     7.3 Withholding. [***].

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

19

 

     7.4 Method of Payments. All amounts payable to Santarus under this Agreement shall be
paid in U.S. Dollars by wire transfer to a bank account it designates. All payments hereunder
shall be made in the legal currency of the United States of America, and all references to “$” or
“Dollars” shall refer to United States dollars. When Licensed Products are sold for monies other
than Dollars, the royalties will first be determined in the foreign currency of the country in
which such Licensed Products were sold and then converted into equivalent Dollars. The exchange
rate will be that rate quoted by The Wall Street Journal on the last Business Day of the reporting
period. Except as otherwise set forth in this Agreement, including Section 7.2 with respect to
royalty payments, all payments due to a Party hereunder shall be due and payable within thirty (30)
days of an invoice from the other Party. All payments under this Agreement shall bear interest
from the date due until paid at a rate equal to [***], or, if less, the maximum rate permitted by
Applicable Law. The payment of such interest shall not limit either Party from exercising any
other rights it may have as a consequence of the lateness of any payment or breach of this
Agreement by the other Party.

     7.5 Royalty Reports. GSK shall, within [***] days following each Calendar Quarter,
make quarterly written reports to Santarus stating in each report, separately for GSK and each of
its Affiliates and Sublicensees, and by country: (a) the number, description and aggregate gross
amounts invoiced and Net Sales of each Licensed Product sold in the GSK Territory during the
immediately preceding quarter, including reasonably detailed descriptions of all itemized
deductions from gross amounts invoiced; (b) the number of Licensed Products sold or distributed on
a product-by-product basis; (c) the calculated amount of royalties due Santarus on account of such
Net Sales; (d) the basis for calculation of royalties due to Santarus, including applicable
deductions or adjustments; (e) the exchange rates used in making such calculations; and (f) the
date of first commercial sale of each Licensed Product. If no royalties are due for a particular
quarter, GSK shall so report to Santarus. GSK shall also make monthly interim written reports to
Santarus stating in each such report the aggregate Net Sales of Licensed Products sold in each
country in the GSK Territory during the immediately preceding month. GSK’s reports under this
Section 7.5 shall be transmitted to Santarus by email (to [***] and [***], or to such other e-mail
address(es) as Santarus may from time to time designate in writing). Quarterly reports shall be
sent within thirty (30) days after the end of each Calendar Quarter and monthly interim reports
shall be sent within ten (10) days after the end of each calendar month. The reports required
under this Section 7.5 may be combined with royalty reports due under the Distribution Agreement;
provided that any such combined report shall set forth the required information separately for each
country in the GSK Territory.

     7.6 Audits. GSK shall keep, and cause its Affiliates and any Sublicensees to keep,
complete and accurate records in sufficient detail to enable a calculation of royalties due to
Santarus on account of Net Sales of Licensed Products in the GSK Territory, determined in
accordance with GAAP (including calculation of gross amounts invoiced for each Licensed Product,
Net Sales of each Licensed Product, all itemized deductions from gross amounts invoiced taken to
calculate Net Sales, and amounts payable hereunder to Santarus for each Licensed Product). For the
sole purpose of verifying amounts relating to this Agreement, Santarus shall have the right no more
than [***] each calendar year, at its own expense, to have agents or representatives of Santarus or
any of its licensors of Santarus Patents review such records for the [***] Calendar Quarters
preceding such review in the location(s) where such records are maintained by GSK and its
Affiliates upon reasonable notice and during regular business hours. Results of such review shall
be made available to GSK. The records and results of such audits shall be deemed Confidential
Information of GSK.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

20

 

In the event that such a review identifies an underpayment greater than [***] of the amounts
that were otherwise due for a [***] during such period, [***]. Further, if the review reflects an
underpayment to Santarus, such underpayment shall be promptly remitted to Santarus, together with
interest calculated in the manner provided in Section 7.4. If the review reflects an overpayment
to Santarus, such overpayment shall be credited against the next payment due Santarus. If the
review reveals an underpayment of more than [***] of the amounts due for any period of [***], GSK
shall reimburse Santarus for the costs of such audit.

ARTICLE 8

INTELLECTUAL PROPERTY RIGHTS

     8.1 Inventions.

          8.1.1 General. With respect to inventions and intellectual property arising during
the course of, or as a result of, each Party’s performance under this Agreement, (a) title to all
inventions and intellectual property made solely by GSK employees or its agents hereunder (each a
“GSK Invention”) shall be solely owned by GSK, (b) title to all inventions and intellectual
property made solely by Santarus employees or its agents hereunder (each a “Santarus Invention”)
shall be solely owned by Santarus, and (c) title to all inventions and intellectual property made
by jointly by GSK employees or agents and Santarus employees or agents shall be jointly owned.
Inventorship of inventions shall be determined in accordance with the laws of inventorship of the
country in which the patent applications directed to the relevant inventions are filed. Except as
expressly provided in this Agreement, it is understood that neither Party shall have any obligation
to account to the other for profits, or to obtain any approval of the other Party to license,
assign or otherwise exploit such jointly owned inventions or intellectual property, by reason of
joint ownership thereof, and each Party hereby waives any right it may have under Applicable Law of
any jurisdiction to require any such approval or accounting.

          8.1.2 GSK Option. In the event that Santarus (alone or with others) develops any
[***], then GSK shall have an option [***], to include all of Santarus’ intellectual property
rights (including Patents) in the GSK Territory thereto Controlled by Santarus within the Santarus
IP for all purposes of this Agreement, as set forth in this Section 8.1.2. Santarus hereby
covenants that it will use Commercially Reasonable Efforts, [***]. Promptly after [***], Santarus
shall notify GSK in writing describing the same and providing such Data in Santarus’ Control as may
be reasonably necessary to evaluate whether GSK desires to exercise its option described in this
Section 8.1.2. In such case, GSK shall notify Santarus in writing within [***] days of receipt of
Santarus’ notice as to whether it desires to exercise such option. If GSK so notifies Santarus
that it desires to exercise its option, then the Parties shall negotiate in good faith for a period
of at least [***] days to determine [***] that GSK shall be required to pay to Santarus, [***];
provided that if the Parties are unable for any reason to agree on such payment amount during such
period, then either Party may submit such issue for dispute resolution pursuant to Article 14.
Notwithstanding anything herein to the contrary, the option granted in this Section 8.1.2 shall not
include any [***] subject to payment obligations to a Third Party (and Santarus shall promptly
disclose such obligations to GSK in writing), unless GSK also agrees in writing to reimburse all
amounts owed to such Third Party as a result of GSK’s

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

21

 

exercise of its license rights to such [***]. In the event GSK does not exercise its option
with respect to a particular [***].

     8.2 Patent Prosecution.

          8.2.1 Santarus Patents. As between the Parties, Santarus shall have the right, to
control the Prosecution and Maintenance of the Santarus Patents using counsel of its choice and GSK
agrees to reimburse Santarus for Santarus’ reasonable out-of-pocket expenses (including amounts
reimbursed therefor to UMissouri or any other licensor of Santarus Patents) in connection with such
activities with respect to the GSK Territory as they are incurred. GSK may elect upon [***] prior
written notice to Santarus not to continue paying for Prosecution and Maintenance of any Santarus
Patent, in which case, the Patent shall be excluded from the Santarus Patents and all of GSK’s
license rights under such Patent shall cease as of the effective date of GSK’s notice. Santarus
agrees to keep GSK reasonably informed of such activities in the GSK Territory with respect to
claims that are subject to GSK’s license rights under this Agreement. GSK shall have the right to
advise and comment upon the prosecution of patent application claims that are subject to GSK’s
license rights under this Agreement in the GSK Territory. Santarus shall, in good faith, consider
and incorporate such advice and comments of GSK to the extent reasonably acceptable to Santarus and
its licensor of such patent application, if applicable. Upon the request of GSK, the Parties shall
discuss in good faith the filing at GSK’s expense of any continuation, continuation-in-part or
divisional to any patent or patent application within the Santarus Patents to be filed in the GSK
Territory beyond those Santarus may elect to file, which continuation, continuation-in-part or
divisional contains claims that are subject to GSK’s license rights under this Agreement.

          8.2.2 Joint Patents. The Parties shall jointly Prosecute and Maintain Patents
claiming inventions that are owned jointly by GSK and Santarus under Section 8.1.1, and each Party
agrees to take all reasonable action to cooperate fully with the other Party in this regard.
Except as otherwise provided in Section 8.2.1, each Party shall be responsible for fifty percent
(50%) of the out-of-pocket expenses in connection with Prosecution and Maintenance of jointly owned
Patents; provided that if either Party notifies the other Party in writing, referencing this
Section 8.2.2 and the applicable Patent that such Party elects not to be responsible for any
further costs under this Section 8.2.2, such Party shall not be required to reimburse the other
Party for its share of costs incurred under this Section 8.2.2 with respect to such Patent after
the date of receipt of written notice, and all right, title and interest in and to such Patent
(including any Patents issuing therefrom) shall be owned by the other Party, and such Patent shall
be excluded from the Santarus Patents for all purposes of this Agreement (subject to the licenses
granted to Santarus under this Agreement).

          8.2.3 Prosecute and Maintain. For purposes of this Section 8.2, “Prosecution and
Maintenance” shall mean, with respect to a Patent, the preparing, filing, prosecuting,
nationalizing, registering and maintaining such Patent, as well as re examinations, reissues,
confirmations, renewals, requests for Patent term extensions, supplemental protection certificates
and the like with respect to such Patent, together with the conduct of interferences, the defense
of oppositions and other similar proceedings with respect to the particular Patent; and “Prosecute
and Maintain” shall have the correlative meaning.

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

22

 

     8.3 Defense of Third Party Infringement Claims. If any Licensed Product developed,
manufactured or commercialized by or under authority of GSK or its Affiliates or Sublicensees
becomes the subject of a Third Party’s claim or assertion of infringement of a Patent relating to
the development, manufacture or commercialization of such Product for applications in the Field in
the GSK Territory, the Party first having notice of the claim or assertion shall promptly notify
the other Party in writing, and, without limiting GSK’s indemnification obligations under Section
10.2, the Parties shall promptly confer to consider the claim or assertion and the appropriate
course of action. Unless the Parties otherwise agree in writing, each Party shall have the right
to defend itself against a suit that names it as a defendant (the “Defending Party”). Neither
Party shall enter into any settlement of any claim described in this Section 8.3 that adversely
affects the other Party’s rights or interests without such other Party’s written consent, which
consent shall not be unreasonably conditioned, withheld or delayed. In any event, the other Party
shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending
Party’s request and expense.

     8.4 Enforcement of Santarus Patents.

          8.4.1 In-Licensed Patents. It is understood and agreed that, with respect to Patents
within the Santarus Patents that are owned by a Third Party and licensed to Santarus, the
provisions set forth in this Section 8.4 shall apply only to the extent consistent with Santarus’
rights under the applicable in-license for such Santarus Patents.

          8.4.2 General Enforcement. Each Party shall promptly notify the other Party in
writing of any actual or suspected infringement of any claim in a Santarus Patent in the GSK
Territory, which claim is subject to GSK’s license rights hereunder (including via unauthorized
importation into the GSK Territory for sale in the GSK Territory) or is subject to a declaratory
judgment action alleging non-infringement or unenforceability. Such notice shall specify in
reasonable detail the nature of such actual or suspected infringement or judicial action. GSK
shall not give notice (written or other) of infringement of any of the Santarus Patents to any
Third Party without Santarus’ prior written consent; provided, however, that GSK may give such
notice to a Third Party, without Santarus’ consent but upon [***] prior written notice to Santarus,
if (a) Santarus has declined to take steps to abate such infringement and GSK has the right to
enforce the Santarus Patents against such Third Party infringer as set forth in this Section 8.4.2;
or (b) disclosure is required by securities or other Applicable Laws to which GSK is subject; or
(c) disclosure is made in the course of a financial audit. Unless the Parties otherwise mutually
agree in writing, Santarus shall have the initial right, using counsel of its choice, to enforce
the Santarus Patents or defend any declaratory action with respect thereto (an “Enforcement
Action”), at its expense, and GSK shall give all reasonable assistance (excluding financial
assistance) to Santarus in such Enforcement Action, at Santarus’ expense. However, if (i) Santarus
elects in writing not to bring or defend an Enforcement Action with respect to any Licensed Product
in the GSK Territory for use in the Field for which GSK has license rights under this Agreement or
(ii) within [***] following a written request by GSK to do so and confirmation of facts reasonably
supporting existence of such actual or suspected infringement with respect to Licensed Products in
the Field and GSK Territory for which GSK has license rights under this Agreement, Santarus fails
to bring or defend an Enforcement Action or take other commercially reasonable action to protect
the Santarus Patents from such infringement, or to abate such infringement (which may in Santarus’
discretion include, without limitation, negotiations for a license (not in conflict with the
licenses granted GSK herein) from

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

23

 

Santarus for the manufacture, use or sale of Licensed Products to be sold outside the GSK
Territory), then GSK shall have the right, at its sole discretion, to institute an Enforcement
Action in its own name using counsel of its choice, at its own expense, and with the right to
control the course of such Enforcement Action (and Santarus shall provide all reasonable
assistance, other than financial, to GSK for such Enforcement Action, at GSK’s expense, including
joining such Enforcement Action if necessary to maintain the Enforcement Action, and Santarus shall
have the right to join and participate in the Enforcement Action whether or not such joinder is
requested by GSK).

          8.4.3 Recoveries. Any recovery received as a result of any Enforcement Action to
enforce a Santarus Patent pursuant to this Section 8.4 shall be used first to reimburse the Parties
for the costs and expenses (including attorneys’ and professional fees and amounts paid or payable
to the UMissouri) incurred in connection with such Enforcement Action (and not previously
reimbursed). Of any remaining amounts, the amount (if any) which is required to be paid to
UMissouri under the terms of the Missouri Agreement or any other licensors of the applicable
Santarus Patents under the terms of the respective in-license agreement, shall then be paid to
UMissouri or such other licensor, and any amounts remaining thereafter shall (a) to the extent
attributable to infringement of claims of the Santarus Patents in the GSK Territory for which
claims GSK has license rights under this Agreement), be shared [***] to [***] and [***] to [***]
and (b) to the extent not attributable to infringement of claims of the Santarus Patents in the GSK
Territory for which claims GSK has license rights under this Agreement, be distributed to, or
retained by, Santarus.

          8.4.4 Limits on Disposition. In no case may GSK enter into any settlement or consent
judgment or other voluntary final disposition that: (a) extends, or purports to exercise, GSK’s
rights under the Santarus IP beyond the rights expressly granted pursuant to this Agreement, (b)
makes any admission regarding wrongdoing by Santarus or UMissouri or any other licensor of Santarus
Patents, or the invalidity, unenforceability or absence of infringement of any Santarus Patents;
(c) subjects Santarus to an injunction or other equitable relief; or (d) obligates Santarus to make
a monetary payment; in all cases without the prior written consent of Santarus. Similarly, in no
case may Santarus enter into any settlement or consent judgment or other voluntary final
disposition that: (i) limits GSK’s rights under the Santarus IP or under this Agreement other than
as expressly stated herein; (ii) makes any admission regarding wrongdoing on the part of GSK, an
Affiliate or Sublicensee, or the invalidity, unenforceability or absence of infringement of any GSK
IP; (iii) subjects GSK to an injunction or other equitable relief; (iv) obligates GSK to make a
monetary payment; or (iv) extends, or purports to exercise, Santarus’ rights under the GSK IP
beyond the rights expressly granted pursuant to this Agreement; in all cases without the prior
written consent of GSK.

ARTICLE 9

REPRESENTATIONS AND WARRANTIES

     9.1 Representations and Warranties of Both Parties. Each Party hereby represents and
warrants to the other Party that, as of the Effective Date:

          9.1.1 Good Standing. Such Party is duly organized, validly existing and in good
standing under the Applicable Law of the state or country of its incorporation, is duly qualified
to

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

24

 

transact the business in which it is engaged in each jurisdiction where failure to be so
qualified would have a material adverse effect upon its business as currently conducted, and has
full corporate power and authority to enter into this Agreement and to carry out the provisions of
this Agreement.

          9.1.2 Power and Authority. Such Party has the requisite power and authority and the
legal right to enter into this Agreement, and to perform its obligations hereunder, and has taken
all necessary corporate action on its part to authorize the execution and delivery of the Agreement
and the performance of its obligations hereunder. All Persons who have executed this Agreement on
behalf of such Party, or who will execute on behalf of such Party any agreement or instrument
contemplated hereby, have been duly authorized to do so by all necessary corporate action.

          9.1.3 Binding Obligation. This Agreement has been duly executed and delivered on its
behalf and (assuming the due execution and delivery hereof by the other Party) each such agreement
is a legal and valid obligation binding upon it and is enforceable, in accordance with its terms,
to the extent provided under Applicable Law.

          9.1.4 No Conflicts. The execution and the delivery of this Agreement by such Party
and the consummation of the transactions contemplated hereby will not, to the best of such Party’s
knowledge, materially conflict with or result in a material breach of any of the terms, conditions
or provisions of, or constitute an express event of default under, any material instrument,
agreement, mortgage, judgment, order, award, or decree to which such Party is a party or by which
it is bound.

          9.1.5 Compliance with Applicable Law. Such Party and its Affiliates are, and will
ensure that they remain throughout the Term, in compliance in all material respects with all
requirements of Applicable Law.

          9.1.6 Litigation and Claims. There is no litigation, arbitration, claim, governmental
or other proceeding (formal or informal), or, to the knowledge of such Party, governmental
investigation pending or threatened in writing against such Party or any of its Affiliates which,
if adversely determined, would have a material adverse effect with respect to such Party performing
its obligations hereunder with respect to Licensed Products in or for the GSK Territory (except, in
the case of Santarus, as publicly disclosed by Santarus).

     9.2 Representations and Warranties of Santarus. Santarus hereby represents and
warrants to GSK that, as of the Effective Date:

          9.2.1 Right, Title and Interest. Except as provided in the Missouri Agreement or as
otherwise described on Exhibit 1.36, Santarus is the sole and exclusive owner or exclusive licensee
of the rights under each of the Santarus Patents granted to GSK pursuant to Section 2.1.1, and to
Santarus’ knowledge, all maintenance fees and annual payments due for the Santarus Patents have
been paid.

          9.2.2 No Third Party Claims. Santarus has not received any written claim or demand
from any Third Party alleging that any infringement, violation or misappropriation of such Third
Party’s intellectual property rights has occurred as a result of Santarus’ activities related to
the PR Product in the United States or the GSK Territory, nor is Santarus aware of any material
actual,

25

 

alleged or threatened infringement, violation or misappropriation by a Third Party of any of
the Santarus IP in the GSK Territory. There are no existing or, to Santarus’ knowledge, threatened
litigation actions, suits, claims, proceedings or governmental investigations in the GSK Territory
involving Licensed Products or Santarus Patents by or against Santarus or any of its Affiliates.

          9.2.3 Clinical and Regulatory Information. The clinical and regulatory data regarding
Licensed Products that Santarus has made available to GSK prior to the Effective Date is true and
accurate in all material respects, and Santarus has, to its knowledge as of the Effective Date,
[***].

          9.2.4 Pharmacovigilance Systems. The information contained in that certain
Self-Certification Regarding Santarus’ Pharmacovigilance Systems is true and accurate in all
material respects.

     9.3 No Reliance by Third Parties. The representations and warranties of a Party set
forth in this Agreement are intended for the sole and exclusive benefit of the other Party hereto,
and may not be relied upon by any Third Party.

     9.4 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 9,
SANTARUS AND GSK EXPRESSLY DISCLAIM ANY REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED, STATUTORY
OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING THE SANTARUS IP),
INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF
THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

ARTICLE 10

INDEMNIFICATION; INSURANCE AND LIMITATIONS

     10.1 Santarus Indemnification Obligations. Santarus will indemnify, defend and hold
harmless GSK, its Affiliates, and their respective officers, directors, trustees, agents, employees
and Sublicensees (collectively, “GSK Indemnitees”), from and against any and all losses,
liabilities, claims, obligations, demands, awards, settlements, penalties, fines, suits, damages,
costs (including costs of investigation, defense and enforcement of this Agreement), fees, taxes,
and expenses, including reasonable attorneys’ fees, experts’ fees and expenses, incurred or
suffered in respect of a claim or action of a Third Party (collectively, “Losses”), that are
incurred or suffered by the GSK Indemnitees or any of them by reason of, arising out of or in
connection with:

          (a) any breach of contract or negligence on the part of Santarus in performing Santarus’
obligations under this Agreement;

          (b) the distribution, marketing, advertisement, promotion or sale of Licensed Product in the
GSK Territory, by or under authority of Santarus after termination of this Agreement;

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

26

 

          (c) the distribution, marketing, advertisement, promotion or sale of Licensed Products outside
of the GSK Territory and outside of the Territory under the Distribution Agreement, including any
actual or alleged infringement of a Third Party’s intellectual property rights, by or under
authority of Santarus or its Affiliates; or

          (d) any violation of Applicable Law by Santarus in the performance of any of Santarus’
obligations under this Agreement;

provided, however, except in each case to the extent that such Loss is attributable to any matter
for which GSK is obligated to indemnify a Santarus Indemnitee as provided in Section 10.2.

     10.2 GSK Indemnification Obligations. GSK will indemnify, defend and hold harmless
Santarus, its Affiliates and licensors (including the UMissouri), and their respective officers,
directors, trustees, agents, curators and employees, inventors of, and sponsors of the research
that led to, any of the inventions covered by Santarus Patents, and their employees (collectively,
“Santarus Indemnitees”), from and against any and all Losses incurred or suffered by the Santarus
Indemnitees or any of them, by reason of, arising out of or in connection with:

          (a) any breach of contract or negligence on the part of GSK in performing GSK’s obligations or
permitted activities under this Agreement;

          (b) the manufacture, storage, handling, distribution, marketing, advertisement, promotion, use
or sale of Licensed Products by or under authority of GSK, its Affiliates or Sublicensees; or

          (c) any violation of Applicable Law by GSK in the performance of any of GSK’s obligations
under this Agreement;

provided, however, except in each case to the extent that such Loss is attributable to any matter
for which Santarus is obligated to indemnify a GSK Indemnitee as provided in Section 10.1.

     10.3 Indemnity Procedures. A Person entitled to indemnification pursuant to either
Section 10.1 or Section 10.2 will hereinafter be referred to as an “Indemnitee.” A Party obligated
to indemnify an Indemnitee hereunder will hereinafter be referred to as an “Indemnitor.” In the
event an Indemnitee is seeking indemnification under either Section 10.1 or Section 10.2, the
Indemnitee will inform the Indemnitor of a claim as soon as reasonably practicable after it
receives notice of the claim, it being understood and agreed that the failure by an Indemnitee to
give notice of a claim as provided in this Section 10.3 will not relieve the Indemnitor of its
indemnification obligation under this Agreement except and only to the extent that such Indemnitor
is actually prejudiced as a result of such failure to give notice. The Indemnitee will permit the
Indemnitor to assume direction and control of the defense of the claim (including, subject to this
Section 10.3, the right to settle the claim solely for monetary consideration to be paid by the
Indemnitor), and, at the Indemnitor’s expense, will co-operate as reasonably requested in the
defense of the claim. The Indemnitee will have the right to retain its own counsel at its own
expense; provided that, if the Indemnitor assumes control of such defense and the Indemnitee
reasonably concludes, based on advice from counsel, that the Indemnitor and the Indemnitee have
conflicting interests with respect to such action, suit,

27

 

proceeding or claim, the Indemnitor will be responsible for the reasonable fees and expenses
of counsel to the Indemnitee solely in connection therewith. The Indemnitor may not settle such
action or claim, or otherwise consent to an adverse judgment in such action or claim, in any manner
which admits liability or wrongdoing of the Indemnitee, or which would subject the Indemnitee to an
injunction, or if such settlement or judgment would materially diminish or limit or otherwise
adversely affect the rights, activities or financial interests of the Indemnitee, without the
express written consent of the Indemnitee.

     10.4 No Punitive or Exemplary Damages. EXCEPT FOR BREACHES OF THE OBLIGATIONS SET
FORTH IN SECTIONS 6.1, 6.2 AND 6.3 AND ARTICLE 12, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR
SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOSS OF PROFITS) SUFFERED BY THE
OTHER PARTY UNDER THIS AGREEMENT, EXCEPT TO THE EXTENT A PARTY IS REQUIRED TO INDEMNIFY THE OTHER
PURSUANT TO THIS ARTICLE 10 WITH RESPECT TO ANY SUCH DAMAGES PAID TO A THIRD PARTY AS PART OF A
CLAIM.

     10.5 Insurance.

          10.5.1 Santarus. Santarus shall maintain self insurance or comprehensive general
liability insurance (“CGL”), including broad form contractual liability, in an amount of at least
[***] Dollars (U.S. $[***]) and product liability coverage in an amount of at least [***] U.S.
Dollars (U.S. $[***]) for bodily injury and property damage. Santarus shall maintain such
insurance during the Term and thereafter for a period of [***]. Santarus shall give GSK at least
[***] notice of any cancellation or termination of such insurance. Santarus will furnish to GSK a
certificate of insurance evidencing such coverage (or evidence reasonably acceptable to GSK of
Santarus level of self-insurance) as of the Effective Date and upon reasonable request by GSK at
any time thereafter.

          10.5.2 GSK. Santarus acknowledges that GSK is self-insured. GSK shall maintain
self-insurance at levels at least consistent with the levels of insurance described for
Sublicensees in this Section 10.5.2 during the Term and for a period of [***] thereafter. GSK
shall ensure that its Sublicensees maintain CGL insurance, including broad form contractual
liability, in an amount of at least [***] U.S. Dollars (U.S. $[***]) and product liability coverage
in an amount of at least [***] U.S. Dollars (U.S. $[***]) for bodily injury and property damage
during the Term and thereafter for a period of [***]. GSK shall give Santarus at least [***] prior
written notice of any cancellation or termination of such insurance. The minimum level of
insurance set forth herein will not be construed to create a limit on GSK’s or its Sublicensees’
liability with respect to its indemnification obligations hereunder. GSK shall give Santarus at
least [***] notice of any cancellation or termination of such insurance. GSK will furnish to
Santarus a certificate of insurance evidencing such coverage (or evidence reasonably acceptable to
Santarus of GSK’s level of self-insurance) as of the Effective Date and upon reasonable request by
Santarus at any time thereafter.

ARTICLE 11

FORCE MAJEURE

     Any delays in performance by any Party under this Agreement, other than with respect to the
payment obligations, shall not be considered a breach of this Agreement if and to the extent caused

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

28

 

by Force Majeure. The Party suffering such Force Majeure event shall notify the other Party in
writing as soon as practicable of such inability and of the period for which such inability is
expected to continue, and any time for performance hereunder shall be extended by the actual time
of delay caused by the Force Majeure event; provided that the Party suffering such occurrence uses
Commercially Reasonable Efforts to mitigate any damages incurred by the other Party.

ARTICLE 12

CONFIDENTIALITY

     12.1 Confidential Information. GSK and Santarus each hereby recognize and acknowledge
that the other Party’s Confidential Information constitutes valuable and confidential information.
Subject to other express provisions of this Agreement, GSK and Santarus each agree as follows that
during the Term, and for a period of [***] years after the effective date of termination of this
Agreement for any reason:

                    (a) The Parties will not disclose, directly or indirectly, in any manner whatsoever to any
Third Parties any Confidential Information received from the other Party (the “Disclosing Party”)
without first obtaining the written consent of the Disclosing Party, and the other Party
(“Recipient”) will keep confidential, all of the Disclosing Party’s Confidential Information that
is disclosed to Recipient. Recipient agrees to use the same level of care in safeguarding the
Disclosing Party’s Confidential Information that Recipient uses with its own confidential
information of a similar nature, but in no event less than reasonable care. Recipient will
restrict disclosure of the Disclosing Party’s Confidential Information solely to those of its (or
its Affiliate’s) employees or representatives having a need to know such Confidential Information
in order to exercise a right granted or fulfill an obligation under, this Agreement.

                    (b) Both Parties shall ensure that each of their respective employees and representatives who
will have access to the Confidential Information of the Disclosing Party are bound by an agreement
to maintain such Confidential Information in accordance with the confidentiality obligations set
forth in this Article 12.

                    (c) Recipient will not use the Disclosing Party’s Confidential Information in any manner
whatsoever other than solely in connection with the performance of its obligations, or exercise of
its rights, under this Agreement in accordance with the terms and conditions set forth in this
Agreement.

                    (d) Except as permitted by this Article 12, GSK and Santarus each agree not to disclose any
terms or conditions of this Agreement or the existence of this Agreement to any Third Party without
the prior written consent of the other Party, provided that each Party will be entitled to disclose
the terms of this Agreement without such consent to its advisors and potential and existing
financing sources, acquirors/acquirees (including to the consultants and advisors of the
foregoing), and to others (including in the case of Santarus, to UMissouri and, in the case of GSK,
to potential and existing Sublicensees), in each case on a need-to-know basis and on the condition
that such Persons agree to keep such Confidential Information in accordance with the obligations
set forth in this Article 12. In addition, either Party may disclose the terms of this Agreement
to the

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

29

 

extent reasonably required by Applicable Law or by applicable rules of any national stock
exchange on which the shares of such Party are listed.

                    (e) In the event Recipient is requested pursuant to, or required by, Applicable Law to
disclose any of the Disclosing Party’s Confidential Information, it will notify the Disclosing
Party promptly in writing so that the Disclosing Party may seek a protective order or other
appropriate remedy or, in the Disclosing Party’s sole discretion, waive compliance with the
confidentiality provisions of this Agreement. At the Disclosing Party’s expense, Recipient will
co-operate in all reasonable respects, in connection with any reasonable actions to be taken for
the foregoing purpose. Recipient may, without liability, disclose the Confidential Information of
the other Party to the extent such disclosure is required under Applicable Law, and Recipient will
exercise reasonable efforts to obtain reliable assurances that confidential treatment will be
accorded to any of the Disclosing Party’s Confidential Information so disclosed.

                    (f) Upon the effective date of the termination of this Agreement for any reason, either Party
may request in writing, and the other Party will either: (i) promptly destroy all copies of the
requesting Party’s Confidential Information in the possession of the other Party and confirm such
destruction in writing to the requesting Party; or (ii) promptly deliver to the requesting Party,
at the other Party’s expense, all copies of such Confidential Information in the possession of the
other Party, provided, however, the other Party will be permitted to retain one (1) copy of the
requesting Party’s Confidential Information for the sole purpose of determining any continuing
obligations hereunder (or in the case of Santarus, fulfill its obligations under the Missouri
Agreement). Additionally, except as otherwise expressly provided herein, upon termination of this
Agreement for any reason, both Parties will immediately cease all use of the other Party’s
Confidential Information including, to the extent reasonably possible, removing all references to
such Confidential Information from its internal analyses, memoranda, compilations, studies or other
documents. All Confidential Information will continue to be subject to the terms of this Agreement
for the period set forth in this Section 12.1.

                    (g) Each Party represents and warrants to the other Party that it has all right, title and
ownership interest in and to its Confidential Information or it has the right to disclose its
Confidential Information to the other Party. Each Party may seek to enforce all rights and legal
remedies available under this Article 12 or by law, including injunctive relief, specific
performance and other equitable remedies in the event of a breach of the provisions of this Article
12 by the other Party.

                    (h) Notwithstanding the provisions of this Article 12, the Parties agree that nothing
contained in this Article 12 will prevent (i) GSK from disclosing any Santarus Confidential
Information, without obtaining Santarus’ prior consent, to any Affiliate of GSK or to any Third
Party who has a need to know such Confidential Information for the purposes of engaging in the
development, manufacture or commercialization of Licensed Products in the Field in the GSK
Territory in accordance with this Agreement; provided that such Affiliate or Third Party is bound
by obligations of confidentiality and non-use no less burdensome than those set forth in this
Agreement with respect to the Confidential Information, (ii) Santarus from disclosing any GSK
Confidential Information, without obtaining GSK’s prior consent, to UMissouri, as required under
the Missouri Agreement, or to any Affiliate of Santarus or to any Third Party who has a need to
know such

30

 

Confidential Information for the purposes of engaging in the development, manufacture or
commercialization of Licensed Products for sale outside of the GSK Territory; provided that such
Affiliate or Third Party is bound by obligations of confidentiality and non-use no less burdensome
than those set forth in this Agreement with respect to the Confidential Information or (iii)
Santarus from disclosing information or data related to Licensed Products in its filings or
submissions to Regulatory Authorities in connection with Licensed Products.

                    (i) The confidentiality obligations set forth in this Article 12 will supersede that certain
Confidentiality Agreement between GlaxoSmithKline Services Unlimited and Santarus dated [***]
(“Confidentiality Agreement”), and will govern any and all information disclosed by either Party to
the other pursuant thereto.

     12.2 Publicity. Any key announcements or publicity regarding the existence of this
Agreement or any terms or subject matter of this Agreement by either GSK or Santarus will be agreed
to by GSK and Santarus in writing in advance of any such announcement or publicity. The Party
preparing any such announcement, publicity or press release will provide the other Party with a
draft thereof reasonably in advance of disclosure so as to permit the other Party to review and
comment on such announcement, publicity or press release, unless Applicable Law otherwise requires
sooner public disclosure. The foregoing notwithstanding, the Parties have agreed on a press
release to announce the execution of this Agreement in the form attached as Exhibit 12.2, together
with a corresponding conference call script and question/answer outline for use in responding to
inquiries about this Agreement. Thereafter, GSK and Santarus may each disclose to Third Parties
the information contained in such press release and question/answer outline without the need for
further approval by the other Party. Each Party agrees that it will cooperate fully with the other
with respect to all disclosures regarding or arising out of the activities under this Agreement as
required by the U.S. Securities Exchange Commission (or any foreign equivalent thereof) and any
other governmental authority, including requests for confidential treatment of proprietary
information of either Party included in any such disclosure.

     12.3 Trial Data; Publication. To the extent that GSK conducts any clinical trials
permitted under the terms and conditions of this Agreement, GSK may post the data generated from
such trials in accordance with GSK’s corporate policy on Public Disclosure and Access to Clinical
Trial and Observational Study Information Data. [***].

ARTICLE 13

TERM AND TERMINATION

     13.1 Term. The term of this Agreement (the “Term”) will commence on the Effective
Date and, unless sooner terminated as provided in this Article 13, shall continue in effect until
GSK has no remaining royalty payment obligations to Santarus pursuant to Section 7.2.

     13.2 Termination for Material Breach. Each Party will be entitled to terminate this
Agreement in its entirety at any time during the Term by written notice to the other Party in the
event that the other Party is in material default or breach of any of its obligations hereunder,
and fails to remedy any such default or breach within sixty (60) days or, in the case of a failure
to pay amounts due hereunder, within fifteen (15) days (respectively, the “Cure Period”) after
written

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

31

 

notice thereof by the non-defaulting/non-breaching Party. If such default or breach is not
corrected within the applicable Cure Period, the non-defaulting/non-breaching Party will have the
right to immediately terminate this Agreement by giving written notice to the Party in default or
breach.

     13.3 Termination for Diligence Failure/Notice. Santarus may, upon written notice to
GSK referencing this Section 13.3, terminate this Agreement with respect to the applicable country
in the event of a Diligence Failure affecting such country as set forth in Section 4.2; provided
that GSK does not cure such Diligence Failure within sixty (60) days of such notice. In addition,
Santarus may terminate this Agreement with respect to any country, upon written notice to GSK
effective immediately, if GSK has given written notice pursuant to Section 4.1 that it does not
intend to launch or commercialize Licensed Products for applications in the Field in such country.

     13.4 Termination Without Cause.

          13.4.1 Mutual. The Parties may terminate this Agreement in its entirety at any time
and for any reason during the Term upon their mutual written agreement; or

          13.4.2 By GSK. GSK may terminate this Agreement in its entirety or with respect to
any particular country at any time and for any reason during the Term upon providing Santarus with
not less than six (6) months’ prior written notice referencing this Section 13.4.2 and specifying
termination of the Agreement in its entirety or the specific country(ies).

     13.5 Bankruptcy. Either Party may terminate this Agreement in its entirety at any
time during the Term by giving written notice to the other Party if the other Party files in any
court or agency pursuant to any statute or regulation of any state or country, a petition in
bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of the Party or of its assets, or if the other Party is served with an
involuntary petition against it, filed in any insolvency proceeding, and such petition will not be
dismissed with sixty (60) days after the filing thereof, or if the other Party proposes or is a
party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit
of creditors.

     13.6 General Effects of Expiration or Termination.

          13.6.1 Accrued Obligations. Expiration or termination of this Agreement for any
reason shall not release either Party from any obligation or liability which, at the time of such
expiration or termination, has already accrued to the other Party or which is attributable to a
period prior to such expiration or termination.

          13.6.2 Termination of License. Upon termination of this Agreement (but not
expiration), all rights and licenses granted to GSK pursuant to Section 2.1 shall concurrently
terminate, and Santarus shall thereafter have the right (itself or through Third Parties) to
continue the development, manufacture and commercialization of Licensed Products in the Field and
GSK Territory without obligation to GSK.

          13.6.3 Non-Exclusive Remedy. Notwithstanding anything herein to the contrary but
without limiting the last sentence of Section 4.2, termination of this Agreement by a Party shall
be without prejudice to other remedies such Party may have at law or equity.

32

 

          13.6.4 General Survival. Sections 4.6, 4.7, 6.1, 6.2, 7.6, 9.3 and 9.4 and Articles
10, 11, 12, 14 and 15 shall survive expiration or termination of this Agreement for any reason.
Additionally, in the event of an expiration of this Agreement in accordance with its terms, but not
earlier termination the following shall survive: Sections 2.3, 4.5, 6.3, 8.2 and 8.4. Except as
otherwise provided in this Section 13.6.4 or in Section 13.7 or 13.8, all rights and obligations of
the Parties under this Agreement shall terminate upon expiration or termination of this Agreement
for any reason.

          13.6.5 Termination Press Releases. In the event of any termination of this Agreement
(whether in its entirety or as to a particular country) for any reason, the Parties shall cooperate
in good faith to coordinate public disclosure, if any, of such termination and the reasons
therefor, and shall not, except to the extent required by Applicable Law or the rules of a
recognized stock exchange, disclose such information without the prior approval of the other Party,
such approval not to be unreasonably withheld, conditioned or delayed. To the extent possible
under the situation, the terminating Party shall provide the non-terminating Party with a draft of
any such public disclosure it intends to issue [***] Business Days in advance and with the
opportunity to review and comment on such statement, it being understood that if the
non-terminating Party does not notify the terminating Party in writing within such [***] Business
Day period (or such shorter period if required by Applicable Law or and the rules of a recognized
stock exchange and, in each case as notified to the non-terminating Party in writing) of any
reasonable objections, such disclosure shall be deemed approved, and in any event the Parties shall
work diligently and reasonably to agree on the text of any such proposed disclosure in an
expeditious manner. The principles to be observed in such disclosures shall be accuracy,
compliance with Applicable Law and regulatory guidance documents, reasonable sensitivity to
potential negative reactions to such news and the need to keep investors and others informed
regarding the Parties’ business and other activities. Accordingly in such situation, the
non-terminating Party shall not withhold, condition or delay its approval of a proposed disclosure
that complies with such principles.

     13.7 [***].

     13.8 Effects of Certain Other Terminations. If GSK electively terminates this
Agreement in its entirety or with respect to a particular country pursuant to Section 13.4.2,
Santarus terminates this Agreement for a particular country in accordance with Section 13.3, either
Party terminates this Agreement pursuant to Section 13.2 or either Party terminates for the other
Party’s bankruptcy pursuant to Section 13.5, then:

          13.8.1 Regulatory Filings. GSK shall promptly assign and transfer to Santarus or its
nominee all Regulatory Filings for Licensed Products in the country(ies) affected by such
termination (or the entire GSK Territory if termination of this Agreement in its entirety) that are
held or controlled by or under authority of GSK or its Affiliates or Sublicensees, and shall take
such actions and execute such other instruments, assignments and documents as may be necessary to
effect the transfer of rights under the Regulatory Filings to Santarus. GSK shall cause each of
its Sublicensees to transfer any such Regulatory Filings to Santarus if this Agreement terminates.
If Applicable Law prevents or delays the transfer of ownership of a Regulatory Filing to Santarus,
GSK shall grant, and does hereby grant, to Santarus an exclusive and irrevocable right of access
and reference to such Regulatory Filing for Licensed Products, and shall cooperate fully to make
the

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

33

 

benefits of such Regulatory Filings available to Santarus or its designee(s). Within [***]
after written notice of such termination, GSK shall provide to Santarus copies of all such
Regulatory Filings, and of all Data and other Know-How pertaining to the Licensed Products not
previously provided. Santarus shall be free to use and disclose such Regulatory Filings and other
items in connection with the exercise of its rights and licenses under this Section 13.8. In the
event that Santarus does not provide to GSK the identity of its nominee(s) within [***] of the
effective date of termination, GSK shall have the right to cancel the Regulatory Filings in the
relevant country(ies) for which such nominee was not provided.

          13.8.2 Technology Licenses. GSK hereby grants Santarus, effective upon the notice of
a termination described in this Section 13.8, a non-exclusive, irrevocable, fully paid up license
in the country(ies) effected by such termination (or the entire GSK Territory if termination of
this Agreement in its entirety), with the right to sublicense, under (a) any GSK IP; provided,
however the GSK IP shall not include any Patents or Know-How subject to payment obligations to a
Third Party, which GSK shall promptly disclose such obligations to Santarus in writing, unless
Santarus agrees in writing to reimburse all amounts owed to such Third Party as a result of
Santarus’ exercise of such license, and (b) any Know-How disclosed to Santarus under this Agreement
or developed or utilized by GSK in connection with the Licensed Products; in each case to make,
have made, use, sell, offer for sale and import Licensed Products.

          13.8.3 Trademarks. GSK hereby assigns and shall cause to be assigned to Santarus all
rights in and to any trademarks specific to one or more Licensed Products that GSK used with
Licensed Product(s) in the country(ies) affected by such termination (or the entire GSK Territory
if termination of this Agreement in its entirety). It is understood that such assignment shall not
include the name of GSK or any of its Affiliates or trademark for GSK or any Affiliate itself.

          13.8.4 Sublicensees. GSK’s sublicenses with respect to Licensed Products shall, at
the request of Santarus, be assigned to Santarus to the furthest extent possible in the
country(ies) effected by such termination (or the entire GSK Territory if termination of this
Agreement in its entirety). In the event Santarus does not request assignment of any such
sublicenses, then the rights of such Sublicensees with respect to Licensed Products shall terminate
upon termination of GSK’s rights with respect to Licensed Products.

          13.8.5 Transition Assistance. GSK agrees to fully cooperate, at its own expense, with
Santarus and its designee(s) to facilitate a smooth, orderly and prompt transition of the
development, manufacture and commercialization of Licensed Products to Santarus or its designee(s)
in the country(ies) effected by such termination (or the entire GSK Territory if termination of
this Agreement in its entirety). Without limiting the foregoing, GSK shall promptly provide
Santarus copies of customer lists, customer data and other customer information and marketing and
promotional materials relating to Licensed Products at GSK’s expense, which Santarus shall have the
right to use for any purpose related to Licensed Products. Upon request by Santarus, GSK shall
transfer to Santarus some or all quantities of Licensed Products in GSK’s or its Affiliates’
possession (as requested by Santarus) intended for sale in the country(ies) effected by such
termination (or the entire GSK Territory if termination of this Agreement in its entirety), within
[***] after the effective date of such termination; provided, however, that Santarus shall
reimburse GSK for the out-of-pocket costs that GSK actually incurred to manufacture or otherwise
acquire the

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

34

 

quantities so provided to Santarus. If any Licensed Product was manufactured by any Third
Party for GSK, or GSK had contracts with vendors which contracts are necessary or useful for
Santarus to take over responsibility for the Licensed Products in the country(ies) effected by such
termination (or the entire GSK Territory if termination of this Agreement in its entirety), then
GSK shall to the extent possible and requested in writing by Santarus, assign all of the relevant
Third-Party contracts to Santarus, and in any case, GSK agrees to cooperate with Santarus to ensure
uninterrupted supply of Licensed Products. If GSK or its Affiliate or Sublicensee manufactured any
Licensed Product at the time of such termination, then GSK (or its Affiliate or Sublicensee) shall
continue to provide for manufacturing of such Licensed Product for Santarus, at [***] therefor,
from the date of written notice of such termination until such time as Santarus is able, using
Commercially Reasonable Efforts to do so but no longer than [***] after the effective date of such
termination, to secure an acceptable alternative commercial manufacturing source from which
sufficient quantities of Licensed Product may be procured and legally sold in the country(ies)
effected by such termination (or the entire GSK Territory if termination of this Agreement in its
entirety).

          13.8.6 Return of Materials. Within [***] after the effective date of a termination of
this Agreement in its entirety, GSK shall destroy all tangible items comprising, bearing or
containing any Confidential Information of Santarus that are in GSK’s or its Affiliates’ possession
or control, and provide written certification of such destruction, or prepare such tangible items
of Confidential Information for shipment to Santarus, as Santarus may direct, at Santarus’ expense;
provided that GSK may retain one copy of such Confidential Information for its legal archives.

ARTICLE 14

DISPUTE RESOLUTION

     14.1 Informal Resolution. In the event of any dispute, controversy or claim arising
out of, relating to or in connection with any provision of this Agreement or the rights or
obligations of the Parties hereunder (a “Dispute”), the Parties will try to settle their
differences amicably between themselves as contemplated herein. Either Party may initiate such
informal dispute resolution by sending written notice setting forth in reasonable detail the nature
of the dispute (the “Dispute Notice”) to the other Party. Within thirty (30) days after such
notice, the President of GSK’s International Pharmaceutical business, or his/her designee with
authority to resolve such matter, and the Chief Executive Officer of Santarus, or his/her designee
with authority to resolve such matter, shall meet to negotiate in good faith a resolution to the
dispute within such thirty (30) day period. If such representatives are unable to promptly resolve
such disputed matter within the said thirty (30) days, either Party may thereafter initiate
arbitration proceedings in accordance with Section 14.2. The provisions of this Section 14.1 will
not restrict in any way the Parties’ rights to seek preliminary injunctive or other equitable
relief from any court having jurisdiction.

     14.2 Arbitration. If a dispute is unresolved following attempted informal dispute
resolution pursuant to Section 14.1, then either Party may initiate arbitration before a panel of
three (3) arbitrators in accordance with the commercial arbitration rules of the American
Arbitration Association (“AAA”) then in force; provided, however, that any dispute related to the
infringement, validity or enforcement of any intellectual property right shall be heard by a court
of competent jurisdiction in the country where such right exists. The following provisions shall
apply with respect to such arbitration:

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

35

 

          14.2.1 Arbitrators. Within thirty (30) days after receipt of the notice of
arbitration by the Party not initiating such arbitration, each Party shall appoint an arbitrator
who is independent of the Parties (which arbitrator shall have reasonable knowledge regarding the
pharmaceutical industry), and those two arbitrators shall appoint the third arbitrator within
thirty (30) days. In the event that the two (2) arbitrators are unable to agree on a third within
the required time, either Party may apply under the applicable rules of the AAA for the appointment
of that third arbitrator, and the selection of an arbitrator under such rules of the AAA shall be
final and binding on the Parties.

          14.2.2 Process. The Parties shall seek to timely appoint their respective arbitrators
and to have the full panel of three (3) arbitrators appointed within three (3) months after the
non-initiating Party received the notice of arbitration, and seek to conclude the arbitration
within nine (9) months after the full arbitration panel has been appointed. The arbitration panel
shall determine what discovery will be permitted; provided that the arbitration panel shall permit
such discovery as the panel deems necessary to permit a fair resolution of the dispute. The
arbitrators shall not order discovery against one Party of a type or nature that is not available
against the other Party. The place of arbitration shall be [***]. The arbitration shall be
conducted in the English language and all evidence shall be presented in English; provided that any
evidence original in a language other than English shall be provided in the original language with
a certified translation in English.

          14.2.3 Final and Binding. The Parties agree that the award rendered shall be final
and binding upon the Parties, and shall be the sole and exclusive remedy with respect to all
disputes, controversies, claims and counterclaims presented to the arbitrators (which shall not
include any dispute related to the infringement, validity or enforcement of any intellectual
property).

          14.2.4 Timing. The Parties and the arbitrators shall use all reasonable efforts to
complete any such arbitration within one (1) year from the filing of notice of a request for such
arbitration unless a Party can demonstrate to the arbitrators that the complexity of the issues or
other reasons warrant the extension of the one (1) year period. In such event, the arbitrators may
extend such period as reasonably required.

          14.2.5 Costs and Fees. [***]. In determining the appropriate remedy(ies) hereunder,
the arbitrators may take into account the number of prior breaches committed by a breaching Party,
the number of prior accusations of breaches alleged by the Parties and any prior breaches found to
be in bad faith.

          14.2.6 Not Public. The arbitration proceedings and the decision shall not be made
public without the joint consent of the Parties, and each Party shall maintain the confidentiality
of such proceedings and decision unless otherwise permitted by the other Party; provided either
Party makes such disclosures as are required to comply with Applicable Law.

     14.3 Courts. Nothing in this Agreement shall be deemed as preventing any Party from
seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over
the Parties and the subject matter of the dispute as necessary to protect any Party’s name,
proprietary information, trade secrets, know-how or any other proprietary rights. Judgment upon
any arbitration award hereunder may be entered in any court having jurisdiction, or application may
be made to

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

36

 

such court for judicial acceptance of the award or an order of enforcement, as the case may
be. The Parties hereby consent to the jurisdiction of the state and Federal courts in and for
[***].

ARTICLE 15

GENERAL PROVISIONS

     15.1 Compliance with Laws/Other. Notwithstanding anything to the contrary contained
herein, all rights and obligations of the Parties are subject to prior compliance with, and each
Party shall comply with, all Applicable Laws, including obtaining all necessary approvals required
by the applicable agencies of the governments of the United States and foreign jurisdictions with
respect to the export to, and sale in, certain countries of products and technologies. In this
regard, the Parties acknowledge that certain of the countries within the GSK Territory are
embargoed countries by United States which may prevent GSK from developing, manufacturing or
commercializing Licensed Products in such countries unless such embargo is lifted or GSK obtains
necessary waivers from the United States government.

     15.2 Notices. Notices required or permitted under this Agreement will be in writing
and sent by prepaid registered or certified air mail or by overnight express mail (e.g., FedEx), or
by facsimile (receipt confirmed and copy provided by prepaid registered or certified air mail
letter or by overnight express mail (e.g., FedEx)), and will be deemed to have been properly served
to the addressee upon receipt of such written communication, to the following addresses of the
Parties, or such other address as each Party may from time to time designate by written notice to
the other Party as set forth herein:

     If to Santarus:

Santarus, Inc.

10590 West Ocean Air Drive, Suite 200

San Diego, California 92130

Attention: President and CEO

Facsimile No.: 858-314-5701

     with a copy to:

Santarus, Inc.

10590 West Ocean Air Drive, Suite 200

San Diego, California 92130

Attention: Legal Affairs Department

Facsimile No.: [***]

     If to GSK:

GlaxoSmithKline Services Unlimited

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Attention : Senior Vice President Commercial Development GSK

 

			
	***  	 	 Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

37

 

Pharmaceuticals International

Facsimile No: — [***]

with a copy to:

GlaxoSmithKline Serrvices Unlimited

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

Attention : Senior Vice President Legal Operations International & Japan

Facsimile No: — [***]

     15.3 Governing Law. The form, execution, validity, construction and effect of this
Agreement will be governed by and construed in accordance with the laws of the State of New York,
without regard to the choice-of-law provisions thereof.

     15.4 Performance by Affiliates. The Parties recognize that each Party may perform
some or all of its obligations under this Agreement through Affiliates; provided, however, that
each Party will remain responsible for and guarantees the performance by its Affiliates and will
cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance. Each Party hereby expressly waives any requirement that the other Party exhaust any
right, power or remedy, or proceeds against an Affiliate, for any obligation or performance
hereunder prior to proceeding directly against such Party.

     15.5 Miscellaneous.

          15.5.1 Binding Effect. This Agreement will be binding upon and inure to the benefit
of the Parties and their respective legal representatives, successors and permitted assigns.

          15.5.2 Headings. Article and Section headings are inserted for convenience of
reference only and do not form a part of this Agreement.

          15.5.3 Counterparts. This Agreement may be executed simultaneously in two (2) or more
counterparts, each of which will be deemed an original.

          15.5.4 Entire Agreement; Amendment; Waiver. This Agreement, together with the
Distribution Agreement, constitutes the entire understanding of the Parties with respect to the
subject matter hereof and supersedes all previous writings and understandings, including the
Confidentiality Agreement. This Agreement may be amended, modified, superseded or cancelled, and
any of the terms may be waived, only by a written instrument executed by each Party or, in the case
of waiver, by the Party waiving compliance. No waiver by any Party of any condition or of the
breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or
more instances, will be deemed to be, or considered as, a further or continuing waiver of any such
condition or of the breach of such term or any other term of this Agreement.

 

			
	 ***   	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

38

 

          15.5.5 No Third Party Beneficiaries. Except as expressly provided in Sections 10.1
and 10.2 (in either case subject to Section 10.3), no Third Party, including any employee of any
Party to this Agreement, will have or acquire any rights by reason of this Agreement.

          15.5.6 Assignment and Successors. Neither party may assign or transfer its rights
under this Agreement or delegate its duties hereunder, by merger, sale of assets, operation of law
or otherwise, without the prior written consent of the other; provided, however, that (a) Santarus
may assign this Agreement without such consent in connection with the sale or transfer of all or
substantially all of its business or assets related to the Licensed Products, and (b) GSK may
assign this Agreement without such consent of Santarus to an Affiliate or an entity that is not a
Competing Third Party and which acquires all or substantially all of GSK’s pharmaceuticals
marketing and distribution business in the GSK Territory, whether by merger, sale of assets or
otherwise. Any attempted assignment, sale or transfer in violation of the prior sentence will be
void. Upon any permitted assignment or transfer of this Agreement by either Party, (i) the other
Party shall be given prompt written notice of such assignment and (ii) the assignee shall agree in
writing to be bound by the terms and conditions set forth herein.

          15.5.7 Severability. If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable, such provision
shall be considered severed from this Agreement, and it is the intention of the Parties that the
remainder of the Agreement will not be affected. The Parties will make a good faith effort to
replace any invalid or unenforceable provision with a valid and enforceable one which as closely as
possible achieves the objectives contemplated by the Parties when entering this Agreement.

          15.5.8 Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other commercially reasonable acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

          15.5.9 Relationship of the Parties. It is not the intent of the Parties hereto to
form any partnership or joint venture. Each Party will, in relation to its obligations hereunder,
be deemed to be and will be an independent contractor, and nothing in this Agreement will be
construed to give such Party the power or authority to act as agent for the other Party for any
purpose, or to bind or commit the other Party in any way whatsoever.

[The remainder of this page is intentionally left blank; signature page follows.]

39

 

     IN WITNESS WHEREOF, the Parties have caused this License Agreement to be executed by their
duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	GLAXO GROUP LIMITED	 	 	 	SANTARUS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Stephen J. Crookes
	 	 	 	By:
	 	/s/ Gerald T. Proehl
	 	 
	 

	 	 

Name: Stephen J. Crookes
	 	 	 	 	 	 

Name: Gerald T. Proehl	 	 
	 

	 	Title:   VP, Business Development — GSKI
	 	 	 	 	 	Title:   President and CEO	 	 

List of Exhibits:

     Exhibit 1.19: GSK Territory

     Exhibit 1.36: Santarus Patents

     Exhibit 12.2: Press Release

 

 

EXHIBIT 1.19

GSK TERRITORY

	 	 	 	 	 
	Afghanistan

	 	Guinea
	 	Paraguay
	Algeria

	 	Guinea Bissau
	 	Peru
	Angola

	 	Guyana
	 	Philippines
	Argentina

	 	Honduras
	 	Qatar
	Bahrain

	 	Hong Kong
	 	Rwanda
	Belize

	 	Indonesia
	 	Sao Tome & Principe
	Benin

	 	Iran
	 	Saudi Arabia
	Bhutan

	 	Iraq
	 	Senegal
	Bolivia

	 	Jordan
	 	Seychelles
	Botswana

	 	Kenya
	 	Sierra Leone
	Brazil

	 	South Korea
	 	Singapore
	Burkina Faso

	 	Kuwait
	 	Somalia
	Burundi

	 	Laos
	 	South Africa
	Cambodia

	 	Lebanon
	 	Sudan
	Cameroon

	 	Liberia
	 	Surinam
	Caribbean

	 	Libya
	 	Syria
	Central African Republic

	 	Madagascar
	 	Taiwan
	Chad

	 	Malawi
	 	Tanzania
	Chile

	 	Malaysia
	 	Thailand
	China

	 	Maldives
	 	Togo
	Colombia

	 	Mali
	 	Tunisia
	Comoros

	 	Mauritania
	 	Turkey
	Congo

	 	Mauritius
	 	UAE
	Costa Rica

	 	Mexico
	 	Uganda
	Cote d’lvoire

	 	Morocco
	 	Uruguay
	Djibouti

	 	Mozambique
	 	Venezuela
	DR Congo

	 	Myanmar
	 	Vietnam
	Ecuador

	 	Namibia
	 	Yemen
	Egypt

	 	Nepal
	 	Zambia
	El Salvador

	 	New Zealand
	 	Zimbabwe
	Equatorial Guinea

	 	Nicaragua	 	 
	Eritrea

	 	Niger	 	 
	Ethiopia

	 	Nigeria	 	 
	Gabon

	 	North Korea	 	 
	Gambia

	 	Oman	 	 
	Ghana

	 	Panama	 	 
	Guatemala

	 	Papua New Guinea	 	 

 

 

EXHIBIT 1.36

SANTARUS PATENTS

	 	 	 	 	 	 	 
	Title	 	Country	 	Application Number	 	Status/Notes
	MISSOURI PATENT PORTFOLIO	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	 	 	 	 	 	 
	Title	 	Country	 	Application Number	 	Status/Notes
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 
	[***]

	 	[***]
	 	[***]
	 	[***]
	 
	 	 	 	 	 	 

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT 12.2

PRESS RELEASE

 

 

	 	 	 	 	 
	COMPANY CONTACT:

	 	 
	 	INVESTOR CONTACT:
	Martha L. Hough

	 	 	 	Lippert/Heilshorn & Associates, Inc.
	VP Finance & Investor Relations

	 	 	 	Jody Cain (jcain@lhai.com)
	(858) 314-5824

	 	 	 	Eleanor Tang (etang@lhai.com)
	Debra P. Crawford

	 	 	 	(310) 691-7100
	Chief Financial Officer
	 	 	 	 
	(858) 314-5708
	 	 	 	 

For Immediate Release

SANTARUS LICENSES RIGHTS TO GLAXOSMITHKLINE FOR ZEGERID

IMMEDIATE-RELEASE OMEPRAZOLE PRODUCTS IN OVER 100 COUNTRIES

Santarus and GSK also sign distribution agreement for ZEGERID prescription products

in Puerto Rico and U.S. Virgin Islands

Conference call to begin at 5:00 p.m. Eastern time today

SAN DIEGO (December 3, 2007) — Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company,
today announced that it has entered into agreements granting exclusive rights to GlaxoSmithKline
plc (GSK), to commercialize prescription and over-the-counter immediate-release omeprazole products
(Licensed Products) for a number of markets in GSK’s International Region (including Africa, Asia,
the Middle-East, and Central and South America), and to distribute and sell ZEGERID®
brand prescription products in Puerto Rico and the U.S. Virgin Islands (USVI).

Under the license agreement, GSK will be responsible for the development, manufacture and
commercialization of Licensed Products in up to 114 countries, excluding the U.S., Europe,
Australia, Japan and Canada. In addition, under a separate distribution agreement, GSK will
distribute, market and sell ZEGERID brand prescription products in Puerto Rico and the USVI
beginning in the first quarter of 2008. GSK will bear all costs for its activities under the
license and distribution agreements.

GSK will pay Santarus an $11.5 million upfront fee and tiered double digit royalties, subject to
reduction in certain circumstances, on net sales of any products sold under the license and
distribution agreements. The term of the license agreement continues so long as GSK is obligated
to pay royalties and the term of the distribution agreement continues as long as GSK sells the
products, unless the agreements are terminated earlier by either GSK or Santarus under specified
circumstances. GSK has an option to make a buy-out payment 20 years after the effective date of
the agreements, after which time, GSK’s royalty obligations generally would end. To support GSK’s
initial launch costs, Santarus will waive the first $2.5 million of aggregate royalties payable
under the license and distribution agreements.

“As a leading global pharmaceutical company, GSK has well established international
commercialization capabilities. We believe its demonstrated success in the gastrointestinal
therapeutic area make GSK an ideal partner for Santarus in the covered markets,” said Gerald T.
Proehl, president and chief executive officer of Santarus. “We also believe this relationship with
GSK is a major advancement of our strategic objective to leverage our immediate-release proton pump
inhibitor intellectual property in international markets and to further diversify our potential
sources of future revenues.”

“This agreement combines GSK’s commercial strength in these countries with a great opportunity in
the form of ZEGERID immediate-release omeprazole products,” commented Dr. Russell Greig, President,
GSK Pharmaceuticals International.

 

 

      Conference Call

     Santarus has scheduled an investor conference call regarding this announcement at 5:00 p.m.
Eastern time (2:00 p.m. Pacific time) today, December 3, 2007. Individuals interested in
participating in the call may do so by dialing 888-803-8275 for domestic callers, or 706-643-7736
for international callers. A telephone replay will be available for 48 hours following conclusion
of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international
callers, and entering reservation code 26421314. The live conference call also will be available
via the Internet by visiting the Investor Relations section of the Santarus Web site at
www.santarus.com, and a recording of the call will be available on the company’s Web site for 14
days following the completion of the call.

      About Currently Marketed ZEGERID Prescription Products in the U.S.

     ZEGERID (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension contain a
combination of omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which
raises the gastric pH and thus protects the omeprazole from acid degradation.

     In the U.S., ZEGERID Capsules and ZEGERID Powder for Oral Suspension are indicated for the
treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD),
erosive esophagitis, and gastric and duodenal ulcers. ZEGERID Powder for Oral Suspension is also
indicated for the reduction of risk of upper gastrointestinal bleeding in critically ill patients.

     These ZEGERID products offer a distinct pharmacological profile — rapidly reaching maximal plasma
levels (in approximately 30 minutes) and providing strong acid control, with a median 24-hour
gastric pH of greater than 4 ranging from 12.2 hours to 18.6 hours, depending on the strength and
dosage form, after repeated once-daily dosing. ZEGERID can be conveniently taken once-a-day on an
empty stomach, at least one hour before a meal.

PPIs are widely prescribed for a variety of diseases and disorders of the upper digestive tract.
All currently marketed oral PPIs in the U.S., other than ZEGERID, are delayed-release formulations
that utilize an enteric coating to protect the PPI from acid degradation, thereby delaying
absorption and initial acid suppression. Unlike delayed-release PPIs, ZEGERID Capsules and Powder
for Oral Suspension utilize an antacid in lieu of an enteric coating. The antacid neutralizes
stomach acid and protects the PPI, omeprazole, from gastric acid degradation and allows for its
rapid absorption and suppression of gastric acid.

           Important Safety Information

     The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal
pain. In critically ill patients treated with ZEGERID, adverse events generally reflected the
serious, underlying medical condition of the patients, and were similar for patients treated with
ZEGERID and with the comparator (acid-controlling) drug. Symptomatic response to therapy does not
preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in
gastric corpus biopsies from patients treated long term with omeprazole.

 

 

     ZEGERID Capsules contain 303 mg of sodium per dose. ZEGERID Powder for Oral Suspension
contains 460 mg of sodium per dose. This should be taken into consideration for patients on a
sodium-restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis
and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any
component of the formulation.

     Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in
capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent
to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent
to, and should not be substituted for, one 40 mg packet.

     About Santarus

     Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and
commercializing proprietary products that address the needs of patients treated by
gastroenterologists or primary care physicians. The company’s current marketing efforts are
primarily focused on ZEGERID Capsules and Powder for Oral Suspension. These products are
immediate-release formulations of omeprazole, a widely prescribed PPI. More information about
Santarus is available on the company’s Web site at www.santarus.com.

Santarus cautions you that statements included in this press release that are not a description of
historical facts are forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by Santarus that any of its plans will be achieved.
Actual results may differ materially from those set forth in this release due to the risks and
uncertainties inherent in Santarus’ business, including, without limitation: risks related to the
license and distribution agreements with GSK, including the success of GSK’s development,
distribution, sales and marketing activities, GSK’s ability to obtain regulatory approvals in the
licensed international markets, GSK’s level of commitment and the potential for termination of one
or both of the agreements; the scope and validity of patent protection for ZEGERID and other
licensed products and Santarus’ and GSK’s ability to commercialize ZEGERID and other licensed
products without infringing the patent rights of others; unexpected adverse side effects or
inadequate therapeutic efficacy of ZEGERID or other licensed products that could delay or prevent
product development or commercialization, or that could result in recalls or product liability
claims; competition from other pharmaceutical or biotechnology companies; and other risks detailed
in Santarus’ prior press releases as well as in public periodic filings with the Securities and
Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

     Santarus® and ZEGERID® are registered trademarks of Santarus, Inc.exv10w21

 

Exhibit 10.21

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.

DISTRIBUTION AGREEMENT

PREAMBLE

     THIS DISTRIBUTION AGREEMENT (“Agreement”) is entered into as of the 30th day of November, 2007
(the “Effective Date”) by and between Santarus, Inc., a Delaware corporation, with its principal
place of business at 10590 West Ocean Air Drive, Suite 200, San Diego, CA 92130 (“Santarus”) and
Glaxo Group Limited, an English company with its principal place of business at 40 Berkeley Avenue
Greenford Middlesex United Kingdom on behalf of itself and its Affiliates (together “GSK”).
Santarus and GSK are sometimes collectively referred to herein as the “Parties” and individually as
a “Party”.

     WHEREAS, Santarus desires to engage GSK to exclusively promote and distribute PR Product (as
hereinafter defined) in the Territory (as hereinafter defined) to ensure that the PR Product is
available to those who need it and to permit GSK to utilize Santarus’ Trademarks (as hereinafter
defined) in connection with the promotion and distribution of PR Product in the Territory, and GSK
desires to be so engaged by Santarus, in each case in accordance with the terms and conditions of
this Agreement;

     WHEREAS, concurrently herewith, the Parties are entering into that certain License Agreement
(the “ROW License”) for the manufacture, development and commercialization of Licensed Products (as
defined in the ROW License) on the terms and conditions set forth therein; and

     WHEREAS, GSK desires to purchase from Santarus, and Santarus agrees to supply to GSK, initial
quantities of PR Product for GSK’s distribution in the Territory.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and
other good and valuable consideration, the receipt and legal sufficiency of which are hereby
mutually acknowledged, GSK and Santarus hereby agree as follows:

ARTICLE 1

DEFINITIONS

The following capitalized terms shall have the meanings set forth below when used in this
Agreement:

          1.1 “Adverse Event” means any untoward medical occurrence in a patient or clinical trial
subject who has been administered a PR Product, where the untoward medical occurrence is temporally
associated with the use of the PR Product, whether or not considered related to the PR Product. An
Adverse Event can therefore be any unfavourable and unintended sign

 

 

(including an abnormal laboratory finding) symptom or disease (new or exacerbated) temporally
associated with the use of a PR Product. For a marketed PR Product, this can also include failure
to produce expected benefits (i.e. lack of efficacy), and adverse events associated with
circumstances of abuse or misuse. In addition to the foregoing, in the context of clinical trials,
an Adverse Event will also mean events associated with or possibly attributable to the clinical
trial protocol design or clinical trial procedures.

          1.2 “Affiliate” with respect to any Person means any other Person, whether de jure or de
facto, that directly or indirectly, controls, is controlled by, or is under common control with
such first Person, as applicable, for as long as such control exists. Solely as used in this
definition, “control” means (a) direct or indirect ownership of more than fifty percent (50%) of
the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction) having the power to vote on or direct the affairs of such
Person, as applicable, or (b) the possession, directly or indirectly, of the power to direct or
cause the direction of the policies and management of such Person, as applicable, whether by the
ownership of stock, by contract, or otherwise.

          1.3 “Agreement” has the meaning set forth in the Preamble.

          1.4 “Anti-Kickback Statute” means the Medicare and Medicaid Anti-Kickback Statute set forth at
42 U.S.C. Section 1320a-7b(b).

          1.5 “API” means any active pharmaceutical ingredient in PR Product.

          1.6 “Applicable Law” means all applicable provisions of any and all Federal, national, state,
provincial, and local statutes, laws, rules, regulations, administrative codes, ordinances,
decrees, orders, decisions, injunctions, awards judgments, permits and licenses of or from
governmental authorities relating to or governing the use or regulation of the subject item,
including the Anti-Kickback Statute, the FD&C Act and the PDMA.

          1.7 “Authorized Manufacturer” has the meaning set forth in Section 5.3.

          1.8 “Business Day” means any day other than a day which is a Saturday, a Sunday or any day
banks are authorized or required to be closed in New York, New York.

          1.9 “Calendar Quarter” means each of the consecutive three (3) month periods ending March 31,
June 30, September 30, and December 31, as the case may be.

          1.10 “Certificate of Compliance” means the following document(s) from Santarus’ Third Party
manufacturer(s) of PR Products supplied in the Initial Supply: (a) the certificate of analysis
confirming the identity, strength, quality and purity of each invoiced batch of finished product to
which it pertains and (b) the certificate of manufacturing confirming that each invoiced batch of
PR Product was manufactured, tested, stored and supplied by such Third Party manufacturer in
compliance with its agreement with Santarus, including applicable Specifications, Good
Manufacturing Practices and Applicable Law.

-2-

 

          1.11 “Commercially Reasonable Efforts” means those diligent efforts and resources, with
respect to a particular Party, at the relevant point in time, that are comparable to those
generally used by that Party, in good faith, in the exercise of its reasonable and prudent business
judgment relating to other prescription pharmaceutical products owned or licensed by it or to which
it has exclusive rights in the Territory, which have market potential and are at a stage of product
life similar to the PR Product in the Territory, taking into account measures of relative safety
and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of
the compound or product, the regulatory structure involved, the relative profitability of the
products and other relevant factors including comparative technical, scientific or medical factors.
Such Commercially Reasonable Efforts shall include (i) promptly assigning responsibility for
manufacturing and commercialization activities to specific employees who are held accountable for
progress and monitoring such progress on an on-going basis, (ii) setting and consistently seeking
to achieve specific and meaningful objectives and timelines for carrying out such manufacturing and
commercialization activities, (iii) consistently making and implementing decisions and allocating
resources designed to advance progress with respect to such objectives and timelines, and (iv)
employing compensation systems for its employees working with the PR Product that are similar to
the compensation systems the applicable Party applies with respect to its other programs with
products of similar potential. With respect to PR Products for the Territory, “Commercially
Reasonable Efforts” shall also require active, on-going activities by, or under authority of, GSK
in connection with the marketing, promotion, advertisement, sale and distribution of PR Product in
the Territory.

          1.12 “Confidential Information” means any and all information disclosed to or obtained by
Recipient pursuant to or in connection with the negotiation, execution, delivery and performance of
this Agreement or the consummation of the transactions contemplated hereby and any and all
information regarding, related to, or associated with any or all elements of this Agreement,
including the PR Product or each Party’s operations, that is disclosed by the Disclosing Party to
the Recipient; provided, however, that Confidential Information will not include information which:
(a) at the time of disclosure is in the public domain; (b) after disclosure becomes part of the
public domain, except through breach of this Agreement; (c) the Recipient can demonstrate by
reasonable proof was in its possession prior to the time of disclosure by the Disclosing Party
hereunder, and was not acquired directly or indirectly from the Disclosing Party; (d) the Recipient
can demonstrate by reasonable proof was developed by or on behalf of Recipient independent of and
without reference to the Disclosing Party’s Confidential Information; or (e) becomes available to
Recipient from a Third Party who did not acquire such information directly or indirectly from the
Disclosing Party and who is not otherwise prohibited from disclosing such information.

          1.13 “Confidentiality Agreement” has the meaning set forth in Section 11.1(h).

          1.14 “Cure Period” has the meaning set forth in Section 12.2.

          1.15 “Customers” means Third Party purchasers of PR Product in the Territory.

-3-

 

          1.16 “DDMAC” means the FDA’s Division of Drug Marketing, Advertising and Communications or any
successor agency having similar jurisdiction with respect to PR Product in the Territory.

          1.17 “Data” means any and all research and development data, such as preclinical data,
pharmacology data, chemistry data (including analytical, product characterization, manufacturing,
and stability data), toxicology data, clinical data (including investigator reports (both
preliminary and final), statistical analyses, expert opinions and reports, safety and other
electronic databases), together with supporting data, in each case specifically directed to, or
used in the development of, a PR Product. For clarity, “Data” includes results from any
post-approval clinical studies of PR Products.

          1.18 “Disclosing Party” has the meaning set forth in Section 11.1(a).

          1.19 “Dispute” has the meaning set forth in Section 13.1.1.

          1.20 “Dispute Notice” has the meaning set forth in Section 13.1.1.

          1.21 “Effective Date” means the date first set forth in the Preamble.

          1.22 “FDA” means the United States Food and Drug Administration, or any successor agency
having similar jurisdiction with respect to the PR Product in the Territory.

          1.23 “FD&C Act” means the Federal Food, Drug and Cosmetic Act, as amended, and the regulations
promulgated thereunder from time to time.

          1.24 “FSS” has the meaning set forth in Section 2.2.1.

          1.25 “Force Majeure” means occurrences beyond the reasonable control of the Party affected,
including acts of God, embargoes, governmental restrictions, terrorism, materials shortages or
failure of any supplier (where such shortage or failure is attributable to an event of Force
Majeure suffered by such supplier, except that such shortage or failure need not be attributable to
an event of Force Majeure suffered by such supplier with respect to Santarus’ obligations in
connection with Initial Supply of PR Product), fire, flood, explosion, earthquake, hurricanes,
storms, tornadoes, riots, wars, civil disorder, failure of public utilities or common carriers,
labor disturbances, rebellion or sabotage.

          1.26 “GAAP” means United States generally accepted accounting principles, consistently
applied.

          1.27 “Generic Product” means a pharmaceutical product sold by a Third Party in the Territory,
which pharmaceutical product (a) contains the same APIs as the applicable PR Product being sold in
the Territory by GSK under this Agreement, (b) is bioequivalent to the applicable PR Product being
sold in the Territory by GSK under this Agreement with respect to pharmacokinetic properties and is
AB rated as such by the FDA, (c) is the same dosage form, route of administration and strength of
the applicable PR Product being sold in the Territory by GSK under this Agreement

-4-

 

and sold for the same indication as the PR Product and (d) lawfully being sold in the
Territory by the Third Party under an FDA approved Abbreviated New Drug Application (“ANDA”) or any
equivalent approval as may be available at the time; provided, however, that “Generic Product”
shall not include any OTC Product

          1.28 “Good Manufacturing Practices” means all current good manufacturing practices that apply
to the manufacture of API and clinical or commercial supply of PR Product for the Territory,
including the United States regulations set forth under Title 21 of the United States Code of
Federal Regulations, parts 210 and 211, as may be amended from time-to-time, as well as all
applicable guidance published from time-to-time by the FDA and the International Conference on
Harmonisation Guidelines ICHQ7A Good Manufacturing Practice Guidance for API.

          1.29 “Governmental Authority” means any Federal, state, local or foreign governmental
authority, regulatory agency or other governmental body in the Territory.

          1.30 “GSK” has the meaning set forth in the Preamble.

          1.31 “GSK Indemnitees” has the meaning set forth in Section 9.1.

          1.32 “GSK IP” means (a) any patents and patent applications owned or controlled by GSK or its
Affiliates covering any [***] and (b) any know-how [***].

          1.33 “Important Medical Event” means an Adverse Event that may not be immediately
life-threatening or result in death or hospitalisation but may jeopardise the subject or require
medical or surgical intervention to prevent one of the outcomes listed in (a) — (e) of the
definition of Serious Adverse Event. Examples of such events include invasive or malignant
cancers, intensive treatment (in an emergency room or at home) for allergic bronchospasm, blood
dyscrasias or convulsions that do not result in hospitalisation, or the development of drug
dependency or abuse, overdose or misuse.

          1.34 “Ineligible Person” means an individual or entity who: (a) is currently excluded,
debarred, suspended or otherwise ineligible to participate in the Federal health care programs or
in Federal procurement or nonprocurement programs, or (b) has been convicted of a criminal offense
that falls within the ambit of 42 U.S.C. 1320a-7(a), but has not yet been excluded, debarred,
suspended or otherwise declared ineligible.

          1.35 “Indemnitee” has the meaning set forth in Section 9.3.

          1.36 “Indemnitor” has the meaning set forth in Section 9.3.

          1.37 “Intellectual Property” means all proprietary materials, ideas, inventions, data,
instructions, processes and other information, and all patents and patent applications, in
existence as of the Effective Date or during the Term, that are owned or controlled by Santarus and
generally or specifically claim or cover the manufacture, use, sale or importation of the PR
Product.

          1.38 “Losses” has the meaning set forth in Section 9.1.

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-5-

 

          1.39 “Managed Care Market” means any health maintenance organizations, private health
insurers, pharmaceutical benefit managers, government payors (including Medicare Part D and
Reforma), long-term care providers, organized employer formularies, group purchasing organizations
or other organized buyer groups, which group purchasing organizations or other organized buyer
groups are not themselves retailers or wholesalers of PR Product.

          1.40 “Manufacturing Cost” means all amounts paid or payable by a Party to Third Parties (or to
Santarus with respect to GSK’s Manufacturing Cost for Initial Supply) for manufacture, packaging,
handling, storage, shipment or insurance of PR Products, including any amounts for raw materials or
API, all the foregoing as calculated in accordance with GAAP.

          1.41 “Missouri Agreement” means that certain Exclusive License Agreement between Santarus and
the Curators of the University of Missouri (“UMissouri”) effective as of January 26, 2001, as
amended from time to time.

          1.42 “NDA” means a New Drug Application filed with the FDA for any pharmaceutical product,
requesting permission to place such pharmaceutical product on the market in accordance with 21 CFR
Part 314, and all amendments or supplements filed pursuant to the requirements of the FDA,
including all documents, data and other information concerning such product which are necessary for
FDA approval to market such product in the Territory.

          1.43 “NDC” means National Drug Code.

          1.44 “Net Sales” means the gross amount invoiced by GSK and its Affiliates and any permitted
sub-distributors (the “Selling Party”) to Third Parties for the sales of PR Products in the
Territory. To the extent that the gross amounts invoiced by the Selling Party for such sales of PR
Products do not already reflect deductions or exclusions of the following amounts, the following
may be deducted in calculation of Net Sales, in accordance with GAAP, to the extent such deductions
are at rates customary within the industry and the Territory:

          (i) [***];

          (ii) [***]; and

          (iii) [***].

Net Sales shall not include sales of PR Products between and among GSK and its Affiliates and
permitted sub-distributors who are not wholesalers; provided, however, that Net Sales shall include
the amounts invoiced by the Selling Party (with applicable deductions as set forth above) upon any
resale of such PR Products to a Third Party. With respect to PR Products, if any, that are sold in
“bundles” with other products or services, if the amount invoiced for the applicable PR Products
represents a discount greater than the average discount for all products and services in the
applicable “bundle,” then Net Sales for such “bundled” PR Product shall be determined using a sales
price based on [***].

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-6-

 

References in this Agreement to Santarus’ Net Sales shall have the same meaning set forth above
with respect to the applicable Santarus sales of PR Product with all references above to GSK being
changed to Santarus.

          1.45 “NOV” means a notice of violation, otherwise known as an “untitled letter” sent by DDMAC.

          1.46 “OTC Product” means any pharmaceutical product containing omeprazole as an active
ingredient formulated in combination with one or more buffering agents and for which a prescription
from a health care practitioner is not required in order to dispense, purchase or use such product
in the Territory.

          1.47 “Party” or “Parties” has the meaning set forth in the Preamble.

          1.48 “PDMA” means the Prescription Drug Marketing Act of 1987, as amended, and the regulations
promulgated thereunder from time to time.

          1.49 “Person” means any individual, corporation, partnership, firm, association, joint
venture, joint stock company, trust or other entity, or any government or regulatory administrative
or political subdivision or agency, department or instrumentality thereof.

          1.50 “PhRMA Code” means the PhRMA Code on Interactions with Health Care Professionals, as
amended.

          1.51 “PPI” means any proton pump inhibitor, e.g. omeprazole.

          1.52 “PPI Pharmaceutical Product” means a pharmaceutical product containing one or more PPIs
as active pharmaceutical ingredients.

          1.53 “PR Product” means the pharmaceutical product with omeprazole and sodium bicarbonate as
the active ingredients, as more particularly specified under the following NDAs: NDA #21-849
(capsules) and NDA #21-636 (powder for oral suspension). For the purposes of clarity, “PR
Product” shall be limited to drug product for which a prescription from a health care practitioner
is required in order to dispense, purchase or use such PR Product, and shall exclude any OTC
Product. As of the Effective Date, the PR Product is known as “Zegerid” and is marketed solely in
20 mg and 40 mg powder for oral suspension and capsule dosage forms. “PR Product” also includes
any PR Product Improvements containing omeprazole as one of the active ingredients to be included
as PR Products pursuant to Section 4.3.

          1.54 “PR Product Action” means a recall, field alert, product withdrawal or other field action
relating to PR Product in the Territory.

          1.55 “PR Product Registration” means the approvals or registrations for the PR Product which
have been received by Santarus from Governmental Authorities for the Territory, as the same may be
amended or modified from time to time, including any applicable drug master file and NDA for the PR
Product.

-7-

 

          1.56 “Promotional Activities” has the meaning set forth in Section 3.2.1.

          1.57 “Promotional Materials” has the meaning set forth in Section 3.2.1.

          1.58 “Quality Agreement” means the agreement on standard and customary terms and conditions
detailing the process for and allocation of responsibilities for various activities related to PR
Product release, compliance with Good Manufacturing Practices and the like to be entered into by
the Parties pursuant to Section 5.2.8.

          1.59 “Recipient” has the meaning set forth in Section 11.1(a).

          1.60 “Royalty Term” means the period for which GSK is obligated to pay royalties hereunder, as
set forth in Section 6.2.4.

          1.61 “Santarus” has the meaning set forth in the Preamble.

          1.62 “Santarus Indemnitee” has the meaning set forth in Section 9.2.

          1.63 “Serious Adverse Event” means an Adverse Event which (a) results in death; (b) is
life-threatening; that is, an event where the patient or clinical trial subject was at risk of
death at the time of the event: it does not refer to an event that, hypothetically, might have
caused death if it had been more severe; (c) requires hospitalisation or prolongation of existing
hospitalisation; (d) results in persistent or significant disability or incapacity; (e) is a
congenital anomaly or birth defect; (f) is an Important Medical Event or (g) involves suspected
transmission via a PR Product of an infectious agent.

          1.64 “Specifications” means the applicable specifications for PR Product set forth in the PR
Product Registration.

          1.65 “Term” has the meaning set forth in Section 12.1.

          1.66 “Territory” means the Commonwealth of Puerto Rico and the U.S. Virgin Islands

          1.67 “Third Party” means any Person other than the Parties or their respective Affiliates.

          1.68 “Trademarks” means the ZEGERID(R) trademark(s) set forth on Schedule 1.68, and the
corporate name and logo of Santarus, as and to the extent such marks appear on the drug product,
packaging, labeling or Promotional Materials for the PR Product provided to GSK hereunder by
Santarus or an Authorized Manufacturer.

          1.69 “United States” or “U.S.” means the fifty (50) states of the United States of America and
its territories and possessions, including the District of Columbia, but excluding the Commonwealth
of Puerto Rico and the U.S. Virgin Islands.

-8-

 

          1.70 General Interpretation. Except where the context requires otherwise, (a) the use
of any gender herein shall be deemed to be or include the other gender, (b) the use of the singular
shall be deemed to include the plural (and vice versa), (c) the word “or” is used in the inclusive
sense typically associated with the phrase “and/or,” (d) the words “include”, “includes” and
“including” shall be deemed to be followed by the phrase “without limitation” and shall not be
construed to limit any general statement which it follows to the specific or similar items or
matters immediately following it, (e) the word “will” shall be construed to have the same meaning
and effect as the word “shall,” (f) the words “under authority” shall mean, with respect to a
Person, any other Person (including with respect to GSK, its Affiliates and any sub-distributors)
acting, directly or indirectly, within the scope of authorization or engagement of the first
Person; for clarity, an Affiliate of a Party shall be deemed to be acting “under authority” of such
Party for all purposes hereunder, however neither Party or its Affiliates shall be deemed to be
acting “under authority” of the other Party or the other Party’s Affiliates for any purposes of
this Agreement; (g) any definition of or reference to any agreement, instrument or other document
herein shall be construed as referring to such agreement, instrument or other document as from time
to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (h) any reference herein to any Person
shall be construed to include the Person’s successors, heirs and assigns, (i) the words “herein”,
“hereof” and “hereunder”, and words of similar import, shall be construed to refer to this
Agreement in its entirety and not to any particular provision hereof, (j) all references herein to
Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections,
Exhibits and Schedules of this Agreement, and references to this Agreement include all Exhibits and
Schedules hereto; and (k) references to any specific law or article, section or other division
thereof shall be deemed to include the then-current amendments thereto or any replacement or
successor law thereof. Each accounting term used in this Agreement that is not specifically
defined in this Agreement shall have the meaning given to it under GAAP, but only to the extent
consistent with its usage and the other definitions in this Agreement, and all calculations
hereunder shall be made in accordance with GAAP.

ARTICLE 2

APPOINTMENT OF PROMOTION AND DISTRIBUTION RIGHTS; RIGHTS AND

LIMITATIONS

          2.1 Appointment of Promotion and Distribution Rights.

               2.1.1 Appointment. Subject to the terms and conditions of this Agreement, Santarus
hereby appoints GSK as Santarus’ exclusive distributor of PR Product in the Territory and, in
connection therewith, grants to GSK the exclusive right (except as provided in Section 2.2.3) to
market, promote, advertise, sell and distribute PR Product in the Territory. In connection with
the foregoing, Santarus grants to GSK a license under the Intellectual Property and a license under
the Trademarks as set forth in Section 3.3 to sell and offer to sell PR Product in the Territory in
accordance with such appointment. The appointment and license made in the preceding sentences will
commence on the Effective Date and continue throughout the Term, and for clarity, such appointment
will not survive past any termination of this Agreement.

-9-

 

               2.1.2 Manufacture by Santarus or Authorized Manufacturer. All PR Product sold or
distributed by or under authority of GSK in the Territory during the Term shall be manufactured by
an Authorized Manufacturer in accordance with the terms and conditions of this Agreement (or, in
the case of the Initial Supply, supplied by Santarus as set forth herein). No other right to
manufacture the PR Products is conveyed to GSK hereunder. For clarity, Santarus will retain the
right (itself or through Third Parties) to manufacture in the Territory, and to ship through
distribution channels in the Territory, PR Product for sale outside the Territory.

          2.2 Certain Limitations.

               2.2.1 Territorial Limitations. GSK agrees that it shall, and will cause its
Affiliates and any permitted sub-distributors to, conduct marketing, promotion, advertisement, sale
and distribution of PR Product solely in the Territory. GSK shall not, and will cause its
Affiliates and any permitted sub-distributors not to, sell, market, promote, advertise or
distribute PR Product in the United States or elsewhere outside the Territory. GSK shall not, and
will cause its Affiliates and any permitted sub-distributors not to, knowingly sell or otherwise
offer PR Product, directly or indirectly, to any Customer for resale outside the Territory, or to
any Customer that GSK (or its Affiliate or permitted sub-distributor) reasonably believes is going
to sell such PR Product, directly or indirectly, outside the Territory, unless mutually agreed in
writing upon by both Parties. GSK and its Affiliates shall not negotiate, or enter into, any
contract for sale of PR Product to any Person purchasing PR Products under the Federal Supply
Schedules (also sometimes known as GSA Schedules or Multiple Award Schedules) of the Federal Supply
Service of the United States General Services Administration (“FSS”) or to the United States
Government or any of its subdivisions (whether or not under the FSS), and shall not negotiate any
FSS price for the PR Product.

               2.2.2 Sales Outside Territory. Subject to Applicable Law, GSK will implement
reasonable safeguards so that PR Product is sold to Customers for resale only in the Territory and
not for resale anywhere outside the Territory. These safeguards shall include GSK’s ordinary
practice of managing Customer inventories by, for example, monitoring Customer ordering patterns in
order to discern Customer orders which may include PR Product for resale outside of the Territory.
GSK shall notify Santarus in writing of any such orders within [***] days after receipt thereof and
provide additional information regarding any such orders as reasonably requested by Santarus within
[***] days after receipt of Santarus’ written request therefor. If GSK becomes aware that any of
its Customers has shipped PR Product outside the Territory, or has reason to believe that a
Customer intends to ship PR Product outside the Territory, GSK, to the extent permitted by
Applicable Law, will take Commercially Reasonable Efforts to cause such Customer to cease such
activities. GSK shall, within [***] days after learning that any PR Products sold by GSK under
this Agreement have been sold or dispensed outside of the Territory, notify Santarus in writing of
all pertinent information relating thereto, including the amount of GSK’s Net Sales for such PR
Products. In any such situation, GSK shall be required to pay Santarus an amount equal to [***].
GSK shall use Commercially Reasonable Efforts, to the extent permitted by Applicable Law, to (a)
contractually prohibit each of its wholesalers of PR Product and group purchasing organizations
from shipping PR Product outside of the Territory, (b) contractually require each of its
wholesalers and group purchasing organizations to provide notice to GSK (which GSK shall provide to
Santarus) of any solicitations from Third Parties to sell, trade or otherwise provide PR Product to
the

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-10-

 

wholesaler, (c) contractually require each of its wholesalers to contractually prohibit
wholesalers and group purchasing organizations purchasing PR Product from taking the actions listed
in (a) above and (d) enforce the prohibitions and requirements set forth in clauses (a), (b) and
(c) above. The Parties have agreed in a separate letter agreement of even date hereof, the terms
and conditions of which letter agreement are incorporated herein, the form and timing of reports
whereby GSK shall provide Santarus with data in accordance with its obligations under this Section
2.2.2. In the event a PR Product becomes subject to price controls by Puerto Rico’s Department of
Consumer Affairs or other Governmental Authorities in the Territory, the Parties shall discuss in
good faith the implementation of further safeguards by GSK than those set forth in this Section
2.2.2 to prevent resale of PR Product outside of the Territory. To the extent that GSK receives
reports relating to its or wholesaler sales of PR Product in the Territory, GSK shall promptly
provide copies of these reports to Santarus.

               2.2.3 Santarus. Santarus agrees that it will not sell or distribute PR Product in the
Territory, except as set forth in this Section 2.2.3. Except as set forth in this Section 2.2.3,
Santarus will not knowingly sell or otherwise offer PR Product to any Third Party that Santarus
reasonably believes is going to sell such PR Product, directly or indirectly, in the Territory,
unless mutually agreed in writing by both Parties. If Santarus becomes aware that any of its
customers has shipped PR Product to the Territory or has reason to believe that a customer intends
to ship PR Product to the Territory, it will review with GSK the level of sales of PR Products in
such circumstances, and where the level of such sales exceeds that which occurs in the normal
course of business, GSK and Santarus shall discuss the situation in good faith, with the objective
to confirm that the tracking processes described in the letter agreement referenced in Section
2.2.2 are adequate in light of such sales and other related business considerations arising from
such sales. It is acknowledged by the Parties that (i) certain sales of PR Products outside the
Territory by Santarus to managed care organizations, group purchasing organizations, pharmacy
benefit managers or similar purchasers or retailers (including, for example, [***]), or their
Affiliates, may result in PR Products being shipped to, sold and dispensed to patients in the
Territory (such sale or dispensing in the Territory referred to as an “Inter-Territory Sale”), and
(ii) certain sales of PR Product outside the Territory by Santarus to Persons purchasing PR
Products under the FSS or the United States Government, or to any of its subdivisions (whether or
not purchasing under the FSS), may result in PR Product being shipped to military bases and other
government installations that are in the Territory, and in each case such sales will not constitute
a breach of this Agreement. With respect to Inter-Territory Sales, for so long as royalties are
payable to Santarus pursuant to Section 6.2, Santarus agrees to provide to GSK a credit against
royalties on Net Sales due and payable to Santarus under Section 6.2 in an amount equal to [***].
In the event that royalties are no longer payable to Santarus hereunder, Santarus shall promptly
pay to GSK, rather than giving GSK a credit for, the amounts calculated as described above. On a
monthly basis, GSK shall provide Santarus with written evidence establishing the applicable
Inter-Territory Sales (including evidence of GSK’s sales, if any, of PR Products provided to the
same pharmacy that sold or dispensed the PR Products subject to such Inter-Territory Sales) in a
particular calendar month no later than [***] after the end of the applicable calendar month. GSK
shall be responsible for obtaining commercially available data compiled or provided by one or more
reputable independent Third Parties tracking the sale or dispensing of PR Products in the Territory
in support of establishing Inter-Territory Sales, if any. Santarus shall notify GSK of the
applicable credit for Inter-Territory Sales for a particular Calendar Quarter within [***] after
timely receipt

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-11-

 

from GSK of the information required in this Section 2.2.3 with respect to the last month in a
Calendar Quarter.

          2.3 Restriction of Sub-Distributors. Without the prior written consent of Santarus
(except in relation to GSK Affiliates performing activities for the Territory, where Santarus’
consent will not be required), GSK will not grant to any Third Party any rights to market, promote,
advertise, sell or distribute PR Product, and will not enter into any agreement or arrangement with
respect to co-promoting the PR Product. The foregoing notwithstanding, (i) GSK may employ the
services of Third Parties as contract sales representatives for the promotion of PR Product or
otherwise for the acceptance of orders, storage and shipment of PR Products, generation of invoices
and collection and management of receivables with respect to GSK’s sales of PR Product in the
Territory, and (ii) this provision shall not be construed to prohibit resale of PR Products in the
Territory by GSK’s Customers who are wholesalers.

          2.4 Compliance with PR Product Registration; Resale in Same Packaging. GSK will not
at any time do, and neither will GSK permit its agents or representatives to do, any act in
violation of the PR Product Registration for any PR Product in the Territory. In the event that
any filings are required to be made with or approvals required to be obtained from applicable
Governmental Authorities in order to sell PR Product to GSK, or for GSK to initiate distribution,
marketing, advertisement, sale or promotion of PR Product in the Territory, the Parties will use
Commercially Reasonable Efforts to ensure that such filings and approvals are obtained or made as
expeditiously as reasonably practicable. Without the prior written consent of Santarus, GSK will
not alter in any manner any of the PR Product or its packaging as sold to it by Santarus or the
Authorized Manufacturer hereunder, and will resell PR Product without alteration in the form sold
to it by Santarus or the Authorized Manufacturer. All PR Product manufactured, promoted, marketed
or sold by or under authority of GSK pursuant to this Agreement shall be identified by Santarus’
NDC numbers.

          2.5 No Manufacturing Rights Conveyed on Effective Date. No right or license under any
Trademark, or under any patent rights or know-how or other Intellectual Property owned or
controlled by Santarus or any of its Affiliates is granted under this Agreement to GSK to make or
have made PR Product, except solely as provided in Section 5.3 with respect to GSK’s obtaining
supply of PR Products from an Authorized Manufacturer in accordance with the terms and conditions
set forth in this Agreement.

          2.6 Non-Compete.

               2.6.1 By GSK. During the Term, and for a period of two years thereafter or, if GSK
exercises its right of termination pursuant to Section 12.5.2, the later of (a) the fifth
(5th) anniversary of the Effective Date or (b) the second (2nd) anniversary
of the effective date of any termination of this Agreement, neither GSK nor any of its Affiliates
or sub-distributors will directly or indirectly distribute, market, promote, detail, advertise or
sell any PPI Pharmaceutical Product containing one or more PPIs which is either formulated in
combination with one or more buffering agents, or which is otherwise formulated to provide, in
either case, for immediate release of the PPI (other than PR Product pursuant to this Agreement) in
or for the Territory. The foregoing covenants shall not

-12-

 

restrict GSK or any Affiliate from obtaining rights to, or engaging in research and
development activities related to, products in such class during the restricted time period, so
long as GSK or its Affiliate does not engage in the activities set forth in the first sentence of
this Section 2.6.1.

               2.6.2 By Santarus. During the Term, prior to the third (3rd) anniversary
of the Effective Date, neither Santarus nor any of its Affiliates will directly or indirectly
distribute, market, promote, detail, advertise or sell any PPI Pharmaceutical Product containing
one or more PPIs which is either formulated in combination with one or more buffering agents, or
which is otherwise formulated to provide, in either case, for immediate release of the PPI (other
than PR Product pursuant to this Agreement) in or for the Territory. On or after the third
(3rd) anniversary of the Effective Date, Santarus and any Affiliates shall have the
right to directly or indirectly distribute, market, promote, detail, advertise or sell any PPI
Pharmaceutical Product containing one or more PPIs which is either formulated in combination with
one or more buffering agents, or which is otherwise formulated to provide, in either case, for
immediate release of the PPI, in or for the Territory; provided that Santarus shall discuss with
GSK the out-license of such product to GSK for the Territory; and provided further that in the
event that Santarus grants the right to commercialise the product to any Third Party, or
commercialises the product in its own right, in the Territory, GSK shall be released from its
obligations under Section 2.6.1 on the first commercial sale of such product in the Territory by
such Third Party or Santarus, as the case may be. The foregoing covenants shall not restrict
Santarus or any Affiliate from obtaining rights to, or engaging in research and development
activities related to, products in such class during the restricted time period, so long as
Santarus or its Affiliate does not engage in the activities set forth in the first sentence of this
Section 2.6.2.

          2.7 Know-How Restrictions and Firewall. GSK shall not, and shall ensure its
Affiliates and subcontractors, sub-distributors and other persons acting under its authority do
not, use or practice (or authorize the use or practice of) any Intellectual Property or Santarus
Confidential Information, or any other information regarding the manufacture, formulation, release
profile, efficacy or safety, use, sale or promotion of any PR Product, for the purposes of
manufacturing, developing or commercializing any product (other than PR Products in the Territory
that are supplied to GSK by Santarus or an Authorized Manufacturer in accordance with the terms and
conditions of this Agreement or Licensed Products in the GSK Territory in accordance with the ROW
License). GSK recognizes that, while GSK is Santarus’ distributor of PR Product in the Territory
pursuant to this Agreement, GSK could, subject to Section 2.6.1 and this Section 2.7, develop a PPI
Pharmaceutical Product which would, once launched, compete with Santarus with respect to the PR
Product outside the Territory. GSK acknowledges that Santarus is disclosing to GSK Intellectual
Property and other Confidential Information of Santarus for GSK’s use solely with respect to the PR
Product in the Territory under this Agreement (or as otherwise provided with respect to Licensed
Products in the GSK Territory pursuant to the ROW License), and GSK agrees not to use the
Intellectual Property or Santarus’ Confidential Information, directly or indirectly, in the
research, manufacture, development, sale or marketing of any PPI Pharmaceutical Product other than
(a) PR Product to the extent permitted under this Agreement or (b) Licensed Products to the extent
permitted under the ROW License. GSK shall limit disclosure of Santarus’ Confidential Information
to its and its Affiliates’ employees, consultants and other agents located in the Territory (or the
GSK Territory to the extent permitted under and in accordance with the ROW License) who

-13-

 

need to access such Confidential Information for the manufacture, development or sale of PR
Product in the Territory in accordance with this Agreement (or the GSK Territory to the extent
permitted under the ROW License) and who are bound by obligations of confidentiality and non-use no
less burdensome than those set forth in this Agreement. Confidential Information shall not be
disclosed to any of GSK’s or its Affiliates’ employees, consultants or other agents involved in the
research, development, manufacture or commercialization of any PPI Pharmaceutical Product other
than PR Product as permitted under this Agreement or a Licensed Product as permitted under the ROW
License, nor use or consider any such information or GSK’s plans with regard to the PR Product in
the development, manufacture or commercialization of any PPI Pharmaceutical Product, and GSK agrees
to institute reasonable procedures and safeguards intended to prevent such prohibited disclosures.

          2.8 No Patent Challenges. In partial consideration for the appointment, rights and
licenses granted herein, and access to Santarus know-how and Confidential Information, GSK agrees
that if GSK or any of its Affiliates commences, participates in or actively supports in any way any
challenge to the validity, enforceability, claim construction or coverage of any patents owned or
controlled by Santarus claiming or covering the composition, formulation, manufacture, use or sale
of PR Products in the Territory in any court or before any government or regulatory agency
(national or international) with authority to determine the validity, enforceability or scope of
such patents, or cause or request a review by any such court or government or regulatory agency of
the same, then at any time thereafter Santarus shall be entitled to elect to treat such activity as
permissive termination by GSK under Section 12.5.2 of this Agreement, and such termination shall be
effective immediately upon written notice to GSK.

          2.9 Missouri Agreement. Santarus shall have the obligation to pay all amounts owed to
the UMissouri under the Missouri Agreement, and in accordance with the terms set forth therein,
with respect to sales of PR Products by GSK (and any of its Affiliates and permitted
sub-distributors) pursuant to the terms and conditions of this Agreement. It is understood and
agreed that the sublicense to GSK under this Agreement of rights licensed to Santarus under the
Missouri Agreement is subject to the terms and conditions of the Missouri Agreement applicable to
such a sublicense, and that such obligations are incorporated by reference herein. In the event of
termination (but not earlier expiration) of the Missouri Agreement during the Term of this
Agreement, (i) GSK’s sublicense of Intellectual Property under the Missouri Agreement shall be
assigned by Santarus to the UMissouri with respect to PR Products in the Territory, and this
Agreement will be assigned in part to the UMissouri to effect such assignment of the sublicense,
(ii) this Agreement (including all payment obligations of GSK hereunder) shall otherwise be
retained by Santarus with respect to all matters other than the sublicense of rights under the
Missouri Agreement, and (iii) GSK shall thereafter be responsible for making all payments that
would have been owed by Santarus to UMissouri pursuant to the Missouri Agreement (if the Missouri
Agreement had not been terminated) in respect of GSK’s its Affiliates’ and their sub-distributors’
sales of PR Product in the Territory after the date of such assignment; provided that GSK shall
have the right to offset the amounts so paid to UMissouri in respect of the sales of PR Product
during the Term against amounts due hereunder to Santarus with respect to such sales.

-14-

 

          2.10 License to GSK IP. Subject to the terms and conditions of this Agreement, GSK
hereby grants to Santarus [***] license under all GSK IP to [***]. Additionally, subject to the
terms and conditions of this Agreement, GSK hereby grants to Santarus [***] license under the GSK
IP to [***]. Notwithstanding anything herein to the contrary, the licenses granted in this Section
2.10 shall not include any GSK IP subject to payment obligations to a Third Party (and GSK shall
promptly disclose such obligations to Santarus in writing), unless Santarus agrees in writing to
reimburse all amounts owed to such Third Party as a result of Santarus’ exercise of such license.
In addition, in the event Santarus elects to take a license to such GSK IP, the terms for such
license shall be [***]; provided that no compensation shall be due to GSK if [***].

ARTICLE 3

GSK RESPONSIBILITIES

          3.1 Distribution. In the exercise of its rights and fulfillment of its obligations
under this Agreement, commencing on the Effective Date and continuing during the Term, GSK will:

                    (a) commence promotion, distribution and sales of the PR Product in any dosage form in the
Territory within three (3) months after the Effective Date;

                    (b) provide, at its expense, a traceability system for the PR Product as referred to in
Section 2.2.2 or as otherwise required by Applicable Law;

                    (c) ensure that all sales force personnel promote PR Product in a manner that is consistent
with the PR Product Registration and approved labeling, and in a manner that is permitted by
Applicable Law. If GSK becomes aware of any such activity in contravention of the immediately
foregoing standards, GSK will take prompt affirmative action to ensure that such activity ceases,
and take additional remedial action to advise its sales personnel concerning the activities
described in this subsection;

                    (d) not take any action which constitutes a material violation of Applicable Law or breach of
this Agreement;

                    (e) use Commercially Reasonable Efforts to sell, market, detail, promote, advertise and
distribute the PR Product to Customers in the Territory after the Effective Date and during the
Term. Santarus’ sole remedy for GSK’s failure to comply with this paragraph (e) is termination of
this Agreement pursuant to Section 12.2;

                    (f) use Commercially reasonable Efforts to sell, market, detail, promote, advertise and
distribute the PR Product to Customers in the Territory after the Effective Date and during the
Term in a manner that will not have a material adverse effect on the PR Product in the Territory or
the United States;

                    (g) obtain, as soon as reasonably practicable following the Effective Date and no later than
three (3) months following the Effective Date, and maintain during the Term at GSK’s sole and
exclusive expense, any and all governmental approvals as are required for GSK to fulfill its
obligations hereunder; and

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-15-

 

                    (h) maintain the availability of the current package inserts with respect to the PR Product on
each website maintained by GSK or its Affiliates for the distribution, marketing, promotion,
detailing, advertising or sale of PR Product in the Territory and at such other locations where GSK
or any such Affiliates make information regarding the PR Product available.

          3.2 Promotional Activities and Promotional Materials.

               3.2.1 GSK Activities. GSK will be responsible, at its sole expense, for conducting
all promotional activities for the marketing, promotion and detailing of PR Products in the
Territory (such activities, the “Promotional Activities”) and shall use only advertising and
promotional materials for the PR Product (“Promotional Materials”) that have been provided at GSK’s
expense by or under authority of Santarus to GSK or submitted and approved as set forth in Section
3.2.3 in conducting such Promotional Activities for the PR Product in the Territory. GSK will
ensure that all Promotional Activities comply with, and GSK will be solely responsible and liable
for any failure of the Promotional Activities to comply with, the applicable labeling and PR
Product Registration for the PR Product and Applicable Law.

               3.2.2 Regulatory Issues. GSK will promptly, but in no event within more than [***]
Business Days after GSK’s receipt thereof, provide a copy to Santarus of any correspondence from a
Governmental Authority with respect to PR Product, including the FDA, reflecting any purported
legal or regulatory violations or legal or regulatory action being considered or taken by such
Governmental Authority, including copies of FDA NOV’s and warning letters. Upon request of
Santarus in relation to a matter raised by or to a Governmental Authority or Third Party complaint,
GSK will provide Santarus with a reasonably detailed description of all Promotional Activities
within [***] Business Days of such request by Santarus. GSK will absorb and be solely responsible
for any and all damages, losses, expenses and costs incurred by GSK and its Affiliates arising from
the failure of any Promotional Activities conducted by GSK to comply with the applicable labeling,
the PR Product Registrations or with Applicable Law. Without limiting the rights Santarus may have
under the indemnification provisions of this Agreement, but subject to the limitations on liability
set forth in Section 9.4, GSK will be responsible for and shall promptly reimburse Santarus and its
Affiliates for any and all documented direct damages, losses, expenses and costs suffered or
incurred by Santarus or its Affiliates arising from the failure of any Promotional Activities
conducted by GSK or Promotional Materials created by or under authority of GSK (as opposed to
Promotional Materials created by or under authority of Santarus) to comply with the applicable
labeling of PR Products, the applicable PR Product Registrations, Applicable Law or any comments,
guidance or direction given by DDMAC, the PhRMA Code or the PhRMA Guiding Principles,
Direct-to-Consumer Advertisements About Prescription Medicines, notwithstanding any prior review or
approval of such Promotional Activities or Promotional Materials by Santarus, including any
damages, losses, expenses and costs reasonably incurred by Santarus to so mitigate or limit the
effect or impact of any such failure to comply on Santarus and its Affiliates’ products or
corporate image (including the costs of any remedial action Santarus may choose to undertake to
communicate with physicians or Customers, including so-called “dear doctor letters”).

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-16-

 

               3.2.3 Promotional Materials.

                    (a) Santarus will provide GSK with limited informational copies of certain advertising and
promotional materials in its possession and currently used by Santarus relating to PR Product for
the United States that are relevant to GSK’s Promotional Activities under this Agreement for PR
Products in the Territory. From time to time, Santarus will, at GSK’s expense, provide copies of
additional Promotional Materials then currently used by Santarus relating to PR Product for the
United States that are relevant to GSK’s Promotional Activities under this Agreement for PR
Products in the Territory. At GSK’s request, Santarus shall (i) introduce GSK to its vendors who
print or otherwise produce Promotional Materials relevant to GSK’s Promotional Activites under this
Agreement for PR Products in the Territory so that GSK may purchase Promotional Materials directly
from such vendors and (ii) provide permission to such vendors so that they may provide Promotional
Materials to GSK pursuant to this Section 3.2.3(a).

                    (b) Santarus reserves and retains title and all rights, including copyrights in and to all
Promotional Materials, whether written, visual or electronic works, provided to GSK under this
Agreement. Subject to the foregoing, GSK is granted a nonexclusive right to use, copy, and
distribute such Promotional Materials in the Territory only for the purposes of this Agreement and
in furtherance of the rights granted to GSK hereunder, for the Term for the PR Product to which
such works and materials relate. GSK shall not modify such Promotional Materials or create
independent Promotional Materials for the PR Product, except as set forth in this Section 3.2.3.
GSK will ensure that all copyright notices appear on all copies of the Promotional Materials.

                    (c) In the event GSK wishes to use Promotional Materials other than the Promotional Materials
provided by Santarus to GSK, including modified versions of the Promotional Materials provided by
Santarus, GSK shall provide copies of all such proposed Promotional Materials (including detail
aids, brochures, reprints and other printed materials to be shown to or left with healthcare
providers, letters, brochures and other printed materials intended for consumers, website content,
materials for use in promotional programs and any print, television, radio and other media
advertising materials intended for healthcare providers or consumers) for Santarus’ approval prior
to use, and, following approval by Santarus, Santarus will submit such Promotional Materials, at
GSK’s cost and expense, to DDMAC. Santarus agrees to promptly, and in any event within [***] days,
review and communicate its approval or disapproval of Promotional Materials submitted by GSK under
this Section 3.2.3(c), such approval to be withheld by Santarus only in circumstances where
Santarus believes in good faith that the proposed Promotional Materials pose legitimate scientific,
legal or regulatory, risks or concerns, or concerns that such Promotional Materials could be
detrimental to PR Product commercialization efforts by or under the authority of Santarus in the
United States. Santarus shall have the sole discretion to determine whether it is required or
advisable to submit Promotional Materials to DDMAC for review prior to approval for GSK to use such
Promotional Materials, and Santarus shall have full control over all interactions with DDMAC with
respect to Promotional Materials. GSK shall be responsible for obtaining and providing to Santarus,
at GSK’s expense, any and all translations of such Promotional Materials as may be required in
connection with such review by DDMAC or Applicable Law. GSK shall not use any Promotional
Materials for the PR Products in the Territory that have not been reviewed and approved for use by
Santarus before such use.

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-17-

 

                    (d) GSK grants Santarus the nonexclusive, perpetual right to use, copy, modify, make
derivative works and distribute Promotional Materials created or modified by GSK for use by
Santarus or its designees for PR Product outside the Territory. At Santarus’ request, GSK shall
(i) introduce Santarus to its vendors who print or otherwise produce Promotional Materials so that
Santarus may purchase Promotional Materials directly from such vendors and (ii) provide permission
to such vendors so that they may provide Promotional Materials to Santarus pursuant to this Section
3.2.3(d).

                    (e) Santarus shall have the right to require GSK, upon written notice to GSK, to immediately
cease distributing, disseminating, broadcasting or otherwise using any Promotional Materials in the
event Santarus receives an NOV or warning letter from DDMAC with respect to such Promotional
Materials or if Santarus reasonably believes that such Promotional Materials (i) do not conform to
Applicable Law, or any comments, guidance or direction given by DDMAC, the PhRMA Code or the PhRMA
Guiding Principles or (ii) could reasonably result in liability for Santarus or its Affiliates or
their respective employees, directors, agents, representatives or licensees.

               3.2.4 Certain Activities. GSK will have strategic responsibility and sole authority
and responsibility, at its sole expense and solely in the Territory, for independent and
non-independent symposia, speaker training and engagement programs, advisory board meetings and
other consulting arrangements, and other such events or programs as GSK, in its sole discretion,
deems to be appropriate with respect to the PR Product in the Territory; provided, however, that
any and all such events and programs must comply in all material respects with Applicable Law and
relevant PhRMA and FDA policies, including the FDA’s Guidance on Industry-Supported Educational and
Scientific Activities.

               3.2.5 No GSK Clinical Trials. GSK shall not conduct any in vivo
studies, clinical trials or pharmacoeconomic studies of the PR Product without the prior written
consent of Santarus. Subject to the foregoing, GSK will promptly provide Santarus with copies of
all completed study reports and market research or other studies or reports regarding the PR
Product conducted after the Effective Date regarding PR Product.

               3.2.6 PR Product Returns. After the Effective Date, Santarus and GSK will agree to a
PR Product Returns Policy whereby GSK, at its cost and expense, manages all PR Product that is
returned to GSK, and Santarus manages, at GSK’s cost and expense, all PR Product sold or dispensed
in the Territory that is returned to Santarus. GSK will be responsible for all associated credits
or rebates associated with such returns. Prior to GSK’s first commercial sale of PR Product in the
Territory, GSK will send written notice to all wholesalers operating in the Territory that all
returns of PR Product in the Territory shall be sent to GSK.

          3.3 Use of Trademarks; Trade Dress. After the Effective Date and for the duration of
the Term, and subject to the terms and conditions of this Agreement:

               3.3.1 Trademark License. Santarus hereby grants to GSK an exclusive (except as
otherwise provided in this Agreement), license to use the Trademarks solely to promote, market,
sell

-18-

 

and distribute the PR Product in the Territory during the Term. Unless otherwise agreed by
Santarus in writing, GSK will not identify PR Product by any designation other than the Trademarks.
The use of the Trademarks by GSK will be expressly subject to Sections 3.3.2 and 3.3.3 below.

               3.3.2 Limited Use; Inspections. GSK will use the Trademarks solely with respect to PR
Product purchased from Santarus or an Authorized Manufacturer as provided in this Agreement, only
in accordance with the standards of quality established or approved by Santarus or its designee,
and only in the Territory. GSK will permit duly authorized representatives of Santarus to inspect,
on the premises of GSK or its subcontractors and agents, at reasonable times during normal business
hours and upon not less than [***] Business Days prior written notice, inventory of PR Product,
GSK’s quality control records, and GSK’s facilities used in or relating to the sale of PR Product
to ensure compliance with quality control standards and with applicable terms of this Agreement
pertaining to the use of the Trademarks.

               3.3.3 Usage. Whenever GSK uses the Trademarks in any Promotional Materials or in any
other manner, GSK will clearly indicate that the Trademarks are owned by Santarus. When using the
Trademarks under this Agreement, GSK will comply with all Applicable Law pertaining to the
Trademarks in force at any time in the Territory, and all uses by GSK of the Trademarks in
connection with Promotional Materials shall be consistent with the approval process set forth in
Section 3.2.1 and Section 3.2.3. During the Term, GSK will provide Santarus on a periodic basis,
as requested by Santarus, with copies of any Promotional Materials permitted to be generated by
GSK, for review of the use of the Trademarks by GSK. GSK will promptly take any and all actions
directed by Santarus with respect to GSK’s use of the Trademarks that are reasonably designed to
ensure compliance with the provisions of this Section 3.3.

               3.3.4 Santarus Ownership. GSK acknowledges and agrees that Santarus or its
Affiliates, is, and at all times will remain the owner of the Trademarks. GSK will not at any time
do, cause to be done, or permit any of its employees, agents, contractors and subcontractors to
commit any act inconsistent with, contesting or in any way impairing, or tending to impair, such
ownership. GSK agrees that all use of the Trademarks by GSK will inure to the benefit of and be on
behalf of Santarus or its Affiliates. GSK acknowledges that nothing in this Agreement will give
GSK any right, title or interest in the Trademarks other than the right to use the Trademarks
solely within the Territory in accordance with this Agreement. GSK agrees that it will not
challenge Santarus’ or its Affiliates’ title to, or ownership of, the Trademarks, or attack or
contest the validity of the Trademarks. All goodwill accruing to the Trademarks as a result of the
use of the Trademarks in the performance of this Agreement will belong solely to Santarus or its
Affiliates. In the event that GSK acquires any rights in the Trademarks in connection with GSK’s
activities pursuant to this Agreement, GSK will assign, and hereby does assign, to Santarus or its
Affiliates all such rights, including any related goodwill.

               3.3.5 Internet. GSK is limited to using the Trademarks in connection with the
Internet as follows:

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-19-

 

                    (a) the use must be in compliance with Applicable Law regarding advertising of pharmaceuticals
on the Internet and the approval processes set forth in Sections 3.2.1 and 3.2.3;

                    (b) no license is granted to use or obtain rights to any “.com” generic code domain, or any
other such top-level domain, for any Trademark. All domain names containing the Trademark will be
registered and maintained by and in the name of Santarus or its designee;

                    (c) appropriate disclaimers must be included in any website to the effect that it is intended
for residents within the Territory only; and

                    (d) in using any of the Trademarks on the Internet, GSK will not have and will not represent
in any way that it has any title or right to the ownership or registration or their use, except as
provided in this Agreement. GSK will at all times indicate that each of the Trademarks is a
trademark of Santarus and is used under license.

          3.4 Trademark Infringement by Third Parties.

                    (a) If either Party becomes aware that a Third Party is infringing any Trademark used in
connection with PR Product in the Territory, such Party will promptly give written notice to the
other Party describing in detail the nature of such infringement. Santarus and its Affiliates will
have the sole right, but not the obligation, to enforce any such Trademarks against such Third
Party infringer, in their reasonable discretion, and to settle or compromise any such possible
infringement by taking such action as Santarus or its Affiliates may determine in their sole and
absolute discretion using counsel of their choice. GSK will provide Santarus with all reasonable
assistance (including making documents and records available for review and copying, and making
persons within its control available for pertinent testimony), at Santarus’ expense, in any such
enforcement.

                    (b) If Santarus elects not to exercise its right under Section 3.4(a) above to take steps to
enforce the Trademarks against infringement in the Territory or otherwise to seek abatement of such
infringement within [***] days after a written request by GSK to do so, GSK will thereafter have
the right, but not the obligation, at its expense and in its own name or in the name of any of its
Affiliates, to initiate, maintain, and control legal action to enforce the Trademarks by counsel of
its choice; provided that GSK shall not have any right under this Section 3.4 to enforce the
Trademarks with respect to any usage or infringement outside the Territory, and GSK shall have no
rights to enforce Trademarks related to the corporate name or logo of Santarus. In the event that
GSK initiates and thereafter maintains such legal action against infringement of a Trademark by a
Third Party in the Territory, Santarus at GSK’s expense, will provide GSK cooperation as reasonably
necessary, including agreeing to be named as a party to such legal action. GSK shall not make any
admission or enter into any settlement or other agreement that admits the non-infringement or
unenforceability of any Trademark, or that materially adversely affects Santarus’ rights in and to
any Trademark, without Santarus’ prior written consent.

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-20-

 

                    (c) Any recovery received by a Party from legal action initiated pursuant to this Section 3.4
in the Territory, whether by judgment, award, decree, or settlement, will be used first to
reimburse the prosecuting Party for its out-of-pocket costs and expenses actually incurred in
pursuing such legal action, and second to reimburse the non-prosecuting Party for costs and
expenses actually incurred by such non-prosecuting Party, if any, in connection with such legal
action. The remainder of any recovery in the Territory received under this Section 3.4, to the
extent such recovery relates to infringement of one or more Trademarks other than the corporate
name or logo of Santarus and after reimbursement of costs and expenses of Santarus and GSK, will be
shared by Santarus and GSK with [***] and [***]; provided that any recoveries related to
infringement or misappropriation of a Trademark outside of the Territory shall inure solely to and
be paid to Santarus.

          3.5 Rebates, Administrative Fees and Chargebacks.

               3.5.1 Santarus’ Obligations. Santarus will be responsible for all governmental and
commercial rebates, administrative fees and chargeback claims for all PR Product (if any) dispensed
or purchased in the Territory prior to the Effective Date (it being understood and agreed that the
information contained in any report from the applicable rebate or chargeback program will be deemed
to be the date for purposes of determining the date of such claim). For clarity, Santarus will
also be responsible for all rebates, administrative fees and chargebacks pursuant to any government
and commercial rebate or chargeback programs with respect to PR Product dispensed or purchased,
respectively, outside the Territory in the United States. Santarus will use Commercially Reasonable
Efforts to exclude the Territory from its current and future agreements with the Managed Care
Market. The Parties acknowledge that Santarus shall not be required to incur any additional
financial or other substantive contractual obligations in order to comply with the previous
sentence. Upon GSK’s reasonable request from time to time, Santarus shall provide to GSK a list of
Santarus’ contracts (and expiration dates) with members of the Managed Care Market which Santarus
reasonably believes have operations in the Territory.

               3.5.2 GSK’s Obligations. GSK will be responsible for all rebates, administrative fees
and chargeback claims for PR Product dispensed or purchased in the Territory on and after the
Effective Date during the Term (it being understood and agreed that the information contained in
any report from the applicable rebate or chargeback program will be deemed to be the date for
purposes of determining the date of such claim). GSK will also be responsible for all rebates,
administrative fees and chargebacks pursuant to any government rebate or chargeback programs to
which GSK is a party as permitted under this Agreement with respect to government claims for PR
Product dispensed or purchased in the Territory on and after the Effective Date (it being
understood and agreed that the information contained in any report from the applicable rebate or
chargeback program will be deemed to be the date for purposes of determining the date of such
claim). GSK will reimburse Santarus for all rebates, administrative fees and chargebacks that
Santarus is obligated to pay under agreements or programs with the Managed Care Market with respect
to claims for PR Product dispensed in the Territory on and after the Effective Date. On a monthly
basis, GSK shall promptly provide to Santarus all information reasonably requested by Santarus in
order for Santarus to determine the amount of rebates and chargebacks attributable to PR Products
dispensed in the Territory. All payments due to Santarus by GSK as set forth in the immediately

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-21-

 

preceding sentence will be made by GSK to Santarus within thirty (30) days after GSK’s receipt
of an invoice from Santarus setting forth requested payments in reasonable detail, the form and
timing of which detail have been agreed upon by the Parties in a separate letter agreement of even
date hereof, the terms and conditions of which letter agreement are incorporated herein. Any
rebates, administrative fees or chargebacks to be reimbursed to Santarus by GSK with respect to
agreements or programs with the Managed Care Market entered into by Santarus after the Effective
Date shall be in accordance with Santarus’ normal business practice so as not to provide for higher
rebates, administrative fees or chargebacks in the Territory than in the United States (excluding
the Territory).

          3.6 GSK Pricing.

               3.6.1 GSK Discretion. As of the Effective Date and continuing during the Term, GSK
will have the sole authority to determine the prices of PR Product sold by it in the Territory
during the Term and to establish its own pricing policy for the PR Product in the Territory,
including price increases or decreases and the timing thereof as determined by GSK.

               3.6.2 Rebates, Administrative Fees and Chargebacks under Contracts or Programs for
Territory and United States. Without limiting GSK’s discretion to determine the prices of PR
Products sold by it in the Territory during the Term, the Parties acknowledge that Santarus may
enter into (or may have entered into) one or more agreements or programs with the Managed Care
Market for sales of PR Products both in the United States and in the Territory, and agree that
Santarus shall have the right to negotiate the terms of, and enter into, such agreements or
programs. GSK confirms that it shall reimburse Santarus for all rebates, administrative fees and
chargebacks paid or allowed by Santarus under such agreements or programs on account of PR Products
sold in the Territory by GSK or dispensed in the Territory, as set forth in Section 3.5.2 above.
GSK shall not enter into any agreements or programs with the Managed Care Market with respect to PR
Product, except to the extent such agreements or programs are limited to utilization exclusively
within the Territory.

               3.6.3 Reimbursement to Santarus for Certain Effects Outside the Territory. The
Parties acknowledge that GSK’s pricing of PR Product in the Territory could adversely impact
Santarus’ pricing of PR Product outside of the Territory under government programs, including sales
under the FSS, or the amount of rebates or chargebacks required to be paid by Santarus under
agreements or programs with the Managed Care Market. Consequently, without limiting GSK’s
discretion to determine the prices of PR Products sold by it in the Territory during the Term, the
Parties agree that GSK shall reimburse Santarus for any increase in amounts to be paid by Santarus
or decrease in amounts paid to Santarus under agreements or programs with the Managed Care Market
in respect of PR Products sold by or on behalf of Santarus outside of the Territory to the extent
such increase or decrease is caused by GSK’s pricing for PR Products in the Territory. GSK shall
promptly provide to Santarus all information reasonably requested by Santarus in order for Santarus
to comply with its obligations under agreements or programs with the Managed Care Market or for
Santarus to determine any amounts owed by GSK pursuant to this Section 3.6.3. All payments due to
Santarus by GSK pursuant to this Section 3.6.3 will be made by GSK to Santarus within thirty (30)
days after GSK’s receipt of an invoice from Santarus setting forth requested payments in reasonable
detail.

-22-

 

          3.7 Sales Information. With respect to PR Product sold by GSK after the Effective
Date, GSK will deliver a report in a mutually agreed format to Santarus within [***] days after the
end of each calendar month, which report shall include the relevant sales dollar amount as well as
the number of units of PR Product sold in the prior month and any other information applicable to
Santarus’ calculation of pricing for Santarus’ sales under the FSS, as well as such other
information Santarus reasonably requests in the event that sales of PR Product in the Territory
affect (a) the “best price” (as defined under the Social Security Act, 42 USC Section
1396r-8(c)(1)(C), or any successor statute, and applicable regulations promulgated thereunder), (b)
the “average manufacturer price” (AMP) (as defined under the Social Security Act, 42 USC Section
1396r-8(k)(1), or any successor statute, and applicable regulations promulgated thereunder), or (c)
any other government mandated price in the Territory or the United States. GSK agrees that
Santarus may use all information described in this Section 3.7 as reasonably required in reporting
to the United States Government or any of its subdivisions. Within [***] days after the Effective
Date, GSK shall provide written authorization to IMS Health (including any successors, “IMS”) in
such form and substance required by IMS in order to permit Santarus to obtain all applicable IMS
data with respect to PR Product. On a monthly basis and to the extent permitted by Applicable Law,
GSK shall send Santarus all IMS data in GSK’s possession that may be relevant to calculation of
amounts payable or creditable under this Agreement, including Sections 3.5 and 3.6.

          3.8 Sales Force.

               3.8.1 Training. All members of GSK’s sales force engaged in the promotion of PR
Product (including first tier management and sales representatives) shall complete a PR
Product-related training program conducted by GSK at its cost and expense. In connection with
GSK’s PR Product-related training program, Santarus will, at GSK’s cost and expense, (i) to the
extent available and in Santarus’ possession, provide GSK with copies of any training materials
used by Santarus in training sales representatives in the United States with respect to the PR
Product and (ii) provide support from its sales force training staff to allow for one “train the
trainers” meeting, the contents and structure of which shall be determined at Santarus’ sole
discretion, at Santarus’ San Diego facility or other location reasonably selected by GSK to train
GSK’s sales force training staff. In the event GSK selects a location for the “train the trainers”
meeting other than Santarus’ San Diego facility, GSK shall pay for Santarus’ reasonable costs
incurred in attending such meeting. GSK will have the sole responsibility for materials used by
GSK for sales training purposes with respect to the PR Product. Santarus makes no representations
or warranties that the training or training materials provided by Santarus will meet GSK’s internal
standards or requirements. Ongoing training of GSK’s sales representatives and other personnel
will be the responsibility of GSK at its cost and expense. The contents of any training provided
by GSK that relates to the PR Product will be developed and coordinated by GSK, and GSK will be
solely responsible for training its sales force (including management and sales representatives)
with regard to Applicable Law and directing such sales force and sales force personnel to be
compliant with Applicable Law, regardless of whether GSK utilized Santarus provided materials for
training.

               3.8.2 Sales Force Costs. GSK will be solely responsible for the costs and expenses of
establishing and maintaining its sales force and marketing functions for the PR Product, and for
conducting its other Promotional Activities under this Agreement, and will have the sole authority
to

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-23-

 

control its sales force and direct the activities of its sales force; provided, however, that
all such activities shall be consistent with this Agreement and in compliance in all material
respects with Applicable Law.

               3.8.3 Audit Program. As of the Effective Date and continuing during the Term, GSK
will maintain a compliance and audit program to ensure that the activities of its sales force
(including management and sales representatives) are consistent with the FD&C Act, the
Anti-Kickback Statute, the PDMA and the PhRMA Code.

               3.8.4 No Ineligible Persons. GSK will not hire and during the Term will not employ
any Ineligible Person as either an employee or contractor to conduct any promotional, sales,
distribution or any other activities relating to PR Product in the Territory under this Agreement.
If GSK has actual notice that one of its employees or contractors providing services under this
Agreement has become or is likely to become an Ineligible Person, GSK will remove such Person from
any responsibility associated with this Agreement and the PR Product.

          3.9 Reports. On [***] basis, GSK shall provide Santarus written reports describing in
reasonable detail all Promotional Activities conducted by or for GSK, as well as GSK’s other
efforts to promote, distribute and sell the PR Product in the Territory, as well as sales
forecasts. On [***] basis, the Parties shall meet (telephonically or in person) to discuss GSK’s
then current and anticipated Promotional Activities conducted by or under authority of GSK, as well
as GSK’s other efforts to promote, distribute and sell the PR Product in the Territory.

ARTICLE 4

SANTARUS’ RESPONSIBILITIES

          4.1 PR Product Registrations.

               4.1.1 Retention by Santarus. Santarus will have sole responsibility for maintaining
and will use Commercially Reasonable Efforts to maintain the PR Product Registration with respect
to the Territory at its expense, including filing annual reports in connection with the PR Product
NDA (“Annual Reports”), with copies to GSK, and paying all user fees, product fees and
establishment fees associated with the PR Product Registrations with respect to the Territory.
Santarus will keep GSK informed on a timely basis as to any developments that would reasonably be
anticipated to have a material adverse effect on a PR Product Registration. GSK will cooperate
with Santarus with respect to obtaining and maintaining such PR Product Registrations, and will
execute, acknowledge and deliver such further instruments at Santarus’ request and expense, and use
Commercially Reasonable Efforts to do all such other acts, as promptly as possible, which may be
necessary or appropriate to obtain and maintain the PR Product Registrations with respect to the
Territory. GSK will, on a timely basis and in response to requests made by Santarus from time to
time, provide to Santarus all information that GSK has from time to time during the Term for the PR
Product that is reasonably necessary and relevant to Santarus’ obligations hereunder to fulfill
such PR Product Registration maintenance requirements (including providing sales distribution
information concerning the PR Product and all information reasonably required for inclusion in
Santarus’ Annual Reports).

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-24-

 

               4.1.2 Santarus Control. Santarus will have the final decision-making authority in
every case, in its discretion, on whether and how to supplement, amend or otherwise alter the PR
Product Registrations and any other issues in connection with such PR Product Registrations
(including decisions, subject to Section 7.3, to recall the PR Product) and on whether and how to
communicate with the FDA and other applicable Governmental Authorities in connection with such PR
Product Registrations; provided, however, that Santarus will notify GSK in advance of making any
planned changes to the PR Product Registration that would reasonably be anticipated to impact the
characteristics or performance of the API or finished drug product with respect to PR Products for
the Territory, or other material changes in the specifications or other particulars in the PR
Product Registrations with respect to PR Products for the Territory. In the event that the Parties
provide for an Authorized Manufacturer to manufacture PR Products for sale in the Territory by GSK
(other than a Third Party manufacturer that is then utilized by Santarus for manufacture of the
applicable PR Product for the United States), Santarus will reasonably coordinate and cooperate
with GSK and such Authorized Manufacturer, at GSK’s expense, to supplement, amend or otherwise
alter the PR Registration solely to the extent reasonably necessary to obtain required
authorization for such Authorized Manufacturer to manufacture the PR Product in accordance with the
Specifications, procedures and other requirements set forth in the PR Product Registration for PR
Product sold by Santarus in the United States; provided, however, that Santarus shall not be
obligated to accept or agree to any change in the Specifications, manufacturing process or QA or QC
procedures, or to agree to any modification of the PR Product Registration that could, in Santarus’
reasonable opinion, have an adverse effect on the manufacture, use or sale of PR Product in the
United States by or under authority of Santarus.

               4.1.3 Inspection. Santarus and GSK each will make its respective facilities available
at reasonable times during business hours for inspection by representatives of Governmental
Authorities relating to the manufacture, sale, marketing, promotion, distribution or use of PR
Product in the Territory. Santarus and GSK each will notify the other within [***] of receipt, and
provide a copy thereof, of any notice of any FDA or other Governmental Authority inspection,
investigation or other inquiry, or other material governmental notice or communication, relating to
the manufacture, sale, marketing, promotion, distribution or use of PR Product in the Territory.
GSK and Santarus will cooperate with each other during any such inspection, investigation or other
inquiry. GSK and Santarus will discuss any response to observations or notifications received in
connection with any such inspection, investigation or other inquiry, and each will give the other
an opportunity to comment upon any proposed response before it is made; provided, however, that
Santarus will not be required to discuss with GSK any issues specific to the manufacture of PR
Product, unless it impacts GSK’s ability to distribute the PR Product under this Agreement, or to
obtain the consent or agreement of GSK with respect to issues related thereto. In the event of
disagreement concerning the form or content of any such response, Santarus will be responsible for
deciding the appropriate form and content of any response to any Governmental Authority to the
extent the cited activities relate to any PR Product, including its manufacture, labeling,
packaging, sale, marketing, advertisement, promotion, distribution or use thereof. GSK and
Santarus will provide each other with copies of all correspondence received by it from, or filed by
it with, any Governmental Authority to the extent pertaining to any PR Product in the Territory or
its manufacture, labeling, packaging, sale, marketing, advertisement, promotion, distribution, or
use

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-25-

 

in or for the Territory. Nothing in this Section 4.1.3 will limit or condition the rights of
either Party under Section 7.7.

               4.1.4 Inserts and Package Labeling. Santarus will have sole responsibility and
authority for, and control of, all package inserts and package labeling (and any changes or
supplements thereto) for PR Product, and will have the responsibility at its expense for securing
any approvals required by FDA or any changes or supplements thereto. GSK will not at any time do,
and neither will GSK permit its agents or representatives to do, any act in violation of the PR
Product Registration. In the event that any filings are required to be made with or approvals
required to be obtained from applicable Governmental Authorities in order to change or supplement
the package inserts and labeling, Santarus will have the sole responsibility for and authority to
effect such filings and the sole right and discretion on how to effect such changes at Santarus’
expense. Santarus will promptly, but in no event less than [***] Business Days, advise GSK in
writing of any changes or supplements to the package inserts and package labeling for PR Product.
The Parties acknowledge and agree that PR Product shall be sold under a Santarus label.

          4.2 Prosecution and Maintenance of Trademarks and Patents.

               4.2.1 Trademarks. Santarus will register and maintain, or cause to be registered and
maintained, at its cost and expense, the Trademarks in the Territory during the Term. GSK shall
neither use nor seek to register, anywhere in the world, any trademark which is confusingly similar
to any Trademark, or to any other trademarks, trade names, trade dress or logos used by or on
behalf of Santarus or its Affiliates or licensees in connection with any PR Product commercialized
hereunder; provided, however, that nothing in this Section 4.2.1 shall be construed to prevent GSK
from enforcing its own trademark, trade name, trade dress or logo rights.

               4.2.2 Patents; Prosecution; Notice of Infringement. Notwithstanding any other
provision of this Agreement to the contrary, Santarus shall retain the right but not the obligation
to prosecute, maintain or abandon any patent rights and know-how owned or controlled by Santarus
covering the PR Product. Santarus shall promptly advise GSK of any material developments
regarding the prosecution, maintenance or abandonment of patent rights owned or controlled by
Santarus covering the PR Product in the Territory, which developments will likely have a material
adverse effect on GSK’s distribution of PR Product in the Territory. GSK will promptly notify
Santarus in the event GSK becomes aware of any actual or threatened infringement in the Territory
of any patent within the Intellectual Property.

               4.2.3 Contracts for Supply. Santarus will have the sole right, but not the
obligation, at its sole discretion and expense, to maintain and enforce any contract entered into
by Santarus covering the supply of any compounds, intermediates, biomaterials, packaging
components, containers or other materials used in the manufacture of PR Product to be supplied to
GSK as part of the Initial Supply hereunder.

          4.3 PR Product Improvements. Santarus will have no obligation, express or implied, to
develop new formulations, indications, dosages, presentations, forms of administration or
preparations for PR Product. However, if Santarus does develop (alone or with others) [***],

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-26-

 

including the pharmaceutical product with omeprazole, sodium bicarbonate and magnesium
hydroxide more particularly specified under NDA #21-850 (chewable tablet formulation) (a “PR
Product Improvement”), GSK will have the option [***], to have such PR Product Improvement (but not
any corresponding OTC Product) included under the definition of PR Product (to the extent Santarus
is not otherwise prohibited from doing so), as set forth below in this Section 4.3. Santarus
hereby covenants that it will use Commercially Reasonable Efforts, [***]. Promptly after [***],
Santarus shall notify GSK in writing describing the same and providing such Data as Santarus
reasonably believes is necessary for GSK to evaluate whether it desires to exercise its option
described in this Section 4.3, to the extent Santarus is not otherwise prohibited from providing
such Data to GSK. In such case, GSK shall notify Santarus in writing within [***] days of receipt
of Santarus’ notice as to whether it desires to exercise such option. If GSK so notifies Santarus
that it desires to exercise its option, then the Parties shall negotiate in good faith for a period
of at least [***] days to determine [***] that GSK shall be required to pay to Santarus, which
determination shall be based upon [***]; provided that if the Parties are unable for any reason to
agree on such payment amount during such period, then either Party may submit such issue for
dispute resolution pursuant to Article 13; and provided further that no such payment shall be
required by GSK with respect to the chewable tablet formulation described above. Notwithstanding
anything herein to the contrary, the option granted in this Section 4.3 shall not include any PR
Product Improvement subject to payment obligations to a Third Party (and Santarus shall promptly
disclose such obligations to GSK in writing), unless GSK also agrees in writing to reimburse all
amounts owed to such Third Party as a result of GSK’s exercise of its license rights to such PR
Product Improvement. [***].

ARTICLE 5

SUPPLY AND MANUFACTURE OF PR PRODUCT

          5.1 Supply and Manufacture of PR Product. In order to ensure the quality of PR
Product to be sold by GSK under the Trademarks, GSK shall market, promote, sell and distribute in
the Territory only PR Product obtained by GSK (i) from Santarus as part of the Initial Supply as
set forth in Section 5.2 or (ii) from an Authorized Manufacturer as set forth in Section 5.3, and
in each case subject to the other terms and conditions as set forth in this Agreement.

          5.2 Initial Supply. Subject to the terms and conditions of this Agreement, during the
Initial Supply Term, Santarus agrees to supply and sell to GSK, and GSK agrees to purchase from
Santarus, PR Products for the Territory (such PR Products sold by Santarus to GSK referred to
herein as the “Initial Supply”). GSK shall purchase the Initial Supply from Santarus at the
applicable transfer price specified in Section 6.1. PR Product sold by Santarus from its inventory
to GSK as part of the Initial Supply will have a minimum of [***] shelf life remaining on the PR
Product as of the delivery date to the carrier for GSK with respect to PR Product for trade [***]
with respect to PR Product for samples); provided that (a) [***]; (b) [***]; and (c) [***].
Santarus in addition confirms that in relation to any supply of [***]. As used herein, “Initial
Supply Term” means the period ending on the earlier of (i) the date that GSK receives shipment of
PR Products from an Authorized Manufacturer pursuant to an agreement agreed between GSK and such

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-27-

 

Authorized Manufacturer as set forth in Section 5.3, and (ii) twelve (12) months from the
Effective Date; provided, however, that the Parties shall discuss in good faith extending the
Initial Supply Term for up to six (6) months in the event that GSK has not entered into an
agreement with an Authorized Manufacturer for PR Product as set forth in Section 5.3 within twelve
(12) months after the Effective Date, despite using Commercially Reasonable Efforts to do so.
Santarus shall have no obligation to supply PR Products to GSK after the end of the Initial Supply
Term. For clarity, after the end of the Initial Supply Term, GSK shall be responsible for
obtaining its requirements for PR Products for the Territory from the Authorized Manufacturer, and
Santarus shall have no liability with respect to such Authorized Manufacturer’s performance or
breach of the agreement between GSK and such Authorized Manufacturer.

               5.2.1 Forecasts for Initial Supply and for Planning. Not less than [***] days before
the first of each calendar month after the Effective Date, GSK shall provide to Santarus a [***]
month rolling forecast for its purchase of PR Products for each dosage form and strength. For
forecasts provided during the Initial Supply Term, the initial [***] months of such forecast (or
the portion thereof that is within the Initial Supply Term) shall be binding, and GSK shall place
purchase orders for the PR Products during such period as set forth in such forecast, and the
remainder shall be a good faith estimate of the anticipated volumes of all PR Product to be ordered
by GSK during such period. Santarus shall not be obligated to accept purchase orders for supply of
PR Product in excess of [***] of the binding portion of the rolling forecasts for each dosage form
and strength of PR Products. Notwithstanding the foregoing, purchase orders for supply of PR
Product during the first [***] months after the Effective Date shall be addressed as set forth in
Section 5.2.2. Except as provided in Section 5.2.2, below, Santarus will use Commercially
Reasonable Efforts to accept and fill [***] of firm orders by GSK issued in accordance with the
[***] months binding portion of such forecasts. Each such forecast will be signed by an authorized
representative of GSK indicating approval of such forecast.

               5.2.2 First Orders; Initial Limitation on Purchase Volumes. GSK’s purchase orders for
each dosage form and strength of PR Product for the first [***] months after the Effective Date
shall be issued within [***] days after the Effective Date. It is understood that Santarus shall
not be obligated to ship (or have shipped) PR Products prior to [***] days following the receipt of
GSK’s purchase order with respect to this initial [***] month period, and shall have no obligation
to accept orders for, or supply to GSK, PR Products during the first [***] months after the
Effective Date in excess of the amounts set forth on Schedule 5.2.2 for each dosage form and
strength of PR Product.

               5.2.3 Delivery Quantities and Frequency. Purchase orders by GSK with respect to the
[***] PR Products for commercial sale shall be for shipment [***], and purchase orders by GSK with
respect to [***] PR Products for commercial sale shall be for shipment [***]. Quantities of PR
Product actually shipped by Santarus may vary from the quantities specified in any purchase order
accepted by Santarus by up to [***] and still be deemed to be in compliance with such purchase
order; provided, however, that GSK will only be invoiced for the quantities that Santarus actually
ships pursuant to the purchase order. Regardless of any shipment dates set forth in GSK’s
forecasts or issued purchase orders, Santarus shall have no obligation to deliver PR Products more
frequently than [***] per Calendar Quarter.

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-28-

 

               5.2.4 Rejection of Initial Supply PR Product by GSK; Remedies.

                    (a) GSK may reject PR Product supplied by Santarus hereunder for failure to meet
Specifications and will notify Santarus of any such rejection of PR Product within [***] days after
delivery of such PR Product to GSK or its designee, and will set forth in such notification the
basis under this Agreement for such rejection, including any testing or inspection results;
provided, however, in the case of any PR Product having latent defects, which upon examination in
accordance with GSK’s reasonable testing or inspection procedures could not have been discovered,
GSK must give notice to Santarus within [***] days after discovery of such defect (but in no case
after expiration of the PR Product), setting forth the basis for such rejection. Failure to so
notify Santarus of, or to identify the basis under this Agreement for, rejection of any PR Product
within such [***] day periods will constitute acceptance of such PR Product.

                    (b) If Santarus agrees with GSK’s notification of non-conforming PR Product, or Santarus fails
to contest such notification in writing within [***] days after receipt of such notification,
Santarus will, at Santarus’ option, (i) credit GSK for the invoiced amount paid by GSK to Santarus
for such rejected PR Product or (ii) make replacement PR Product available for shipment as promptly
as reasonably practicable, and in no event less than [***] days, at no additional cost to GSK. At
Santarus’ option and cost, GSK will either deliver such non-conforming PR Product to Santarus or
destroy the same and provide to Santarus written documentation reasonably satisfactory to Santarus
to the effect that such non-conforming PR Product has been destroyed in accordance with Applicable
Law. If the Parties are unable to agree as to whether a shipment of PR Product supplied by
Santarus conforms with the Specifications, such question shall be submitted to an independent
quality control laboratory mutually agreed upon by the Parties on one hand and the Third Party
manufacturer on the other. The findings of such independent laboratory shall be binding upon the
Parties. The cost of the independent quality control laboratory shall be borne by the Party whose
results are shown by such laboratory to have been incorrect. Subject to Santarus’ indemnification
obligation under Section 9.1(a) or 9.1(d) (which are subject to Section 5.2.9), GSK’s exclusive
remedy for any non-conforming PR Product will be as provided in this Section 5.2.4.

               5.2.5 Shipment. GSK acknowledges and agrees that PR Product in the Initial Supply
will be delivered from the site of Santarus’ Third Party manufacturer of PR Products, the site of
Santarus’ Third Party distributor or other designee of Santarus, and will be shipped FCA (Incoterms
2000) the Third Party’s facility, and that title to and risk of loss with respect to PR Product
supplied by Santarus to GSK or its designee as part of the Initial Supply under this Section 5.2
will pass from Santarus to GSK upon delivery of PR Product to the carrier designated by GSK (or if
no carrier is designated by GSK, such carrier as Santarus or its designee may reasonably select).
GSK will be responsible for procuring insurance for the transport of PR Product from the facilities
of the Third Party to the shipping address designated by GSK in its purchase order. GSK shall not
permit PR Product in the Initial Supply to be shipped to any location other than directly to the
Territory. GSK acknowledges and agrees that, except for quantities of PR Product supplied by
Santarus as part of the Initial Supply pursuant to this Section 5.2, shipping terms and risk of
loss shall be determined in accordance with GSK’s contract with the applicable Authorized
Manufacturer, and Santarus shall have no liability with respect thereto.

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-29-

 

               5.2.6 Manufacture of PR Product. Santarus will manufacture PR Product in the Initial
Supply, or cause PR Product in the Initial Supply to be manufactured, in accordance with Good
Manufacturing Practices, Applicable Law, the Specifications, the Quality Agreement and the
applicable PR Product Registration, as each may be amended from time to time. At the time that
Santarus supplies PR Product to the carrier, such PR Product will not be adulterated or misbranded
within the meaning of the FD&C Act.

               5.2.7 Certificate of Compliance. Santarus will be responsible for batch release with
respect to PR Product within the Initial Supply, and will provide, or cause to be provided to GSK,
whichever the case may be, Certificates of Compliance for each lot of PR Product provided to GSK.

               5.2.8 Quality Agreement. Within thirty (30) days after the Effective Date, but in any
event prior to shipment of PR Product to GSK, the Parties will enter into the Quality Agreement.
The Quality Agreement shall be reviewed and revised, as may be necessary, annually by the Parties.
If there is a conflict between the Quality Agreement and this Agreement, this Agreement will
control.

               5.2.9 Accommodation; Limitation on Liability. GSK acknowledges that the Initial
Supply is provided as an accommodation to GSK in connection with appointing GSK as the exclusive
distributor for PR Products in the Territory and authorizing GSK to promote, distribute and sell PR
Products in the Territory under the terms and conditions of this Agreement. Accordingly, the
Parties agree that Santarus shall have no liability with respect to non-conformance of, or the
costs of complaint inspections, PR Product Actions or similar activities relating to, any PR
Product supplied by Santarus as part of the Initial Supply or noncompliance by the Authorized
Manufacturer with Applicable Law, Good Manufacturing Practices or the Quality Agreement, except
solely the extent of amounts recovered by Santarus from the applicable Authorized Manufacturer
therefor (and solely to the extent allocable to PR Products for the Territory supplied to, and paid
for by, GSK hereunder as part of the Initial Supply). In the event of any shortage of supply of PR
Product or API to either Party as a result of a Force Majeure, [***].

               5.2.10 Subcontracts; GSK Review of Agreements. Santarus may subcontract all or any
part of the manufacture or supply of the Initial Supply of PR Products without the consent of GSK;
provided, however, that, subject to Section 5.2.9, Santarus will remain responsible for all of its
obligations to GSK under this Agreement, including the performance of its subcontractors in
supplying PR Product in the Initial Supply to GSK, and Santarus will provide GSK with reasonable
notification of any addition or removal of Third Parties involved in the supply chain of PR Product
during the Initial Supply Term. Upon request of GSK during the Initial Supply Term, Santarus will
provide GSK redacted copies of its agreements with Authorized Manufacturers of PR Products supplied
to GSK as part of the Initial Supply.

               5.2.11 Section Applicable Only to Initial Supply. It is understood and agreed that
the provisions of this Section 5.2 apply only with respect to the Initial Supply of PR Products
from Santarus to GSK. It is understood and agreed that corresponding matters regarding PR Product
supplied to GSK by an Authorized Manufacturer shall be governed by the agreement between GSK

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-30-

 

and such Authorized Manufacturer, and Santarus shall have no liability with respect to such
Authorized Manufacturer’s performance or breach of such agreement.

          5.3 Manufacture of PR Product by GSK. GSK shall assume responsibility for obtaining
supplies of, and managing its supply chain for, PR Products for the Territory as soon as reasonably
practicable after the Effective Date.

               5.3.1 Contract with Authorized Manufacturer. Promptly following the Effective Date,
Santarus shall introduce GSK to Santarus’ Third Party manufacturers of PR Products and API (each an
"Authorized Manufacturer”) not already introduced by Santarus to enable GSK to negotiate an
agreement between GSK and each such Authorized Manufacturer for the supply of PR Products and API
by such Authorized Manufacturer to GSK for GSK’s distribution and sale solely within the Territory
or the GSK Territory under the ROW License. Each such agreement shall:

                    (a) require that the Authorized Manufacturer’s manufacture, handling, storage, analysis and
testing and other activities with respect to the PR Product for the Territory be conducted in
accordance with Good Manufacturing Practices, all Applicable Law, the PR Product Registration
(including any future modifications thereof), and using the same manufacturing, testing and
analysis procedures as are used in connection with manufacture of Santarus’ PR Product for the
United States market;

                    (b) expressly provide that Santarus’ prior approval shall be required before implementation of
any planned change in the manufacture, handling, testing and analysis or storage of PR Products for
the Territory;

                    (c) [***];

                    (d) provide the right for Santarus to inspect the facilities, inventories and records of such
Authorized Manufacturer with respect to PR Products supplied, or to be supplied, to GSK for the
Territory;

                    (e) prohibit PR Product to be shipped from the manufacturer anywhere other than directly to
the Territory;

                    (f) not prohibit the manufacturer from manufacturing or supplying PR Product or API, as
applicable, to Santarus or its designees; and

                    (g) be consistent in all respects with the terms and provisions of this Agreement, including
the provisions regarding use of the Trademarks in connection with the packaging and labeling of the
PR Products for the Territory.

               5.3.2 Supply Shortage. In the event that Santarus and GSK are using the same
Authorized Manufacturer for PR Products or API and there is any shortage of supply of PR Products
or API to either Party as a result of a Force Majeure event, [***].

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

-31-

 

               5.3.3 Additional Equipment or Tooling. Nothing in this Agreement shall be construed
as conveying rights for one Party to use tooling or equipment purchased by the other Party for a
manufacturer or supplier or as requiring Santarus to share the cost of additional equipment or
tooling necessary for a manufacturer to meet increased supply due to GSK’s use of the same
manufacturer as Santarus.

               5.3.4 GSK Inventories. GSK shall use Commercially Reasonable Efforts to maintain
sufficient levels of inventory of raw materials, API and PR Product in order to meet market demand
for PR Product in the Territory.

               5.3.5 Additional Authorized Manufacturers. GSK may notify Santarus in writing at any
time that GSK desires another manufacturer to be deemed an Authorized Manufacturer of PR Product.
Santarus’ consent in writing shall be required prior to any manufacturer becoming an Authorized
Manufacturer of PR Product, which consent shall not be unreasonably withheld, conditioned or
delayed. In the event Santarus consents to a manufacturer becoming an Authorized Manufacturer:

                    (a) GSK shall reimburse Santarus for its costs and expenses incurred as a result of such
manufacturer becoming an Authorized Manufacturer, including those costs and expenses incurred in
connection with establishment fees, inspections, investigations and audits of the manufacturer,
regulatory filings, correspondence and other interactions with Governmental Authorities and similar
activities directly related to GSK’s use of the additional Authorized Manufacturer;

                    (b) GSK and the manufacturer shall provide all data, information and records reasonably
required by Santarus in order to file and maintain the PR Product Registrations;

                    (c) The manufacturer must be approved by FDA as a manufacturer of PR Product for the
Territory;

                    (d) GSK’s contracts with such manufacturer shall comply with the requirements set forth in
Section 5.3.1; and

                    (e) GSK shall introduce Santarus to the manufacturer and, upon Santarus’ request, facilitate
one or more meetings between Santarus and the manufacturer for the purpose of negotiating potential
supply by such manufacturer of PR Products or API, as applicable, to Santarus.

ARTICLE 6

PAYMENTS

          6.1 Transfer Price. In addition to the royalties set forth in Section 6.2 below, for
all PR Product supplied by Santarus as set forth in Section 5.2, GSK shall pay Santarus a transfer
price with respect to each formulation and strength of PR Product equal to the applicable amount
per unit set forth on Schedule 6.1 (the “Transfer Price”) with respect to PR Product supplied to
GSK or its designee by or on behalf of Santarus, together with all applicable sales, use, excise and
other taxes (but excluding income tax) and duties imposed by any Government Authority. Except for
and to the

-32-

 

extent of any unexpected increases in Santarus’ Manufacturing Cost or its internal costs
in supplying PR Product to GSK, the Transfer Price shall be fixed for the first [***] of the
Initial Supply Term. In the event the Initial Supply Term is extended pursuant to Section 5.2, the
Parties shall negotiate in good faith the Transfer Price to be applied for such extended period.
Full payment for PR Products supplied by Santarus to GSK shall be due and payable within [***] days
following the date of receipt of Santarus’ invoice which shall be sent to GSK [***].

          6.2 Royalties on Net Sales. In partial consideration for the rights and licenses
granted to GSK under this Agreement, GSK shall pay to Santarus tiered royalties on Net Sales of PR
Products in the Territory during the Royalty Term at the applicable rates set forth in Section
6.2.1 below, subject to adjustment as set forth in Section 6.2.2 below and subject to Section
6.2.3. Royalties with respect to Net Sales made in each Calendar Quarter shall be paid within
[***] days following the applicable Calendar Quarter end.

               6.2.1 Royalty Rates. It is understood and agreed that applicable royalty rates on Net
Sales of PR Products under this Agreement shall be determined based on the total aggregate of (i)
Net Sales of PR Products under this Agreement, together with (ii) any and all Net Sales (as defined
under the ROW License) of Licensed Products (as defined under the ROW License) (collectively,
“Aggregate Product Net Sales”) during the applicable calendar year, as follows:

	 	 	 
	Aggregate Product Net Sales	 	 
	(in U.S. Dollars) During	 	 
	Applicable Calendar Year	 	Royalty Rate
	[***]

	 	[***]
	[***]

	 	[***]
	[***]

	 	[***]

               6.2.2 Reduction for Substantial Generic Competition.

                    (a) Reduction. In the event that, and for so long as, there exists Substantial
Generic Competition in the Territory: (a) the royalty rates payable under Section 6.2.1 for Net
Sales shall be reduced from the rates of [***],[***] and [***] specified in Section 6.2.1, above,
to [***],[***] and [***], respectively, and (b) [***]. As used herein, “Substantial Generic
Competition” means that, during the immediately preceding [***] Calendar Quarters, combined sales
of Generic Products in the Territory by Third Parties equate to at least [***], as measured by IMS
data. For clarity, the royalty reduction set forth in this Section 6.2.2 shall only apply for so
long as there is Substantial Generic Competition, and the royalty rates set forth in Section 6.2.1
shall again apply if Substantial Generic Competition ceases at any time during the Royalty Term
following a royalty reduction pursuant to this Section 6.2.2. GSK shall notify Santarus in writing
within [***] days after GSK becomes aware of any Substantial Generic Competition.

                    (b) Allocation of Reduction Among Royalty Tiers. In the event that Substantial
Generic Competition (as set forth in this Section 6.2.2 or Section 7.2.2 of the ROW
License, as applicable) occurs in any one or more, but not all, of the countries in the
Territory under this Agreement and the GSK Territory under the ROW License, then the royalty
reduction described

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-33-

 

in Section 6.2.2(a) above and under Section 7.2.2 of the ROW License shall be
allocated to a portion of Net Sales in each royalty tier described in Section 6.2.1 above (or
Section 7.2.1 of the ROW License, as applicable) equal to the proportion of Aggregate Product Net
Sales under this Agreement and the ROW License eligible for such reduction compared to the total
Aggregate Product Net Sales. By way of example, and not limitation, if the total Aggregate Product
Net Sales for the first Calendar Quarter of a given calendar year is $50 million, and $10 million
of such Aggregate Product Net Sales occurs in countries with Substantial Generic Competition
(meaning 20% of total Aggregate Product Net Sales for such Calendar Quarter occurred in countries
with Substantial Generic Competition), then (A) the reduced royalty rates set forth in Section
6.2.2 (a) above and in Section 7.2.2 of the ROW License shall apply to 20% of the Aggregate Product
Net Sales in each applicable royalty tier, and (B) the unreduced royalty rates set forth in Section
6.2.1 above and in Section 7.2.1 of the ROW License shall apply to the remaining 80% of the
Aggregate Product Net Sales in each applicable royalty tier.

                    (c) [***]

               6.2.3 Waiver of Certain Amount of Initial Royalties. To support GSK’s
commercialization of PR Products in the Territory and help defray start-up costs of GSK, Santarus
agrees to waive the first Two Million Five Hundred Thousand Dollars ($2,500,000) of combined
royalties due from GSK under this Section 6.2 of this Agreement and Section 7.2 of the ROW License.
For clarity, the waiver of royalties under this Section 6.2.3 and under Section 7.2.3 of the ROW
License together shall not exceed Two Million Five Hundred Thousand Dollars ($2,500,000) in the
aggregate.

               6.2.4 Royalty Term; Buyout Payment. The obligation of GSK to pay royalties under this
Section 6.2 shall continue until the end of the Term, unless GSK pays to Santarus upon the
twentieth (20th) anniversary of the Effective Date an amount (the “Buyout Payment”)
equal to [***]. In the event GSK timely pays the Buyout Payment, GSK’s obligation to pay royalties
under this Section 6.2 shall cease; provided, however, that GSK shall thereafter continue to pay
Santarus continuing royalties equal to the amount of royalties (if any) that Santarus is required
to pay under the Missouri Agreement with respect to PR Products sold by or under authority of GSK
in the Territory.

               6.2.5 Convenience. GSK agrees that substantial commercial value has been and will be
contributed by the appointment as Santarus’ exclusive distributor of PR Products in the Territory
and other rights conveyed to GSK on the terms and conditions set forth in this Agreement, and
acknowledges that Santarus may not own or control patents covering the manufacture, use or
commercialization of PR Products throughout the Royalty Term. For their mutual convenience, the
Parties have agreed to the royalty rates and payment obligations set forth in this Agreement with
respect to Net Sales of PR Products in the Territory, regardless of whether the manufacture, use or
commercialization of PR Products sold by GSK hereunder is covered by patents owned or controlled by
Santarus.

          6.3 Reimbursement of Certain Expenses. GSK acknowledges that Santarus will be the
holder of the applicable NDAs and PR Product Registrations for the PR Products and will,

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-34-

 

therefore,
have certain responsibilities under Applicable Law with respect to reporting and other
communications with the FDA and certain other regulatory activities in connection with the PR
Products for the Territory. Accordingly, GSK agrees to reimburse Santarus, within thirty (30) days
after invoice by Santarus, for internal and out-of-pocket expenses incurred by Santarus after the
Effective Date in connection with regulatory communications and activities (including any
modifications to the PR Product Registration, preparation and submission of Annual Reports and
interactions with DDMAC with respect to Promotional Materials), quality control and assurance,
Adverse Events, Customer complaints, recalls, out-of-specification runs, and other expenses
incurred by Santarus with respect to PR Product for the Territory; provided, however, that if any
such expense is incurred both for the PR Product for the Territory and for PR Product for the
United States market, GSK shall only be responsible to reimburse Santarus for that portion of such
expenses reasonably attributable to the PR Product in or for the Territory. Santarus shall use
Commercially Reasonable Efforts to provide on a regular basis good faith non-binding estimates of
expenses to be reimbursed by GSK under this Section 6.3.

          6.4 Withholding. [***].

          6.5 Method of Payments. All amounts payable to Santarus under this Agreement shall be
paid in U.S. Dollars by wire transfer to a bank account it designates. All payments hereunder
shall be made in the legal currency of the United States of America, and all references to “$” or
“Dollars” shall refer to United States dollars. Except as otherwise set forth in this Agreement,
including Sections 6.1 and 6.2, all amounts payable to Santarus under this Agreement shall be paid
within a maximum of thirty (30) days from receipt of an invoice from Santarus. All payments under
this Agreement shall bear interest from the date due until paid at a rate equal to [***], or, if
less, the maximum rate permitted by Applicable Law. The payment of such interest shall not limit
Santarus from exercising any other rights it may have as a consequence of the lateness of any
payment or breach of this Agreement by GSK.

          6.6 Royalty Reports. GSK shall, within [***] days following each Calendar Quarter,
make quarterly written reports to Santarus stating in each report, separately for GSK and each of
its Affiliates and sub-distributors and separately for Puerto Rico and the U.S. Virgin Islands:
(a) the number, description and aggregate gross amounts invoiced and Net Sales of each PR Product
sold in the Territory during the immediately preceding quarter, including reasonably detailed
descriptions of all itemized deductions from gross amounts invoiced; (b) the number of PR Products
sold or distributed on a product-by-product basis; (c) the calculated amount of royalties due
Santarus on account of such Net Sales; and (d) the basis for calculation of royalties due to
Santarus, including applicable deductions or adjustments, and the royalty due to Santarus thereon.
If no royalties are due for a particular quarter, GSK shall so report to Santarus. GSK’s reports
under this Section 6.6 shall be transmitted to Santarus by email (to [***] and [***], or to such
other e-mail address(es) as Santarus may from time to time designate in writing). Quarterly
reports shall be sent within thirty (30) days after the end of each Calendar Quarter. The reports
required under this Section 6.6 may be combined with royalty reports due under the ROW License;
provided that any such combined report shall set forth the required information separately for the
Territory.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-35-

 

          6.7 Audits.

               6.7.1 By Santarus. GSK shall keep, and cause its Affiliates and any permitted
sub-distributors to keep, complete and accurate records in sufficient detail to enable a
calculation of royalties due to Santarus on account of Net Sales of PR Products in the Territory,
determined in accordance with GAAP (including calculation of gross amounts invoiced for each PR
Product, Net Sales of each PR Product, all itemized deductions from gross amounts invoiced taken to
calculate Net Sales, and amounts payable hereunder to Santarus for each PR Product), as well as a
calculation of any credits for Inter-Territory Sales. For the sole purpose of verifying amounts
relating to this Agreement, Santarus shall have the right no more than [***] each calendar year, at
its own expense, to have agents or representatives of Santarus or any of its licensors of
Intellectual Property review such records for the [***] Calendar Quarters preceding such review in
the location(s) where such records are maintained by GSK and its Affiliates upon reasonable notice
and during regular business hours. Results of such review shall be made available to GSK. The
records and results of such audits shall be deemed Confidential Information of GSK. In the event
that such a review identifies an underpayment greater than [***] of the amounts that were otherwise
due for a [***] during such period, [***]. Further, if the review reflects an underpayment to
Santarus, such underpayment shall be promptly remitted to Santarus, together with interest
calculated in the manner provided in Section 6.5. If the review reflects an overpayment to
Santarus, such overpayment shall be credited against the next payment due Santarus. If the review
reveals an underpayment of more than [***] of the amounts due for any period of [***], GSK shall
reimburse Santarus for the costs of such audit.

               6.7.2 By GSK. Santarus shall keep, and cause its Affiliates to keep, complete and
accurate records in sufficient detail to enable a calculation of any increased Manufacturing Cost
of the PR Products that resulted in any increase in the Transfer Price, a calculation of rebates,
administrative fees or chargebacks payable by GSK pursuant to Section 3.5.2 or a calculation of
amounts payable by GSK under Section 6.3. For the sole purpose of verifying such increase in
Manufacturing Cost and other amounts required to be paid by GSK under Section 3.5.2 or Section 6.3,
GSK shall have the right no more than [***] each calendar year, at its own expense, to have agents
or representatives of GSK review such records for the [***] preceding such review in the
location(s) where such records are maintained by Santarus and its Affiliates upon reasonable notice
and during regular business hours. Results of such review shall be made available to Santarus.
The records and results of such audits shall be deemed Confidential Information of Santarus. In
the event that such a review identifies an overpayment greater than [***] of the amounts that were
otherwise due for a [***] during such period, [***]. Further, if the review reflects an
underpayment to GSK, such underpayment shall be promptly remitted to Santarus, together with
interest calculated in the manner provided in Section 6.5. If the review reflects an overpayment
to Santarus, such overpayment shall be credited against the next payment due Santarus. If such
review reveals an overpayment of more than [***] of the amounts due for any period of [***],
Santarus shall reimburse GSK for the costs of such audit.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-36-

 

ARTICLE 7

COMMUNICATION; AUDITS AND REGULATORY MATTERS

          7.1 Safety Data Exchange. GSK agrees to notify Santarus concerning possible Serious
Adverse Events, and possible Adverse Events that are not Serious Adverse Events, within the
respective time periods, and in accordance with the applicable procedures, set forth in a
pharmacovigilance agreement to be mutually agreed and executed by the Parties within thirty (30)
days of the Effective Date but in any event prior to the first sale of PR Product by or under
authority of GSK, which pharmacovigilance agreement shall be reviewed and revised, as may be
necessary, annually by the Parties.

          7.2 Medical Information Services. On or within [***] after the Effective Date,
Santarus will provide to GSK, Santarus’ current database of Medical Information Letters (if any)
regarding the PR Product; provided, however, that GSK will be solely responsible and liable for any
use or modification of such Medical Information Letters by GSK. From and after the Effective Date,
at GSK’s cost and expense, Santarus will promptly refer all requests and inquiries from healthcare
professionals and consumers of the PR Product in the Territory to GSK, and GSK will provide to
Santarus the telephone number to which such call will be referred. Within thirty (30) days of the
Effective Date and prior to launch, GSK and Santarus will jointly develop written procedures for
the administration of, and response to, medical inquiries concerning PR Product in the Territory by
consumers, physicians, pharmacists and other health care professionals. GSK and Santarus will each
comply with the provisions thereof at GSK’s cost and expense.

          7.3 PR Product Recalls, Complaints and other Matters.

               7.3.1 PR Product Complaints.

                    (a) Each Party will use its Commercially Reasonable Efforts to provide, within [***] after
receipt, but not longer than [***] after receipt, the other Party with written notice via facsimile
of all complaints it receives that relate to, or arise from, PR Product sold in the Territory,
including those concerning manufacture, packaging, safety or efficacy of such PR Product,
Promotional Materials or Promotional Activities. Notwithstanding the foregoing, each Party will
use its Commercially Reasonable Efforts to, within [***] after receipt, provide the other Party
with written notice via facsimile of all reports of complaints of tampering or contamination that
relate to, or arise from, PR Product sold in the Territory.

                    (b) Santarus will investigate all complaints that may be attributable to the manufacture,
packaging, safety or efficacy of PR Product supplied to GSK by Santarus as part of the Initial
Supply and provide a written summary to GSK. GSK will investigate all other complaints associated
with PR Product supplied to GSK by Santarus as part of the Initial Supply and all complaints that
may be attributable to the manufacture, packaging, safety, or efficacy of PR Product after Initial
Supply and provide a written summary to Santarus. GSK also will provide a written response on each
complaint to each complainant with a copy to Santarus. The Parties will reasonably cooperate with
each other concerning the investigation of such PR Product complaints, and will provide such
information as reasonably requested by the other Party in connection with

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-37-

 

such investigations. Santarus and GSK will develop procedures for providing information on PR
Product complaints and inquiries and such procedures will be outlined in the Quality Agreement.
Nothing in this Section 7.3.1 will affect the Parties’ obligations with respect to
pharmacovigilance reporting, as detailed in Section 7.1 or under any pharmacovigilance agreement
between the Parties.

               7.3.2 Recalls, Withdrawals, Field Alerts and Other Field Corrections.

                    (a) GSK will promptly provide to Santarus any information obtained by it or its Affiliates
suggesting that a PR Product Action is or may be necessary; provided that GSK will use its
Commercially Reasonable Efforts to provide Santarus with such information within [***] after
receipt by GSK. Further, GSK will cooperate with Santarus in obtaining any additional information
that may bear upon whether to initiate any PR Product Action. The final decision regarding whether
to initiate a PR Product Action will, however, rest with Santarus.

                    (b) Santarus will provide GSK with prompt notice of any determination by Santarus to initiate
a PR Product Action, and GSK will immediately comply with all reasonable applicable policies
established by Santarus from time to time and communicated to GSK in order to effectuate such PR
Product Actions (provided that Santarus will use its Commercially Reasonable Efforts to provide GSK
with such determination within [***] after such determination is made). Further, GSK will
undertake whatever actions may be reasonably requested by Santarus to facilitate a PR Product
Action, including ensuring dissemination of information to its distributors and other Customers and
administering the retention, return and disposition of the applicable PR Product inventory in the
Territory.

                    (c) The reasonable costs of any PR Product Actions attributable or allocable to handling,
storage, possession, use, marketing distribution, promotion or sale of PR Products in or for the
Territory, or to regulatory or promotional activities for PR Products in or for the Territory
(including the reasonable costs of notifying GSK’s Customers, the reasonable costs associated with
shipment of the PR Products from GSK’s (and its Affiliates’) Customers, reasonable credits extended
to GSK’s and its Affiliates’ Customers as a result of the PR Product Action, and other reasonable
costs incurred) will be borne by GSK.

                    (d) The reasonable costs of any PR Product Actions attributable or allocable to the
manufacture of PR Products in or for the Territory during the Initial Supply (including the
reasonable costs of notifying GSK’s Customers, the reasonable costs associated with shipment of the
PR Products from GSK’s (and its Affiliates’) Customers, reasonable credits extended to GSK’s and
its Affiliates’ Customers as a result of the PR Product Action, and other reasonable costs
incurred) will be borne by Santarus, but only to the extent of amounts recovered by Santarus from
the applicable Authorized Manufacturer therefor (and solely to the extent allocable to PR Products
for the Territory supplied to, and paid for by, GSK hereunder as part of the Initial Supply).

          7.4 Additional Covenants of GSK. GSK (a) shall not give any Customers any guarantee
or warranty on behalf of Santarus, (b) shall enter into all sale contracts for PR Product as a
principal (as opposed to an agent of Santarus), (c) shall follow up and investigate Customer and

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-38-

 

tampering complaints related to PR Product, subject to Section 7.3, and keep Santarus
informed, as appropriate, as to the nature, status and resolution of such complaints on a timely
basis with sufficient information to Santarus to investigate such complaints, and (d) shall, upon
receipt by GSK of any PR Product, handle, use and store PR Product in compliance with Good
Manufacturing Practices, the Quality Agreement and Applicable Law.

          7.5 Compliance with Applicable Law. Each Party shall maintain in full force and
effect all necessary licenses, permits and other authorizations required by Applicable Law to carry
out its duties and obligations under this Agreement. Each Party shall comply with all Applicable
Laws in all material respects, provided that GSK will be solely responsible for compliance with
Applicable Laws pertaining to the marketing, promotion, advertisement, sale or distribution of the
PR Product in the Territory by or on behalf of GSK (including Applicable Laws that apply to
documentation and records retention pertaining to the distribution and use of PR Product in the
Territory). GSK will store and distribute the PR Product in compliance with all Applicable Laws.
Each Party will cooperate with the other to provide such letters, documentation and other
information on a timely basis as the other Party may reasonably require to fulfill its reporting
and other obligations to Government Authorities under Applicable Law with respect to activities
hereunder. Except for such amounts as are expressly required to be paid by a Party to the other
under this Agreement, each Party will be solely responsible for any costs incurred by it to comply
with its obligations under Applicable Law.

          7.6 Reasonable Cooperation. Santarus and GSK each hereby agrees to use Commercially
Reasonable Efforts to take, or cause to be taken, all actions and to do, or cause to be done, all
things necessary or proper to make effective the transactions contemplated by this Agreement,
including such actions as may be reasonably necessary to obtain approvals and consents of
Governmental Authorities necessary to fulfill its respective obligations under this Agreement.

          7.7 Distribution and Manufacturing Compliance Audits.

               7.7.1 GSK Facilities. From time to time as Santarus may elect during the Term (but no
more than [***] each calendar year), during normal business hours and upon reasonable notice from
Santarus (but not less than [***] prior notice), duly authorized representatives of Santarus,
reasonably acceptable to GSK, may review and inspect, to the extent relevant to GSK’s marketing and
distribution of PR Product, the premises, facilities, records, inventory and documentation
maintained by GSK or any distribution facility where PR Product is stored for the purpose of
determining compliance by GSK with its obligations under this Agreement.

               7.7.2 Authorized Manufacturer. GSK shall permit, and shall ensure that each Authorized
Manufacturer permits, Santarus to review and inspect upon reasonable notice, to the extent relevant
to the manufacture and distribution of PR Products, the premises, facilities, inventories of PR
Products and materials used in the manufacture thereof, records and documentation maintained by
such Authorized Manufacturer for the purpose of determining compliance with the PR Product
Registration and Applicable Law.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-39-

 

               7.7.3 Urgent Inspection. In the event of an Adverse Event, any proposed or actual
inspection by a Governmental Authority, or other emergency involving PR Product, Santarus will have
the right at any time upon oral or written notice to GSK of [***] to conduct an inspection of each
distribution facility of GSK or its designee and on the premises of GSK or its designee where PR
Product is kept, inventory of PR Product, storage documentation and GSK’s quality control records
relating to the storage of PR Product to ensure compliance with Applicable Law and with applicable
terms of this Agreement. GSK will promptly respond to Santarus’ request and the Parties will agree
on the time, scope and manner of the inspection. For the avoidance of doubt, Santarus’ audit,
inspection and physical inventory rights under this Section 7.7.3 will not extend to any portions
of the distribution facilities of GSK, documents, records or other information which do not relate
to PR Product, and GSK may redact information not related to PR Product from any documents
deliverable to Santarus in connection with Santarus’ exercise of its audit, inspection and physical
inventory rights hereunder.

          7.8 Notice of Regulatory Action. GSK and Santarus agree to provide the other Party
with written notice in the event that it receives notice of any regulatory violations which
directly relate to the PR Product in or for the Territory and which would affect the Parties’
ability to meet its obligations under this Agreement.

ARTICLE 8

REPRESENTATIONS AND WARRANTIES

          8.1 Representations and Warranties of Both Parties. Each Party hereby represents and
warrants to the other Party that, as of the Effective Date:

               8.1.1 Good Standing. Such Party is duly organized, validly existing and in good
standing under the Applicable Law of the state or country of its incorporation, is duly qualified
to transact the business in which it is engaged in each jurisdiction where failure to be so
qualified would have a material adverse effect upon its business as currently conducted, and has
full corporate power and authority to enter into this Agreement and to carry out the provisions of
this Agreement.

               8.1.2 Power and Authority. Such Party has the requisite power and authority and the
legal right to enter into this Agreement, and to perform its obligations hereunder, and has taken
all necessary corporate action on its part to authorize the execution and delivery of the Agreement
and the performance of its obligations hereunder. All Persons who have executed this Agreement on
behalf of such Party, or who will execute on behalf of such Party any agreement or instrument
contemplated hereby, have been duly authorized to do so by all necessary corporate action.

               8.1.3 Binding Obligation. This Agreement has been duly executed and delivered on its
behalf and (assuming the due execution and delivery hereof by the other Party) each such agreement
is a legal and valid obligation binding upon it and is enforceable, in accordance with its terms,
to the extent provided under Applicable Law.

               8.1.4 No Conflicts. The execution and the delivery of this Agreement by such Party
and the consummation of the transactions contemplated hereby will not, to the best of such Party’s

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-40-

 

knowledge, materially conflict with or result in a material breach of any of the terms,
conditions or provisions of, or constitute an express event of default under, any material
instrument, agreement, mortgage, judgment, order, award or decree to which such Party is a party or
by which it is bound.

               8.1.5 Compliance with Applicable Law. Such Party and its Affiliates are, and will
ensure that they remain throughout the Term, in compliance in all material respects with all
requirements of Applicable Law.

               8.1.6 Litigation and Claims. There is no litigation, arbitration, claim, governmental
or other proceeding (formal or informal), or, to the knowledge of such Party, governmental
investigation pending or threatened in writing against such Party or any of its Affiliates which,
if adversely determined, would have a material adverse effect with respect to such Party performing
its obligations hereunder with respect to PR Products in or for the Territory (except, in the case
of Santarus, as publicly disclosed by Santarus).

          8.2 Representations and Warranties of Santarus. Santarus hereby represents and
warrants to GSK that, as of the Effective Date:

               8.2.1 Regulatory Filings. Santarus has provided GSK with access to review each of the
PR Product Registrations, including all material amendments and supplements thereto, relating to
the PR Product with respect to the Territory, and of all material FDA correspondence pertaining to
such PR Product Registrations. Santarus is the lawful holder of all rights under each of the PR
Product Registrations. Santarus has complied in all material respects with all Applicable Law in
connection with the preparation and submission to the FDA of each of the PR Product Registrations,
and each of the PR Product Registrations has been approved by the FDA.

               8.2.2 Trademarks. Santarus is the owner of all of the issued Trademark registrations
listed in Schedule 1.68, and the Trademark registrations are in full force and effect and have been
maintained to date.

               8.2.3 No Third Party Claims. Santarus has not received any written claim or demand
from any Third Party alleging that any infringement, violation or misappropriation of such Third
Party’s intellectual property rights has occurred as a result of Santarus’ activities related to
the PR Product in the United States or the Territory, nor is Santarus aware of any material actual,
alleged or threatened infringement, violation or misappropriation by a Third Party of any of the
Trademarks in the Territory.

               8.2.4 Clinical and Regulatory Information. The clinical and regulatory data regarding
the PR Product that Santarus has made available to GSK prior to the Effective Date is true and
accurate in all material respects, and Santarus has to its knowledge, as of the Effective Date,
[***].

               8.2.5 Managed Care Market Agreements. Santarus’ agreements or programs with the
Managed Care Market do not provide for higher rebates, administrative fees or chargebacks with
respect to PR Product in the Territory than in the United States.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-41-

 

          8.3 Representations and Warranties of GSK. GSK hereby represents and warrants to
Santarus that, as of the Effective Date, neither GSK nor any of its Affiliates are debarred,
suspended or otherwise excluded by any Governmental Authority from receiving government contracts
in the Territory, nor is it, or its Affiliates or any of its employees debarred under the
applicable provisions of the FD&C Act.

          8.4 No Reliance by Third Parties. The representations and warranties of a Party set
forth in this Agreement are intended for the sole and exclusive benefit of the other Party hereto,
and may not be relied upon by any Third Party.

          8.5 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THERE
ARE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, MADE OR GIVEN BY EITHER PARTY HEREUNDER,
INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, INCLUDING PR
PRODUCTS IN THE INITIAL SUPPLY, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD
PARTY.

ARTICLE 9

INDEMNIFICATION; INSURANCE AND LIMITATIONS

          9.1 Santarus Indemnification Obligations. Santarus will indemnify, defend and hold
harmless GSK, its Affiliates, and their respective officers, directors, trustees, agents, employees
and permitted sub-distributors (collectively, “GSK Indemnitees”), from and against any and all
losses, liabilities, claims, obligations, demands, awards, settlements, penalties, fines, suits,
damages, costs (including costs of investigation, defense and enforcement of this Agreement), fees,
taxes, and expenses, including reasonable attorneys’ fees, experts’ fees and expenses, incurred or
suffered in respect of a claim or action of a Third Party (collectively, “Losses”), that are
incurred or suffered by the GSK Indemnitees or any of them by reason of, arising out of or in
connection with:

                    (a) subject to Section 5.2.9, any breach of contract or negligence on the part of Santarus in
performing Santarus’ obligations under this Agreement;

                    (b) the distribution, marketing, advertisement, promotion or sale of PR Product in the
Territory, by or under authority of Santarus (i) prior to the Effective Date, (ii) after the
termination of this Agreement, or (iii) during the Term of this Agreement pursuant to Santarus’
retained rights under Section 2.2.3;

                    (c) the distribution, marketing, advertisement, promotion or sale of PR Product outside of the
Territory and outside of the GSK Territory under the ROW License, including any actual or alleged
infringement of a Third Party’s intellectual property rights, by or under authority of Santarus or
its Affiliates; or

                    (d) any violation of Applicable Law by Santarus in the performance of any of Santarus’
obligations under this Agreement;

-42-

 

provided, however, except in each case to the extent that such Loss is attributable to any matter
for which GSK is obligated to indemnify a Santarus Indemnitee as provided in Section 9.2 below.

          9.2 GSK Indemnification Obligations. GSK will indemnify, defend and hold harmless
Santarus, its Affiliates and licensors (including the UMissouri), and their respective officers,
directors, trustees, agents, curators and employees (collectively, “Santarus Indemnitees”), from
and against any and all Losses incurred or suffered by the Santarus Indemnitees or any of them, by
reason of, arising out of or in connection with:

                    (a) Any breach of contract or negligence on the part of GSK in performing GSK’s obligations or
permitted activities under this Agreement;

                    (b) the manufacture (excluding manufacture as part of the Initial Supply), storage, handling,
distribution, marketing, advertisement, promotion, use or sale of PR Product, by or under authority
of GSK, its Affiliates or sub-distributors; or

                    (c) any violation of Applicable Law by GSK in the performance of any of GSK’s obligations
under this Agreement;

provided, however, except in each case to the extent that such Loss is attributable to any matter
for which Santarus is obligated to indemnify a GSK Indemnitee as provided in Section 9.1 above.

          9.3 Indemnity Procedures. A Person entitled to indemnification pursuant to either
Section 9.1 or Section 9.2 will hereinafter be referred to as an “Indemnitee.” A Party obligated
to indemnify an Indemnitee hereunder will hereinafter be referred to as an “Indemnitor.” In the
event an Indemnitee is seeking indemnification under either Section 9.1 or Section 9.2, the
Indemnitee will inform the Indemnitor of a claim as soon as reasonably practicable after it
receives notice of the claim, it being understood and agreed that the failure by an Indemnitee to
give notice of a claim as provided in this Section 9.3 will not relieve the Indemnitor of its
indemnification obligation under this Agreement except and only to the extent that such Indemnitor
is actually prejudiced as a result of such failure to give notice. The Indemnitee will permit the
Indemnitor to assume direction and control of the defense of the claim (including, subject to this
Section 9.3, the right to settle the claim solely for monetary consideration to be paid by the
Indemnitor), and, at the Indemnitor’s expense, will co-operate as reasonably requested in the
defense of the claim. The Indemnitee will have the right to retain its own counsel at its own
expense; provided that if the Indemnitor assumes control of such defense and the Indemnitee
reasonably concludes, based on advice from counsel, that the Indemnitor and the Indemnitee have
conflicting interests with respect to such action, suit, proceeding or claim, the Indemnitor will
be responsible for the reasonable fees and expenses of counsel to the Indemnitee solely in
connection therewith. The Indemnitor may not settle such action or claim, or otherwise consent to
an adverse judgment in such action or claim, in any manner which admits liability or wrongdoing of
the Indemnitee, or which would subject the Indemnitee to an injunction, or if such settlement or
judgment would materially diminish or limit or otherwise adversely affect the rights, activities or
financial interests of the Indemnitee, without the express written consent of the Indemnitee.

-43-

 

          9.4 No Punitive or Exemplary Damages. EXCEPT FOR BREACHES OF THE OBLIGATIONS SET
FORTH IN SECTIONS 2.6 AND 2.7 AND ARTICLE 11, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR
SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOSS OF PROFITS) SUFFERED BY THE
OTHER PARTY UNDER THIS AGREEMENT, EXCEPT TO THE EXTENT A PARTY IS REQUIRED TO INDEMNIFY THE OTHER
PURSUANT TO ARTICLE 9 WITH RESPECT TO ANY SUCH DAMAGES PAID TO A THIRD PARTY AS PART OF A CLAIM.

          9.5 Insurance.

               9.5.1 Santarus. Santarus shall maintain self insurance or comprehensive general
liability insurance (“CGL”), including broad form contractual liability, in an amount of at least
[***] Dollars ($[***]) and product liability coverage in an amount of at least [***] Dollars
($[***]) for bodily injury and property damage. Santarus shall maintain such insurance during the
Term and thereafter for a period of [***]. Santarus shall give GSK at least [***] days notice of
any cancellation or termination of such insurance. Santarus will furnish to GSK a certificate of
insurance evidencing such coverage (or evidence reasonably acceptable to GSK of Santarus level of
self-insurance) as of the Effective Date and upon reasonable request by GSK at any time thereafter.

               9.5.2 GSK. Santarus acknowledges that GSK is self-insured. GSK shall maintain
self-insurance at levels at least consistent with the levels of insurance described for
sub-distributors in this Section 9.5.2 during the Term and for a period of [***] thereafter. GSK
shall ensure that its sub-distributors maintain CGL insurance, including broad form contractual
liability, and product liability coverages, in an amount of at least [***] Dollars ($[***]) and in
an amount of at least [***] Dollars ($[***]) for bodily injury and property damage during the Term
and thereafter for a period of [***]. GSK shall give Santarus at least [***] days prior written
notice of any cancellation or termination of such insurance. The minimum level of insurance set
forth herein will not be construed to create a limit on GSK’s or its sub-distributors’ liability
with respect to its indemnification obligations hereunder. GSK shall give Santarus at least [***]
days notice of any cancellation or termination of such insurance. GSK will furnish to Santarus a
certificate of insurance evidencing such coverage (or evidence reasonably acceptable to Santarus of
GSK’s level of self-insurance) as of the Effective Date and upon reasonable request by Santarus at
any time thereafter.

ARTICLE 10

FORCE MAJEURE

          10.1 Force Majeure. Any delays in performance by any Party under this Agreement,
other than with respect to the payment obligations, shall not be considered a breach of this
Agreement if and to the extent caused by Force Majeure. The Party suffering such Force Majeure
event shall notify the other Party in writing as soon as practicable of such inability and of the
period for which such inability is expected to continue, and any time for performance hereunder
shall be extended by the actual time of delay caused by the Force Majeure event; provided that the
Party suffering such occurrence uses Commercially Reasonable Efforts to mitigate any damages
incurred by the other Party.

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-44-

 

ARTICLE 11

CONFIDENTIALITY

          11.1 Confidential Information. GSK and Santarus each hereby recognize and acknowledge
that the other Party’s Confidential Information constitutes valuable and confidential information.
Subject to other express provisions of this Agreement, GSK and Santarus each agree as follows that
during the Term, and for a period of [***] years after the effective date of termination of this
Agreement for any reason:

                    (a) The Parties will not disclose, directly or indirectly, in any manner whatsoever to any
Third Parties any Confidential Information received from the other Party (the “Disclosing Party”)
without first obtaining the written consent of the Disclosing Party, and the other Party
(“Recipient”) will keep confidential, all of the Disclosing Party’s Confidential Information that
is disclosed to Recipient. Recipient agrees to use the same level of care in safeguarding the
Disclosing Party’s Confidential Information that Recipient uses with its own confidential
information of a similar nature, but in no event less than reasonable care. Recipient will
restrict disclosure of the Disclosing Party’s Confidential Information solely to those of its (or
its Affiliate’s) employees or representatives having a need to know such Confidential Information
in order to exercise a right granted or fulfill an obligation under, this Agreement.

                    (b) Both Parties shall ensure that each of their respective employees and representatives who
will have access to the Confidential Information of the Disclosing Party are bound by an agreement
to maintain such Confidential Information in accordance with the confidentiality obligations set
forth in this Article 11.

                    (c) Recipient will not use the Disclosing Party’s Confidential Information in any manner
whatsoever other than solely in connection with the performance of its obligations, or exercise of
its rights, under this Agreement in accordance with the terms and conditions set forth in this
Agreement.

                    (d) Except as permitted by this Article 11, GSK and Santarus each agree not to disclose any
terms or conditions of this Agreement or the existence of this Agreement to any Third Party without
the prior written consent of the other Party, provided, that each Party will be entitled to
disclose the terms of this Agreement without such consent to its advisors and potential and
existing financing sources, acquirors/acquirees (including to the consultants and advisors of the
foregoing), and to others (including in the case of Santarus, to UMissouri and, in the case of GSK,
to potential and existing permitted sub-distributors), in each case on a need-to-know basis and on
the condition that such Persons agree to keep such Confidential Information in accordance with the
obligations set forth in this Article 11. In addition, either Party may disclose the terms of this
Agreement to the extent reasonably required by Applicable Law or by applicable rules of any
national stock exchange on which the shares of such Party are listed.

                    (e) In the event Recipient is requested pursuant to, or required by, Applicable Law to
disclose any of the Disclosing Party’s Confidential Information, it will notify the Disclosing
Party promptly in writing so that the Disclosing Party may seek a protective order or

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-45-

 

other appropriate remedy or, in the Disclosing Party’s sole discretion, waive compliance with
the confidentiality provisions of this Agreement. At the Disclosing Party’s expense, Recipient
will co-operate in all reasonable respects, in connection with any reasonable actions to be taken
for the foregoing purpose. Recipient may, without liability, disclose the Confidential Information
of the other Party to the extent such disclosure is required under Applicable Law, and Recipient
will exercise reasonable efforts to obtain reliable assurances that confidential treatment will be
accorded to any of the Disclosing Party’s Confidential Information so disclosed.

                    (f) Upon the effective date of the termination of this Agreement for any reason, either Party
may request in writing, and the other Party will either: (i) promptly destroy all copies of the
requesting Party’s Confidential Information in the possession of the other Party and confirm such
destruction in writing to the requesting Party; or (ii) promptly deliver to the requesting Party,
at the other Party’s expense, all copies of such Confidential Information in the possession of the
other Party, provided, however, the other Party will be permitted to retain one (1) copy of the
requesting Party’s Confidential Information for the sole purpose of determining any continuing
obligations hereunder (or in the case of Santarus, fulfill its obligations under the Missouri
Agreement). Additionally, except as otherwise expressly provided herein, upon termination of this
Agreement for any reason, both Parties will immediately cease all use of the other Party’s
Confidential Information including, to the extent reasonably possible, removing all references to
such Confidential Information from its internal analyses, memoranda, compilations, studies or other
documents. All Confidential Information will continue to be subject to the terms of this Agreement
for the period set forth in this Section 11.1.

                    (g) Each Party represents and warrants to the other Party that it has all right, title and
ownership interest in and to its Confidential Information or it has the right to disclose its
Confidential Information to the other Party. Each Party may seek to enforce all rights and legal
remedies available under this Article 11 or by law, including injunctive relief, specific
performance and other equitable remedies in the event of a breach of the provisions of this Article
11 by the other Party.

                    (h) Notwithstanding the provisions of this Article 11, the Parties agree that nothing
contained in this Article 11 will prevent (i) GSK from disclosing any Santarus Confidential
Information, without obtaining Santarus’ prior consent, to any Affiliate of GSK or to any Third
Party who has a need to know such Confidential Information for the purposes of engaging in the
manufacture or commercialization of PR Products in the Territory in accordance with this Agreement;
provided that such Affiliate or Third Party is bound by obligations of confidentiality and non-use
no less burdensome than those set forth in this Agreement with respect to the Confidential
Information, (ii) Santarus from disclosing any GSK Confidential Information, without obtaining
GSK’s prior consent, to UMissouri, as required under the Missouri Agreement, or to any Affiliate of
Santarus or to any Third Party who has a need to know such Confidential Information for the
purposes of engaging in the development, manufacture or commercialization of Licensed Products for
sale outside of the GSK Territory; provided that such Affiliate or Third Party is bound by
obligations of confidentiality and non-use no less burdensome than those set forth in this
Agreement with respect to the Confidential Information, or (iii) Santarus from disclosing
information or data related to PR Products in its filings or submissions to Governmental
Authorities in connection with

-46-

 

PR Products or new formulations, indications, dosages, presentations, forms of administration
or preparations for PR Products. The confidentiality obligations set forth in this Article 11 will
supersede that certain Confidentiality Agreement between GlaxoSmithKline Services Unlimited and
Santarus dated [***] (“Confidentiality Agreement”), and will govern any and all information
disclosed by either Party to the other pursuant thereto.

          11.2 Publicity. Any key announcements or publicity regarding the existence of this
Agreement or any terms or subject matter of this Agreement by either GSK or Santarus will be agreed
to by GSK and Santarus in writing in advance of any such announcement or publicity. The Party
preparing any such announcement, publicity or press release will provide the other Party with a
draft thereof reasonably in advance of disclosure so as to permit the other Party to review and
comment on such announcement, publicity or press release, unless Applicable Law otherwise requires
sooner public disclosure. The foregoing notwithstanding, the Parties have agreed on a press
release to announce the execution of this Agreement in the form attached as Schedule 11.2, together
with a corresponding conference call script and question/answer outline for use in responding to
inquiries about this Agreement. Thereafter, GSK and Santarus may each disclose to Third Parties
the information contained in such press release and question/answer outline without the need for
further approval by the other Party. Each Party agrees that it will cooperate fully with the other
with respect to all disclosures regarding or arising out of the activities under this Agreement as
required by the Securities Exchange Commission and any other Governmental Authority, including
requests for confidential treatment of proprietary information of either Party included in any such
disclosure.

          11.3 Trial Data; Publication. To the extent that GSK conducts any clinical trials
permitted under the terms and conditions of this Agreement, GSK may post the data generated from
such trials in accordance with GSK’s corporate policy on Public Disclosure and Access to Clinical
Trial and Observational Study Information Data. [***].

ARTICLE 12

TERM AND TERMINATION

          12.1 Term. The term of this Agreement (the “Term”) will commence on the Effective
Date and, unless sooner terminated as provided in this Article 12, shall continue in effect for so
long as GSK promotes, distributes or sells PR Product in the Territory.

          12.2 Termination for Material Breach. Each Party will be entitled to terminate this
Agreement in its entirety at any time during the Term by written notice to the other Party in the
event that the other Party is in material default or breach of any of its obligations hereunder,
and fails to remedy any such default or breach within sixty (60) days or, in the case of a failure
to pay amounts due hereunder, within fifteen (15) days (respectively, the “Cure Period”) after
written notice thereof by the non-defaulting/non-breaching Party. If such default or breach is not
corrected within the applicable Cure Period, the non-defaulting/non-breaching Party will have the
right to immediately terminate this Agreement by giving written notice to the Party in default or
breach.

          12.3 Termination for Safety Issues. Either Party may, upon prior written notice to
the other, immediately terminate this Agreement at any time during the Term if the withdrawal of
the

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-47-

 

PR Product in the Territory or in the United States is commenced by Santarus or ordered or
required by a Governmental Authority.

          12.4 Termination for no Launch in the Territory. Santarus may, upon written notice to
GSK, immediately terminate this Agreement in the event that GSK does not commence promotion,
distribution and sales of the PR Product in the Territory within three (3) months after the
Effective Date; provided, however, that such three (3) month period shall be extended to the extent
that a delay in GSK’s promotion, distribution and sales of the PR Product in the Territory has been
caused by a breach of this Agreement by Santarus.

          12.5 Termination Without Cause.

               12.5.1 Mutual. The Parties may terminate this Agreement in its entirety at any time
and for any reason during the Term upon their mutual written agreement; or

               12.5.2 By GSK. GSK may terminate this Agreement in its entirety at any time and for
any reason during the Term upon providing Santarus with not less than six (6) months’ prior written
notice.

          12.6 Bankruptcy. Either Party may terminate this Agreement in its entirety at any
time during the Term by giving written notice to the other Party if the other Party files in any
court or agency pursuant to any statute or regulation of any state or country, a petition in
bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of the Party or of its assets, or if the other Party proposes a written
agreement of composition or extension of its debts in the aggregate or if the other Party is served
with an involuntary petition against it, filed in any insolvency proceeding, and such petition will
not be dismissed with sixty (60) days after the filing thereof, or if the other Party proposes or
is a party to any dissolution or liquidation, or if the other Party makes an assignment for the
benefit of creditors.

          12.7 Effect of Termination. Upon the effective date of termination of this Agreement
for any reason, all licenses and rights granted to GSK by Santarus under this Agreement, including
under the Intellectual Property and Trademarks, and GSK’s right to promote, distribute and sell
Products under the PR Product Registration, will terminate, and all rights therein will revert to
Santarus. Upon such termination, GSK will:

                    (a) at Santarus’ discretion, either destroy all Promotional Materials, or assign and transfer
to Santarus all such Promotional Materials (including any copyrights therein);

                    (b) offer to sell to Santarus GSK’s then-current inventory of PR Product at GSK’s cost to the
extent that the PR Products have a [***] remaining shelf life; provided, however, that GSK shall
have the non-exclusive right, for a period of up to [***] after termination of this Agreement, to
sell (in the Field in the Territory) any remaining stocks of PR Products on hand at the time of
such termination that are not purchased by Santarus, such sales to be made in accordance with, and
subject to, all applicable payment, reporting, indemnity and other obligations set forth in this
Agreement; and provided further that GSK agrees that it and its Affiliates and permitted
Sublicensees shall, on request of Santarus and for a period not to exceed [***] following such

 

			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-48-

 

termination, continue to distribute (on a non-exclusive basis) existing stocks of PR Products
in the Field in the Territory in accordance with, and subject to, the terms and conditions of this
Agreement.

                    (c) assign to Santarus at Santarus’ request GSK’s rights in any or all Third Party agreements
for licenses, services or supplies used in the promotion, distribution, marketing, advertisement or
sale of PR Product in the Territory during the Term, to the extent such agreements are assignable
and can be limited to PR Product in the Territory;

                    (d) return to Santarus all relevant records, materials or Confidential Information relating to
PR Product in GSK’s (or any of its Affiliates’ or contractors’) possession;

                    (e) cease all marketing, sale, promotion, advertising and distribution of PR Product in the
Territory; and

                    (f) At GSK’s cost and expense, take all steps reasonably requested by Santarus to transition
the distribution process for PR Product in the Territory back to Santarus or its designees.

          12.8 Survival Upon Termination.

               12.8.1 General. The following provisions will survive any termination of this
Agreement: Articles 9, 11, 13 and 14 and Sections 2.6.1, 2.7, 2.10 (subject to Section 12.8.4),
3.2.2, 3.2.3(d), 3.3.4, 3.6.3, 4.1.3, 5.2.9, 6.7, 12.7 and 12.8.

               12.8.2 Payments. Upon termination of this Agreement, Santarus will have the right to
retain any sums already paid by GSK hereunder, and Santarus will have the right to receive all
royalties and other payments accrued prior to such termination.

               12.8.3 Accrued Liabilities. Termination of this Agreement will not relieve the
Parties of any liability which accrued hereunder prior to the effective date of such termination,
including any payment obligations, nor preclude either Party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this Agreement nor
prejudice either Party’s right to obtain performance of any obligation.

               12.8.4 No Licenses Survive. For the avoidance of doubt, upon the termination of this
Agreement for any reason, all of the rights and licenses to the PR Product and under the
Intellectual Property and the Trademarks granted by Santarus to GSK pursuant to this Agreement will
terminate and GSK will no longer have any rights to the PR Product or under the Intellectual
Property or Trademarks. Upon the termination of this Agreement for Santarus’ breach pursuant to
Section 12.2, all of the rights and licenses under the GSK IP granted by GSK to Santarus pursuant
to this Agreement will terminate and Santarus will no longer have any rights under the GSK IP.

-49-

 

ARTICLE 13

DISPUTE RESOLUTION

     13.1 Dispute Resolution.

               13.1.1 Informal Resolution. Except with regard to any matters which are to be
resolved as set forth in Section 5.2.4(b), in the event of any dispute, controversy or claim
arising out of, relating to or in connection with any provision of this Agreement or the rights or
obligations of the Parties hereunder (a “Dispute”), the Parties will try to settle their
differences amicably between themselves as contemplated herein. Either Party may initiate such
informal dispute resolution by sending written notice setting forth in reasonable detail the nature
of the dispute (the “Dispute Notice”) to the other Party. Within thirty (30) days after such
notice, the President of GSK’s International Pharmaceutical business or his/her designee with
authority to resolve such matter, and the Chief Executive Officer of Santarus, or his/her designee
with authority to resolve such matter, shall meet to negotiate in good faith a resolution to the
dispute within such thirty (30) day period. If such representatives are unable to promptly resolve
such disputed matter within the said thirty (30) days, either Party may thereafter initiate
arbitration proceedings in accordance with Section 13.1.2. The provisions of this Section 13.1.1
will not restrict in any way the Parties’ rights to seek preliminary injunctive or other equitable
relief from any court having jurisdiction.

               13.1.2 Arbitration. If a dispute is unresolved following attempted informal dispute
resolution pursuant to Section 13.1.1, then either Party may initiate arbitration before a panel of
three (3) arbitrators in accordance with the commercial arbitration rules of the American
Arbitration Association (“AAA”) then in force; provided, however, that any dispute related to the
infringement, validity or enforcement of any intellectual property right shall be heard by a court
of competent jurisdiction in the country where such right exists. The following provisions shall
apply with respect to such arbitration:

                    (a) Arbitrators. Within thirty (30) days after receipt of the notice of arbitration
by the Party not initiating such arbitration, each Party shall appoint an arbitrator who is
independent of the Parties (which arbitrator shall have reasonable knowledge regarding the
pharmaceutical industry), and those two arbitrators shall appoint the third arbitrator within
thirty (30) days. In the event that the two (2) arbitrators are unable to agree on a third within
the required time, either Party may apply under the applicable rules of the AAA for the appointment
of that third arbitrator, and the selection of an arbitrator under such rules of the AAA shall be
final and binding on the Parties.

                    (b) Process. The Parties shall seek to timely appoint their respective arbitrators
and to have the full panel of three (3) arbitrators appointed within three (3) months after the
non-initiating Party received the notice of arbitration, and seek to conclude the arbitration
within nine (9) months after the full arbitration panel has been appointed. The arbitration panel
shall determine what discovery will be permitted; provided that the arbitration panel shall permit
such discovery as the panel deems necessary to permit a fair resolution of the dispute. The
arbitrators shall not order discovery against one Party of a type or nature that is not available
against the other Party. The place of arbitration shall be [***]. The arbitration shall be
conducted in the English

 

 
			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-50-

 

language, and all evidence shall be presented in English; provided that any evidence original
in a language other than English shall be provided in the original language with a certified
translation in English.

                    (c) Final and Binding. The Parties agree that the award rendered shall be final and
binding upon the Parties, and shall be the sole and exclusive remedy with respect to all disputes,
controversies, claims and counterclaims presented to the arbitrators (which shall not include any
dispute related to the infringement, validity or enforcement of any intellectual property).

                    (d) Timing. The Parties and the arbitrators shall use all reasonable efforts to
complete any such arbitration within one (1) year from the filing of notice of a request for such
arbitration unless a Party can demonstrate to the arbitrators that the complexity of the issues or
other reasons warrant the extension of the one (1) year period. In such event, the arbitrators may
extend such period as reasonably required.

                    (e) Costs and Fees. [***]. In determining the appropriate remedy(ies) hereunder, the
arbitrators may take into account the number of prior breaches committed by a breaching Party, the
number of prior accusations of breaches alleged by the Parties and any prior breaches found to be
in bad faith.

                    (f) Not Public. The arbitration proceedings and the decision shall not be made public
without the joint consent of the Parties, and each Party shall maintain the confidentiality of such
proceedings and decision unless otherwise permitted by the other Party; provided either Party makes
such disclosures as are required to comply with Applicable Law.

               13.1.3 Courts. Nothing in this Agreement shall be deemed as preventing any Party from
seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over
the Parties and the subject matter of the dispute as necessary to protect any Party’s name,
proprietary information, trade secrets, know-how or any other proprietary rights. Judgment upon
any arbitration award hereunder may be entered in any court having jurisdiction, or application may
be made to such court for judicial acceptance of the award or an order of enforcement, as the case
may be. The Parties hereby consent to the jurisdiction of the state and Federal courts in and for
[***].

ARTICLE 14

MISCELLANEOUS PROVISIONS

          14.1 Notices. Notices required or permitted under this Agreement will be in writing
and sent by prepaid registered or certified air mail or by overnight express mail (e.g., FedEx), or
by facsimile (receipt confirmed and copy provided by prepaid registered or certified air mail
letter) or by overnight express mail (e.g., FedEx), and will be deemed to have been properly served
to the addressee upon receipt of such written communication, to the following addresses of the
Parties, or such other address as each Party may from time to time designate by written notice to
the other Party as set forth herein:

 

 
			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-51-

 

          If to Santarus:

               Santarus, Inc.

               10590 West Ocean Air Drive, Suite 200

               San Diego, California 92130

               Attention: President and CEO

               Facsimile No.: 858-314-5701

          with a copy to:

               Santarus, Inc.

               10590 West Ocean Air Drive, Suite 200

               San Diego, California 92130

               Attention: Legal Affairs Department

               Facsimile No.: [***]

          If to GSK:

               GlaxoSmithKline Services Unlimited

               980 Great West Road

               Brentford

               Middlesex

               TW8 9GS

               United Kingdom

               Attention : Senior Vice President Commercial Development GSK

               Pharmaceuticals International

               Facsimile No: — [***]

          with a copy to:

               GlaxoSmithKline Serrvices Unlimited

               980 Great West Road

               Brentford

               Middlesex

               TW8 9GS

               United Kingdom

               Attention : Senior Vice President Legal Operations International & Japan

               Facsimile No: — [***]

          14.2 Governing Law. The form, execution, validity, construction and effect of this
Agreement will be governed by and construed in accordance with the laws of the State of New York,
without regard to the choice-of-law provisions thereof.

 

 
			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-52-

 

          14.3 Performance by Affiliates. The Parties recognize that each Party may perform
some or all of its obligations under this Agreement through Affiliates; provided, however, that
each Party will remain responsible for and guarantees the performance by its Affiliates and will
cause its Affiliates to comply with the provisions of this Agreement in connection with such
performance. Each Party hereby expressly waives any requirement that the other Party exhaust any
right, power or remedy, or proceeds against an Affiliate, for any obligation or performance
hereunder prior to proceeding directly against such Party.

          14.4 Miscellaneous.

               14.4.1 Binding Effect. This Agreement will be binding upon and inure to the benefit
of the Parties and their respective legal representatives, successors and permitted assigns.

               14.4.2 Headings. Article and Section headings are inserted for convenience of
reference only and do not form a part of this Agreement.

               14.4.3 Counterparts. This Agreement may be executed simultaneously in two (2) or more
counterparts, each of which will be deemed an original.

               14.4.4 Entire Agreement; Amendment; Waiver. This Agreement, together with the ROW
License, constitutes the entire understanding of the Parties with respect to the subject matter
hereof and supersedes all previous writings and understandings, including the Confidentiality
Agreement. This Agreement may be amended, modified, superseded or cancelled, and any of the terms
may be waived, only by a written instrument executed by each Party or, in the case of waiver, by
the Party waiving compliance. No waiver by any Party of any condition or of the breach of any term
contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, will
be deemed to be, or considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement.

               14.4.5 No Third Party Beneficiaries. Except as expressly provided in Sections 9.1 and
9.2 (in either case subject to Section 9.3), no Third Party, including any employee of any Party to
this Agreement, will have or acquire any rights by reason of this Agreement.

               14.4.6 Assignment and Successors. Neither party may assign or transfer its rights
under this Agreement or delegate its duties hereunder, by merger, sale of assets, operation of law
or otherwise, without the prior written consent of the other; provided, however, that (a) Santarus
may assign this Agreement without such consent in connection with the sale or transfer of all or
substantially all of its business or assets related to the PR Product, and (b) GSK may assign this
Agreement without such consent of Santarus to an Affiliate or an entity that is not a Competing
Third Party and which acquires all or substantially all of GSK’s pharmaceuticals marketing and
distribution business in the Territory, whether by merger, sale of assets or otherwise. Any
attempted assignment, sale or transfer in violation of the prior sentence will be void. Upon any
permitted assignment or transfer of this Agreement by either Party, (i) the other Party shall be
given prompt written notice of such assignment and (ii) the assignee shall agree in writing to be
bound by the terms and conditions set forth herein. As used herein, “Competing Third Party” means
[***].

 

 
			
	***	 	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission.  Confidential treatment has been requested with respect to the omitted portions.

-53-

 

               14.4.7 Severability. If any provision of this Agreement is or becomes invalid or is
ruled invalid by any court of competent jurisdiction or is deemed unenforceable, such provision
shall be considered severed from this Agreement, and it is the intention of the Parties that the
remainder of the Agreement will not be affected. The Parties will make a good faith effort to
replace any invalid or unenforceable provision with a valid and enforceable one which as closely as
possible achieves the objectives contemplated by the Parties when entering this Agreement.

               14.4.8 Further Actions. Each Party agrees to execute, acknowledge and deliver such
further instruments, and to do all such other commercially reasonable acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

               14.4.9 Relationship of the Parties. It is not the intent of the Parties hereto to
form any partnership or joint venture. Each Party will, in relation to its obligations hereunder,
be deemed to be and will be an independent contractor, and nothing in this Agreement will be
construed to give such Party the power or authority to act as agent for the other Party for any
purpose, or to bind or commit the other Party in any way whatsoever.

[The remainder of this page is intentionally left blank; signature page follows.]

-54-

 

     IN WITNESS WHEREOF, the Parties have caused this Distribution Agreement to be executed by
their duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	GLAXO GROUP LIMITED	 	 	 	SANTARUS, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Stephen J. Crookes	 	 	 	By:	 	/s/ Gerald T. Proehl	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 	 	Name: Stephen J. Crookes	 	 	 	 	 	Name: Gerald T. Proehl	 	 
	 

	 	Title:
	 	  VP, Business Development — GSKI
	 	 	 	 	 	Title:
	 	  President and CEO	 	 

 

SCHEDULE 1.70

TRADEMARKS

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Appl. No./	 	Reg. No./	 	 	 	 
	MARK	 	COUNTRY	 	Date	 	Date	 	CLASS: GOODS/SERVICES	 	STATUS
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]
	[***]

	 	[***]
	 	[***]
	 	[***]
	 	[***]
	 	[***]

 

	***	 	Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

 

SCHEDULE 5.2.2

MAXIMUM SUPPLY FOR INITIAL SIX (6) MONTHS

	 	 	 
	Product	 	Quantity1
	40 mg capsules trade

	 	[***]
	40 mg capsules samples

	 	[***]
	40 mg powder trade

	 	[***]
	40 mg powder samples

	 	[***]
	20 mg capsules trade

	 	[***]
	20 mg capsules samples

	 	[***]
	20 mg powder trade

	 	[***]
	20 mg powder samples

	 	[***]

 

			
	1	 	[***].

	***	 	Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

 

SCHEDULE 6.1

TRANSFER PRICE

	 	 	 
	Product	 	Price ($)/Unit1
	40 mg capsules trade

	 	[***]
	40 mg capsules samples

	 	[***]
	40 mg powder trade

	 	[***]
	40 mg powder samples

	 	[***]
	20 mg capsules trade

	 	[***]
	20 mg capsules samples

	 	[***]2
	20 mg powder trade

	 	[***]2
	20 mg powder samples

	 	[***]2

 

			
	1	 	Trade Unit measure is per bottle for capsules and per
carton for powder. Samples unit measure is per 5-capsule bottle and per
3-packet carton.
	 
	2	 	[***].

	***	 	Certain information on this page has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

 

SCHEDULE 11.2

PRESS RELEASE

 

 

	 	 	 
	     COMPANY CONTACT:

	 	INVESTOR CONTACT:
	     Martha L. Hough

	 	Lippert/Heilshorn & Associates, Inc.
	     VP Finance & Investor Relations

	 	Jody Cain (jcain@lhai.com)
	     (858) 314-5824

	 	Eleanor Tang (etang@lhai.com)
	     Debra P. Crawford

	 	(310) 691-7100
	     Chief Financial Officer
	 	 
	     (858) 314-5708
	 	 

For Immediate Release

SANTARUS LICENSES RIGHTS TO GLAXOSMITHKLINE FOR ZEGERID

IMMEDIATE-RELEASE OMEPRAZOLE PRODUCTS IN OVER 100 COUNTRIES

Santarus and GSK also sign distribution agreement for ZEGERID prescription products

in Puerto Rico and U.S. Virgin Islands

Conference call to begin at 5:00 p.m. Eastern time today

SAN DIEGO (December 3, 2007) — Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company,
today announced that it has entered into agreements granting exclusive rights to GlaxoSmithKline
plc (GSK), to commercialize prescription and over-the-counter immediate-release omeprazole products
(Licensed Products) for a number of markets in GSK’s International Region (including Africa, Asia,
the Middle-East, and Central and South America), and to distribute and sell ZEGERID®
brand prescription products in Puerto Rico and the U.S. Virgin Islands (USVI).

Under the license agreement, GSK will be responsible for the development, manufacture and
commercialization of Licensed Products in up to 114 countries, excluding the U.S., Europe,
Australia, Japan and Canada. In addition, under a separate distribution agreement, GSK will
distribute, market and sell ZEGERID brand prescription products in Puerto Rico and the USVI
beginning in the first quarter of 2008. GSK will bear all costs for its activities under the
license and distribution agreements.

GSK will pay Santarus an $11.5 million upfront fee and tiered double digit royalties, subject to
reduction in certain circumstances, on net sales of any products sold under the license and
distribution agreements. The term of the license agreement continues so long as GSK is obligated
to pay royalties and the term of the distribution agreement continues as long as GSK sells the
products, unless the agreements are terminated earlier by either GSK or Santarus under specified
circumstances. GSK has an option to make a buy-out payment 20 years after the effective date of
the agreements, after which time, GSK’s royalty obligations generally would end. To support GSK’s
initial launch costs, Santarus will waive the first $2.5 million of aggregate royalties payable
under the license and distribution agreements.

“As a leading global pharmaceutical company, GSK has well established international
commercialization capabilities. We believe its demonstrated success in the gastrointestinal
therapeutic area make GSK an ideal partner for Santarus in the covered markets,” said Gerald T.
Proehl, president and chief executive officer of Santarus. “We also believe this relationship with
GSK is a major advancement of our strategic objective to leverage our immediate-release proton pump
inhibitor intellectual property in international markets and to further diversify our potential
sources of future revenues.”

 

 

“This agreement combines GSK’s commercial strength in these countries with a great opportunity in
the form of ZEGERID immediate-release omeprazole products,” commented Dr. Russell Greig, President,
GSK Pharmaceuticals International.

      Conference Call

     Santarus has scheduled an investor conference call regarding this announcement at 5:00 p.m.
Eastern time (2:00 p.m. Pacific time) today, December 3, 2007. Individuals interested in
participating in the call may do so by dialing 888-803-8275 for domestic callers, or 706-643-7736
for international callers. A telephone replay will be available for 48 hours following conclusion
of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international
callers, and entering reservation code 26421314. The live conference call also will be available
via the Internet by visiting the Investor Relations section of the Santarus Web site at
www.santarus.com, and a recording of the call will be available on the company’s Web site for 14
days following the completion of the call.

      About Currently Marketed ZEGERID Prescription Products in the U.S.

     ZEGERID (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension contain a
combination of omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which
raises the gastric pH and thus protects the omeprazole from acid degradation.

     In the U.S., ZEGERID Capsules and ZEGERID Powder for Oral Suspension are indicated for the
treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD),
erosive esophagitis, and gastric and duodenal ulcers. ZEGERID Powder for Oral Suspension is also
indicated for the reduction of risk of upper gastrointestinal bleeding in critically ill patients.

     These ZEGERID products offer a distinct pharmacological profile — rapidly reaching maximal
plasma levels (in approximately 30 minutes) and providing strong acid control, with a median
24-hour gastric pH of greater than 4 ranging from 12.2 hours to 18.6 hours, depending on the
strength and dosage form, after repeated once-daily dosing. ZEGERID can be conveniently taken
once-a-day on an empty stomach, at least one hour before a meal.

     PPIs are widely prescribed for a variety of diseases and disorders of the upper digestive
tract. All currently marketed oral PPIs in the U.S., other than ZEGERID, are delayed-release
formulations that utilize an enteric coating to protect the PPI from acid degradation, thereby
delaying absorption and initial acid suppression. Unlike delayed-release PPIs, ZEGERID Capsules and
Powder for Oral Suspension utilize an antacid in lieu of an enteric coating. The antacid
neutralizes stomach acid and protects the PPI, omeprazole, from gastric acid degradation and allows
for its rapid absorption and suppression of gastric acid.

      Important Safety Information

     The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal
pain. In critically ill patients treated with ZEGERID, adverse events generally reflected the
serious, underlying medical condition of the patients, and were similar for patients treated with
ZEGERID and with the comparator (acid-controlling) drug. Symptomatic response to therapy does not
preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in
gastric corpus biopsies from patients treated long term with omeprazole.

 

 

     ZEGERID Capsules contain 303 mg of sodium per dose. ZEGERID Powder for Oral Suspension
contains 460 mg of sodium per dose. This should be taken into consideration for patients on a
sodium-restricted diet. Sodium bicarbonate is contraindicated in patients with metabolic alkalosis
and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any
component of the formulation.

     Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in
capsules, 1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent
to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent
to, and should not be substituted for, one 40 mg packet.

About Santarus

     Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and
commercializing proprietary products that address the needs of patients treated by
gastroenterologists or primary care physicians. The company’s current marketing efforts are
primarily focused on ZEGERID Capsules and Powder for Oral Suspension. These products are
immediate-release formulations of omeprazole, a widely prescribed PPI. More information about
Santarus is available on the company’s Web site at www.santarus.com.

     Santarus cautions you that statements included in this press release that are not a description of
historical facts are forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by Santarus that any of its plans will be achieved.
Actual results may differ materially from those set forth in this release due to the risks and
uncertainties inherent in Santarus’ business, including, without limitation: risks related to the
license and distribution agreements with GSK, including the success of GSK’s development,
distribution, sales and marketing activities, GSK’s ability to obtain regulatory approvals in the
licensed international markets, GSK’s level of commitment and the potential for termination of one
or both of the agreements; the scope and validity of patent protection for ZEGERID and other
licensed products and Santarus’ and GSK’s ability to commercialize ZEGERID and other licensed
products without infringing the patent rights of others; unexpected adverse side effects or
inadequate therapeutic efficacy of ZEGERID or other licensed products that could delay or prevent
product development or commercialization, or that could result in recalls or product liability
claims; competition from other pharmaceutical or biotechnology companies; and other risks detailed
in Santarus’ prior press releases as well as in public periodic filings with the Securities and
Exchange Commission.

     You are cautioned not to place undue reliance on these forward-looking statements, which speak only
as of the date hereof. All forward-looking statements are qualified in their entirety by this
cautionary statement and Santarus undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. This caution is made under the safe harbor
provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

     Santarus® and ZEGERID® are registered trademarks of Santarus, Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]